var title_f30_25_31120="Stool sample 7";
var content_f30_25_31120=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stool sample 7",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_25_31120=[""].join("\n");
var outline_f30_25_31120=null;
var title_f30_25_31121="Retained surgical sponge on plain abdominal film";
var content_f30_25_31121=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retained surgical sponge on plain abdominal film",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anteroposterior view of an enema study in a 28-year-old woman. Area of stricture involving the descending colon (thick arrow) is caused by extrinsic compression from a retained surgical sponge (ie, gossypiboma). Note the soft-tissue mass with gas bubbles next to stricture (thin arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Manzella A, Filho PB, Albuquerque E, et al. Imaging of gossypibomas: Pictorial review. AJR Am J Roentgenol 2009; 193:S94. Reprinted with permission from the American Journal of Roentgenology. Copyright &copy; 2009 American Roentgen Ray Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_25_31121=[""].join("\n");
var outline_f30_25_31121=null;
var title_f30_25_31122="Histol lentigo maligna melanoma";
var content_f30_25_31122=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lentigo maligna melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power light photomicrograph of a lentigo maligna melanoma. Within a background of epidermal atrophy, the neoplastic melanocytes are arrayed along the dermo-epidermal junction in a lentiginous pattern. Small dyshesive nests are also seen along the junction (black arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_25_31122=[""].join("\n");
var outline_f30_25_31122=null;
var title_f30_25_31123="Vindesine: Drug information";
var content_f30_25_31123=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vindesine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F234309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Vinca Alkaloid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F234282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols. I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     3-4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /week",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1-2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 and 2 every 2 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1-2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1-5 (continuous infusion) every 2-4 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1-2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1-5 every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Dosage reductions of 50% to 75% have been suggested for &ldquo;severe&rdquo; hepatic dysfunction; however, specific guidelines have not been published.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F234283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage reductions of 50% to 75% have been suggested for &ldquo;severe&rdquo; hepatic dysfunction; however, specific guidelines have not been published.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F234267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution: 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F234258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Investigational agent in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F234268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Usually administered as a rapid I.V. push (2-3 minutes) or short (15-20 minutes) infusion; 24-hour continuous infusions are occasionally used. Avoid extravasation. Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F234305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of acute lymphocytic leukemia, chronic myelogenous leukemia; advanced breast cancer; malignant melanoma; lymphomas (Hodgkin and non-Hodgkin's)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3402926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       To prevent fatal inadvertent intrathecal injection, it is recommended by ISMP that all doses be dispensed in a small minibag.",
"       <b>",
"        Fatal if given intrathecally.",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F234307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pyrexia, malaise (up to 60%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (6% to 92%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Mild nausea and vomiting (7% to 27%), constipation (10% to 17%) - related to the neurotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (50%) and thrombocytopenia (14% to 26%), may be dose limiting; thrombocytosis (20% to 28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Nadir: 6-12 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Recovery: Days 14-18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (40% to 70%); loss of deep tendon reflexes (35% to 60%, may be dose limiting); myalgia (up to 60%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rashes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Loss of taste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Facial paralysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute chest pain, ECG changes, paralytic ileus, jaw pain, photophobia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F234271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to vindesine, vinca alkaloids, or any component of the formulation; intrathecal administration (fatal); demyelinating form of Charcot-Marie-Tooth syndrome; severe granulocytopenia (&lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) or severe thrombocytopenia; bacterial infection",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F234261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution (if at all) in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurologic impairment: Use with caution (if at all) in patients with neurologic problems.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cross-resistance: Vindesine has been reported to be cross-resistance with vincristine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation: Vinca alkaloids are vesicants; avoid extravasation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Not for intrathecal administration:",
"     <b>",
"      Intrathecal administration may be fatal.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14081457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies suggest teratogenic effects. Use during pregnancy only if the potential benefits to the mother outweigh potential risks to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F234286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14081458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use during breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Eldisin (AT);",
"     </li>",
"     <li>",
"      Eldisine (AR, AU, BE, CH, DE, FI, FR, GB, IT, LU, NL, SE, ZA);",
"     </li>",
"     <li>",
"      Enisan (ES);",
"     </li>",
"     <li>",
"      Fildesin (JP);",
"     </li>",
"     <li>",
"      Gesidine (PT);",
"     </li>",
"     <li>",
"      XI AI KE (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F234260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vindesine is a semisynthetic vinca alkaloid, having a mechanism of action similar to the other vinca derivatives. It arrests cell division in metaphase through inhibition of microtubular formation of the mitotic spindle. The drug is cell-cycle specific for the S phase.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F234270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 8 L/kg; minimal distribution to adipose tissue or CNS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triphasic; Alpha: 2 minutes; Beta: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Terminal: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces; urine (~3% to 25% of dose as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dancey J and Steward WP, &ldquo;The Role of Vindesine in Oncology - Recommendations After 10 Years' Experience,&rdquo;",
"      <i>",
"       Anticancer Drugs",
"      </i>",
"      , 1995, 6(5):625-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31123/abstract-text/8845472/pubmed\" id=\"8845472\" target=\"_blank\">",
"        8845472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joel S, &ldquo;The Comparative Clinical Pharmacology of Vincristine and Vindesine: Does Vindesine Offer Any Advantage in Clinical Use?&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1996, 21(6):513-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31123/abstract-text/8599802/pubmed\" id=\"8599802\" target=\"_blank\">",
"        8599802",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rhomberg W, Eiter H, Soltesz E, et al, &ldquo;Long-Term Application of Vindesine: Toxicity and Tolerance,&rdquo;",
"      <i>",
"       J Cancer Res Clin Oncol",
"      </i>",
"      , 1990, 116(6):651-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31123/abstract-text/2254384/pubmed\" id=\"2254384\" target=\"_blank\">",
"        2254384",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sorenson JB and Hansen HH, &ldquo;Is There a Role for Vindesine in the Treatment of Nonsmall Cell Lung Cancer?&rdquo;",
"      <i>",
"       Invest New Drugs",
"      </i>",
"      , 1993, 11(2-3):103-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31123/abstract-text/8262725/pubmed\" id=\"8262725\" target=\"_blank\">",
"        8262725",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10303 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-103.10.120.51-1F944A4537-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_25_31123=[""].join("\n");
var outline_f30_25_31123=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234309\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234282\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062226\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234283\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234267\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234258\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234387\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234268\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234305\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3402926\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234307\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234271\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234261\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14081457\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234286\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14081458\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539953\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234260\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234270\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10303\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10303|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_25_31124="Trigger avoidance in asthma";
var content_f30_25_31124=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Trigger avoidance in asthma (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/25/31124/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/25/31124/contributors\" id=\"au7150\">",
"       William Bailey, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/25/31124/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/25/31124/contributors\" id=\"se560\">",
"       Bruce S Bochner, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/25/31124/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/25/31124/contributors\" id=\"de128\">",
"       Anna M Feldweg, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/25/31124?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ASTHMA TRIGGER OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Asthma is a chronic lung condition with inflammation, constriction of the airways, and difficulty breathing. Asthma attacks, or worsening of asthma symptoms, can occur after exposure to factors known as triggers.",
"    </p>",
"    <p>",
"     Not all patients with asthma have the same triggers. Finding out which factors trigger an attack and taking steps to avoid the triggers are important parts of good asthma management.",
"    </p>",
"    <p>",
"     A number of other topics about asthma are available separately. For adults, (see",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/63/39925?source=see_link\">",
"      \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"     </a>",
"     ) and (see",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/6/31841?source=see_link\">",
"      \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/25/29075?source=see_link\">",
"      \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/26/1442?source=see_link\">",
"      \"Patient information: Exercise-induced asthma (Beyond the Basics)\"",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     For children, (see",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/0/37892?source=see_link\">",
"      \"Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44083?source=see_link\">",
"      \"Patient information: Asthma inhaler techniques in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/60/18374?source=see_link\">",
"      \"Patient information: Asthma treatment in children (Beyond the Basics)\"",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      IDENTIFYING AND MANAGING ASTHMA TRIGGERS",
"     </span>",
"    </p>",
"    <p>",
"     One of the best ways to identify asthma triggers is to pay careful attention to the pattern of asthma symptoms. For example, if symptoms occur primarily at home, something in that environment may be involved. If symptoms flare in the spring or fall, an outdoor allergy is more likely to blame.",
"    </p>",
"    <p>",
"     Using blood tests or skin tests can provide additional information about possible asthma triggers by determining if a person is sensitive (or allergic) to a particular substance.",
"    </p>",
"    <p>",
"     Once asthma triggers have been identified, the person has several options:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Avoid the trigger entirely",
"      </li>",
"      <li>",
"       Limit exposure to the trigger if it cannot be completely avoided",
"      </li>",
"      <li>",
"       If exposure to the trigger can be predicted, consult with a healthcare provider about taking an extra dose of medicine before exposure to the trigger",
"      </li>",
"      <li>",
"       Immunotherapy (allergy shots) can be helpful for allergic triggers (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/8/41092?source=see_link&amp;anchor=H19#H19\">",
"        \"Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)\", section on 'Allergy shots'",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      INDOOR ASTHMA TRIGGERS",
"     </span>",
"    </p>",
"    <p>",
"     Allergens are substances that can cause an allergic reaction and are major triggers in many people with asthma. Sensitivity to indoor allergens is especially common in asthmatics. The most common indoor allergens that affect asthmatics include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Dust mites",
"      </li>",
"      <li>",
"       Mold",
"      </li>",
"      <li>",
"       Animal danders (skin, fur, feathers, saliva)",
"      </li>",
"      <li>",
"       Cockroaches",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The bedroom of the asthmatic person should be given special consideration because the greatest number of hours are typically spent there. However, to be effective, measures must be made to reduce allergens throughout the entire home.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Dust mites",
"     </span>",
"     &nbsp;&mdash;&nbsp;Dust mites are microscopic organisms that are present in most households. They avoid light and absorb humidity from the atmosphere (ie, they do not drink). Mites may live in bedding, sofas, carpets, or any woven material if the humidity is high enough.",
"    </p>",
"    <p>",
"     Measures that help limit exposure to dust mites are detailed in the table (",
"     <a class=\"graphic graphic_table graphicRef79168 \" href=\"mobipreview.htm?6/14/6380\">",
"      table 1",
"     </a>",
"     ) and include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Create a physical barrier to the source of the mites by covering pillows and mattresses with plastic or another impermeable fabric cover designed for this purpose. \"Hypoallergenic\" unbleached or organic cotton bedding covers are intended for people who have contact sensitivities to fabric dyes and are not recommended for containing dust mites.",
"      </li>",
"      <li>",
"       Decrease the population of dust mites in the home by washing bedding and pillows in warm water and detergent or drying them in an electric dryer on the hot setting once per week.",
"      </li>",
"      <li>",
"       Remove carpets from the bedroom. Minimize the number of stuffed toys in the child's bedroom and wash them weekly.",
"      </li>",
"      <li>",
"       Control humidity. Mites thrive in humid environments. Opening windows in dry climates and using air conditioning in humid ones decreases humidity in the home and reduces the number of mites. Avoid using a humidifier.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Moving to or spending more time on upper floors of buildings may help, as upper floors tend to be less humid than lower floors or basements. The household humidity should be between 30 and 50 percent if possible. Inexpensive humidity monitors can be purchased at most hardware stores.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Mold",
"     </span>",
"     &nbsp;&mdash;&nbsp;Mold spores can trigger symptoms of allergic rhinitis in allergic patients. Mold thrives in damp environments. Areas such as air conditioning vents, water traps, refrigerator drip trays, shower stalls, leaky sinks, and damp basements are particularly vulnerable to mold growth if not cleaned regularly.",
"    </p>",
"    <p>",
"     To reduce the growth of mold, it is necessary to remove existing mold and reduce humidity to prevent future growth of mold. Humidity can be reduced by removing sources of standing water and persistent dampness by removing house plants, fixing leaky plumbing, correcting sinks and showers that do not drain completely, removing bathroom carpeting that is exposed to steam and moisture, and dehumidifying damp areas to levels below 50 percent.",
"    </p>",
"    <p>",
"     Indoor garbage pails should be regularly disinfected, and an electric dehumidifier should be used to remove moisture from the basement. Old books, newspapers, clothing, and bedding should not be stored in the home. Water damaged carpets should be thrown out because it is difficult or impossible to eliminate mold in this situation, even with thorough cleaning.",
"    </p>",
"    <p>",
"     Mold thrives on soap film that covers tiles, sinks, and grout. Sinks, tubs, and other surfaces with visible mold growth should be cleaned at least every four weeks with dilute bleach [one ounce (30 mL) bleach diluted in one quart (one liter) of water]. Other surfaces with visible mold growth should be also cleaned with a bleach solution. The use of bleach by people with asthma is discussed below. (See",
"     <a class=\"local\" href=\"#H13\">",
"      'Irritants'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Animal danders",
"     </span>",
"     &nbsp;&mdash;&nbsp;Animal dander is made up of the dead skin cells or scales (like dandruff) that are constantly shed by animals. Asthma can be triggered by proteins from the \"dander,\" saliva, and urine of common house pets, such as cats and dogs. Any breed of dog and cat is capable of being allergenic, although the levels given off by individual animals may vary to some degree. In cats, the protein that causes most people's allergies is found in the cat's saliva, skin glands, and",
"     <span class=\"nowrap\">",
"      urinary/reproductive",
"     </span>",
"     tract. Accordingly, short-haired cats are not necessarily less allergenic than long-haired animals, and furless cats have allergens that are similar to furred cats.",
"    </p>",
"    <p>",
"     Other warm-blooded animals, such as rodents, birds, and ferrets can also trigger asthma in an allergic individual. Pets without feathers or fur, such as reptiles, turtles, and fish, rarely cause allergy, although deposits of fish food that build up under the covers of fish tanks are an excellent source of food for dust mite colonies.",
"    </p>",
"    <p>",
"     If a person with asthma is found to be allergic to a pet, the most effective option is to remove the pet from the home. Limiting an animal to a certain area in the house is not effective because some allergens are carried on clothing or spread in the air. Once a pet has left a home, careful cleaning of carpets, sofas, curtain, and bedding must follow. This is particularly true for cat allergens because they are \"sticky\" and adhere to a variety of indoor surfaces. Even after a cat has been removed from a home and it has been thoroughly cleaned, it can take months for the level of cat allergens to drop. For this reason, it may take months for the allergic person's symptoms to fully reflect the absence of the pet.",
"    </p>",
"    <p>",
"     If it is not possible to remove the animal, measures can be taken to decrease exposure to the animal dander (",
"     <a class=\"graphic graphic_table graphicRef58126 \" href=\"mobipreview.htm?18/57/19355\">",
"      table 2",
"     </a>",
"     ), although none of these methods is as effective as removing the animal.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Cockroaches",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cockroach droppings contain allergens that have been shown to trigger asthma in sensitive individuals. Cockroaches thrive in warm environments with easily accessible food and water. Unfortunately, efforts to control cockroach populations in infested areas are often less than successful. Still, certain measures are recommended, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Use multiple baited traps or poisons",
"      </li>",
"      <li>",
"       Remove garbage and food waste promptly from the home",
"      </li>",
"      <li>",
"       Wash dishes and cooking utensils immediately after use",
"      </li>",
"      <li>",
"       Remove cockroach debris quickly",
"      </li>",
"      <li>",
"       Eliminate any standing water from leaking faucets or drains",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      The role of air filters",
"     </span>",
"     &nbsp;&mdash;&nbsp;Air filtering devices, including HEPA filters, other mechanical filters, and electrostatic filters, are widely advertised to reduce indoor allergens. These may be marketed as components of heating or cooling systems, as individual units for use in a room or area, or as units that are worn by individuals. These devices are expensive and few have been scientifically proven to significantly improve allergy symptoms.",
"    </p>",
"    <p>",
"     Certain types of air filters (eg, ionizers) produce ozone, which is a respiratory irritant for some people. These devices have not been proven safe or effective and are not recommended (",
"     <a class=\"external\" href=\"file://www.epa.gov/iaq/pubs/ozonegen.html\">",
"      www.epa.gov/iaq/pubs/ozonegen.html",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     There are several factors that interfere with how well air filters work, and these may partly explain why studies have shown mixed results:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Most air filters probably can remove pollens and pet danders from the air because these allergens are light and do remain airborne. However, if there is a pet, carpeting, upholstered furniture, access to outside air, or some other reservoir of allergen in the vicinity, the allergen is continuously released from these items as people move around the house. There is far more allergen in these reservoirs then the air filter can remove. Therefore, allergens continuously enter the air, even as it is being filtered, and the benefit of an air filter is minimal.",
"      </li>",
"      <li>",
"       In contrast, in a room where there are no carpets, drapes, upholstered furniture, access to outside air, and pets are not allowed, running an air filter probably can improve air quality.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In addition, a vacuum cleaner with a HEPA (high-efficiency particulate air) filtration system and a double thickness bag can help to reduce allergen levels. This is recommended to avoid rebreathing the debris that is captured by vacuuming. A controlled trial has reported a reduction in cat and dog, but not dust mite, allergen levels, and clinical improvement in asthma and allergic rhinitis symptoms in homes cleaned with vacuums equipped with HEPA filters, compared to vacuums without specialized filters [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/25/31124/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      CONTROLLING OTHER ASTHMA TRIGGERS",
"     </span>",
"    </p>",
"    <p>",
"     In addition to indoor allergens, other factors may be identified as asthma triggers.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Respiratory infections",
"     </span>",
"     &nbsp;&mdash;&nbsp;Infections that cause airway inflammation can trigger asthma, including colds, influenza (flu), bronchitis, ear infections, sinus infections, and pneumonia. An asthma attack that occurs along with a respiratory infection may be more severe than one that occurs at other times. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=see_link\">",
"      \"Patient information: Influenza symptoms and treatment (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/38/30308?source=see_link\">",
"      \"Patient information: Pneumonia in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/11/44210?source=see_link\">",
"      \"Patient information: The common cold in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     To reduce the risk of a serious flare related to respiratory infection, a person with asthma should:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Call a healthcare provider at the first sign of an infection.",
"      </li>",
"      <li>",
"       Get a flu shot once a year.",
"      </li>",
"      <li>",
"       Get a pneumonia vaccine (if needed based on other risk factors).",
"      </li>",
"      <li>",
"       Wash hands frequently, especially when in contact with an infected person, and avoid contact with infected people when possible.",
"      </li>",
"      <li>",
"       Use treatments prescribed for symptoms, such as nasal steroids and decongestants.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Medicines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sensitivity to medications can also trigger asthma. In particular, aspirin, some other antiinflammatory drugs, such as ibuprofen (Advil&reg;, Motrin&reg;) and naproxen (Aleve&reg;, Anaprox&reg;) and certain beta blocker heart medicines may cause an attack in certain individuals. Acetaminophen (Tylenol&reg;) does not cause symptoms in most aspirin-sensitive patients.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Outdoor allergens",
"     </span>",
"     &nbsp;&mdash;&nbsp;Asthma symptoms that worsen outdoors at certain times of year are likely to be triggered by an allergy to pollen or other plant material. Affected individuals should stay indoors as much as possible during the season when their asthma tends to flare, use air conditioning when possible, and keep windows closed. Exercising outdoors or participating activities that require exertion should be avoided when levels of air pollution are high.",
"    </p>",
"    <p>",
"     Patients should also try to avoid cutting grass, digging around plants, or participating in other outdoor activities that seem to worsen asthma symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Irritants",
"     </span>",
"     &nbsp;&mdash;&nbsp;A variety of irritants can trigger asthma. Irritants can be found inside or outside, and include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Cigarette smoke and ashes &mdash; A person with asthma should never smoke, smoking should not be allowed in the person's home, and second-hand smoke should be avoided whenever possible. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"        \"Patient information: Quitting smoking (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Aerosol sprays, perfumes &mdash; Non-aerosol products should be used, and exposure to offending perfumes avoided.",
"      </li>",
"      <li>",
"       Gas stoves, fireplace smoke and cooking odors &mdash; Wood-burning stoves, fireplaces, and pellet stoves and unvented gas stoves or heaters can worsen asthma symptoms. Cooking areas should be well ventilated.",
"      </li>",
"      <li>",
"       Air pollution, car exhaust, gas fumes &mdash; Patients should avoid unnecessary exposure to car exhaust, and outdoor exercise should be avoided when pollution levels are high. United States air quality ratings can be obtained online (",
"       <a class=\"external\" href=\"file://airnow.gov/\">",
"        file://airnow.gov/",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Formaldehyde and volatile organic compounds &mdash; Odors from new linoleum flooring, carpeting, particleboard, wallcoverings, furniture, and recent painting can worsen asthma symptoms in some people.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Chemicals",
"     </span>",
"     &nbsp;&mdash;&nbsp;Industrial or occupational exposure to chemicals is responsible for about 15 percent of cases of asthma. If symptoms tend to flare in a workplace where chemicals are in use, the patient and healthcare provider can discuss strategies to limit exposure.",
"    </p>",
"    <p>",
"     If possible, people whose asthma is triggered by strong odors should avoid the use of chlorine and bleach-based cleaning products. If these cleaners are needed to control the growth of mold in the home, ventilate the area thoroughly during and after use, and if possible, have a non-asthmatic person perform the cleaning. Other troubling odors include perfumes, air fresheners, scented room sprays and candles, and cooking oils.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Menstrual cycle",
"     </span>",
"     &nbsp;&mdash;&nbsp;Between 20 and 40 percent of women with asthma report that their asthma symptoms worsen just before or during their menstrual period (called perimenstrual asthma). Women with hormonally-triggered asthma tend to have more severe asthma than women whose asthma is unaffected by hormonal changes. Perimenstrual asthma is thought to be triggered by changes in hormone levels, but exactly how it happens is unclear.",
"    </p>",
"    <p>",
"     The best way to treat menstrual-associated asthma flares is not known. Some experts recommend the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Use a rescue inhaler when necessary and avoid other potential asthma triggers.",
"      </li>",
"      <li>",
"       Use of a leukotriene modifier",
"       <span class=\"nowrap\">",
"        (montelukast/Singulair&reg;,",
"       </span>",
"       <span class=\"nowrap\">",
"        zafirlukast/Accolate&reg;,",
"       </span>",
"       or",
"       <span class=\"nowrap\">",
"        zileuton/Zyflo&reg;)",
"       </span>",
"       may help to prevent asthma flares related to hormonal changes.",
"      </li>",
"      <li>",
"       Women with asthma who are sensitive to antiinflammatory medications (eg,",
"       <span class=\"nowrap\">",
"        ibuprofen/Advil/Motrin,",
"       </span>",
"       <span class=\"nowrap\">",
"        naproxen/Aleve,",
"       </span>",
"       aspirin) should not take these medications for menstrual cramps.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Physical activity",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although exercise can trigger asthma in certain people, it should",
"     <strong>",
"      not",
"     </strong>",
"     be avoided. Exercise strengthens the cardiovascular system and may decrease sensitivity to asthma triggers. To minimize the effects of this trigger, asthmatics should:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Take one or two puffs from an albuterol inhaler five minutes before beginning exercise.",
"      </li>",
"      <li>",
"       Start any new exercise regime slowly, gradually building strength and endurance.",
"      </li>",
"      <li>",
"       Warm up gradually at the beginning of each exercise session.",
"      </li>",
"      <li>",
"       Take all medications on schedule.",
"      </li>",
"      <li>",
"       Avoid exercising outdoors in extremely cold weather and cover the mouth and nose with a scarf to help warm the inspired air when temperatures are low.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A detailed review of managing exercise-induced asthma is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/26/1442?source=see_link\">",
"      \"Patient information: Exercise-induced asthma (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26717012\">",
"     <span class=\"h2\">",
"      Food additives",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sulfites are added to foods to prevent spoiling and discoloration. Foods containing sulfites (potatoes, shrimp, dried fruit, beer, wine, vinegar) may occasionally trigger asthma in sensitive individuals. If sulfite sensitivity has been identified, the patient should be sure to read food labels to make sure sulfites are not present.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1197110\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1197117\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/2/16419?source=see_link\">",
"      Patient information: Avoiding asthma triggers (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/11/4275?source=see_link\">",
"      Patient information: Asthma in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/58/17315?source=see_link\">",
"      Patient information: Asthma in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/31/41457?source=see_link\">",
"      Patient information: Allergic bronchopulmonary aspergillosis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1197125\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/63/39925?source=see_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/6/31841?source=see_link\">",
"      Patient information: How to use a peak flow meter (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/25/29075?source=see_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/26/1442?source=see_link\">",
"      Patient information: Exercise-induced asthma (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/0/37892?source=see_link\">",
"      Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44083?source=see_link\">",
"      Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/60/18374?source=see_link\">",
"      Patient information: Asthma treatment in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/8/41092?source=see_link\">",
"      Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=see_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/38/30308?source=see_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/11/44210?source=see_link\">",
"      Patient information: The common cold in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1197133\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34569?source=see_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/9/44184?source=see_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Academy of Allergy, Asthma, and Immunology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.aaaai.org/\">",
"        www.aaaai.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of Allergy, Asthma, and Immunology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.acaai.org/\">",
"        www.acaai.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/25/31124/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 20, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/25/31124?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31124/abstract/1\">",
"      Popplewell EJ, Innes VA, Lloyd-Hughes S, et al. The effect of high-efficiency and standard vacuum-cleaners on mite, cat and dog allergen levels and clinical progress. Pediatr Allergy Immunol 2000; 11:142.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31124/abstract/3\">",
"      Platts-Mills TA, Vervloet D, Thomas WR, et al. Indoor allergens and asthma: report of the Third International Workshop. J Allergy Clin Immunol 1997; 100:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31124/abstract/4\">",
"      Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med 1990; 323:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31124/abstract/5\">",
"      Wood RA, Johnson EF, Van Natta ML, et al. A placebo-controlled trial of a HEPA air cleaner in the treatment of cat allergy. Am J Respir Crit Care Med 1998; 158:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31124/abstract/6\">",
"      Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev 2013; 2:CD000364.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f30_25_31124=[""].join("\n");
var outline_f30_25_31124=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ASTHMA TRIGGER OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           IDENTIFYING AND MANAGING ASTHMA TRIGGERS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           INDOOR ASTHMA TRIGGERS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           CONTROLLING OTHER ASTHMA TRIGGERS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/14/6380\" title=\"table 1\">",
"           Dust mite avoidance PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/57/19355\" title=\"table 2\">",
"           Animal dander avoid PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f30_25_31125="Primary dysmenorrhea in adolescents";
var content_f30_25_31125=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary dysmenorrhea in adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/25/31125/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/25/31125/contributors\">",
"     Chantay Banikarim, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/25/31125/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/25/31125/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/25/31125/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/25/31125/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/25/31125/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/25/31125/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary dysmenorrhea refers to recurrent, crampy lower abdominal pain that occurs during menstruation in the absence of pelvic pathology. It is the most common gynecologic complaint among adolescent females. Secondary dysmenorrhea refers to painful menstruation in the presence of pelvic pathology. It is more common among women in the fourth and fifth decades of life.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of primary dysmenorrhea in adolescents will be discussed in this topic review. Treatment of primary dysmenorrhea in adult women is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28233?source=see_link\">",
"     \"Treatment of primary dysmenorrhea in adult women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea, vomiting, diarrhea, headache, dizziness, or back pain may accompany the crampy abdominal pain. The pain and associated symptoms typically begin several hours prior to the onset of menstruation and continue for one to three days. The severity of the disorder can be categorized by a grading system based upon the degree of menstrual pain, presence of systemic symptoms, and impact on daily activities (",
"    <a class=\"graphic graphic_table graphicRef65347 \" href=\"mobipreview.htm?22/16/22795\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31125/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysmenorrhea generally does not occur until ovulatory menstrual cycles are established. Maturation of the hypothalamic-pituitary-gonadal axis leading to ovulation occurs at different rates; approximately 18 to 45 percent of teens have ovulatory cycles two years postmenarche, 45 to 70 percent by two to four years, and 80 percent by four to five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31125/abstract/2\">",
"     2",
"    </a>",
"    ]. Dysmenorrhea occasionally accompanies anovulatory cycles, especially if heavy bleeding and clots are present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27685?source=see_link\">",
"     \"Physiology of the normal menstrual cycle\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of dysmenorrhea among adolescent females ranges from 60 to 93 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31125/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Many adolescents report limitations on daily activities, such as missing school, sporting events, and other social activities, because of dysmenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31125/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. However, only 15 percent of females seek medical advice for menstrual pain, signifying the importance of screening all adolescent females for dysmenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31125/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysmenorrhea appears to be caused by excess production of endometrial prostaglandin (PG) F2 alpha or an elevated PGF2 alpha:PGE2 ratio. Excessive levels of endometrial, but not plasma, PGE2 and PGF2 alpha have been detected in women with primary dysmenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31125/abstract/8\">",
"     8",
"    </a>",
"    ]. These compounds can cause dysrhythmic uterine contractions, hypercontractility, and increased uterine muscle tone leading to uterine ischemia. They also can account for nausea, vomiting, and diarrhea via stimulation of the gastrointestinal tract. The role of prostaglandins in the pathogenesis of primary dysmenorrhea is supported by the observation that nonsteroidal antiinflammatory drugs (NSAIDS) (ie, prostaglandin synthetase inhibitors) often alleviate the symptoms of primary dysmenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31125/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of an adolescent female presenting with menstrual cramps begins with a complete medical and menstrual history to exclude secondary causes of dysmenorrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete history should include the following information:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age at menarche",
"     </li>",
"     <li>",
"      Duration of menstrual cycles",
"     </li>",
"     <li>",
"      Interval between menstrual periods (from first day of one period to the first day of the following period)",
"     </li>",
"     <li>",
"      Date of last two menstrual periods",
"     </li>",
"     <li>",
"      Onset and duration of cramps",
"     </li>",
"     <li>",
"      Presence or absence of nausea, vomiting, diarrhea, back pain, dizziness, or headache during menstruation",
"     </li>",
"     <li>",
"      Severity of symptoms (ie, the impact of symptoms on daily activities such as school attendance, sports participation, and other social activities)",
"     </li>",
"     <li>",
"      Medication use &mdash; Type, dose, timing in relation to the onset of cramps and perceived effectiveness in terms of pain relief and ability to engage in all daily activities",
"     </li>",
"     <li>",
"      Sexual history &mdash; Current sexual activity, type of contraception, history of sexually transmitted diseases, and history of pelvic inflammatory disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Typical symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical features of primary dysmenorrhea are menstrual pain that is crampy or dull and localized to the lower quadrants of the abdomen. There may be associated nausea, vomiting, diarrhea, fatigue, back pain, headache, or dizziness. The pain and related discomforts typically occur at the onset of or a few days prior to the onset of menstruation, persist for one to three days, and are of variable severity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;These historical features can help distinguish primary dysmenorrhea from secondary disease (",
"    <a class=\"graphic graphic_table graphicRef78903 \" href=\"mobipreview.htm?18/0/18443\">",
"     table 2",
"    </a>",
"    ) and from other disorders. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of painful menses occurring at menarche is unlikely to be primary dysmenorrhea, because most females are anovulatory for several months to several years after menarche. The presence of pelvic pain unrelated to menses also suggests secondary dysmenorrhea.",
"     </li>",
"     <li>",
"      Menstrual pain that has become progressively worse over time is characteristic of endometriosis, which may present as cyclic or noncyclic pain. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11402?source=see_link\">",
"       \"Diagnosis and treatment of endometriosis in adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adolescents who have had pelvic infections (eg, gonorrhea, chlamydia) may develop adhesions that result in pelvic pain, especially during menstruation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link\">",
"       \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pelvic examination should be performed in all females with significant symptoms to exclude the causes of secondary dysmenorrhea. An internal pelvic examination may be deferred in young, nonsexually active adolescents with only mild menstrual cramps.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical diagnosis of primary dysmenorrhea can be made if the characteristic clinical symptoms develop in an ovulatory adolescent and the pelvic examination is normal. Primary dysmenorrhea is diagnosed after the causes of secondary dysmenorrhea (ie, painful menstruation in the presence of pelvic pathology) have been excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of menstrual pain and limitation of daily activities will help guide treatment decisions (",
"    <a class=\"graphic graphic_table graphicRef65347 \" href=\"mobipreview.htm?22/16/22795\">",
"     table 1",
"    </a>",
"    ). General measures for therapy include patient reassurance and education.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     First line treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs are considered the first line of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31125/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. In randomized trials of NSAIDs, approximately 70 to 90 percent of patients have effective pain relief (",
"    <a class=\"graphic graphic_table graphicRef71912 \" href=\"mobipreview.htm?28/52/29516\">",
"     table 3",
"    </a>",
"    ), a value that is greater than that with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31125/abstract/9-13,17,18\">",
"     9-13,17,18",
"    </a>",
"    ]. NSAIDs are also generally more effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    for treatment of dysmenorrhea.",
"   </p>",
"   <p>",
"    NSAIDs should be started at the onset of menses and continued for the first one to two days of the menstrual cycle or for the usual duration of crampy pain. Patients with severe symptoms should begin taking NSAIDs one to two days prior to the onset of menses. They should be taken with food to minimize side effects such as gastrointestinal irritation or bleeding. Generally, we use NSAIDs that are COX-1 inhibitors, because of the uterotonic effects reported with COX-2 inhibitors and possible associations with serious adverse events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of observed variations in patient response that may result in part from the pharmacodynamics of a particular drug, the current thought is that if a patient fails an NSAID of one class, the substitution of an NSAID of a different class is a reasonable therapeutic option.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     Ibuprofen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    are used commonly for the treatment of dysmenorrhea in clinical practice.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/63/41976?source=see_link\">",
"     Mefenamic acid",
"    </a>",
"    is unique in that it both inhibits prostaglandin synthetase and blocks the action of the prostaglandins that are already formed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31125/abstract/19\">",
"     19",
"    </a>",
"    ]. A trial of mefenamic acid should be considered for patients who do not respond to the propionic acid group of medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Second line treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination oral contraceptive pills (OCPs) can be given to patients who fail to respond to or cannot tolerate NSAIDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31125/abstract/20\">",
"     20",
"    </a>",
"    ]. OCPs prevent menstrual pain by suppressing ovulation, thereby decreasing uterine prostaglandin levels. An additional mechanism may result from the reduction of menstrual flow after several months of use. Randomized trials in adults and adolescents demonstrate moderate efficacy in pain relief [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31125/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The efficacy of OCPs for primary dysmenorrhea has not been directly compared to NSAIDs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28233?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of primary dysmenorrhea in adult women\", section on 'Hormonal contraception'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a sexually active female, OCPs may be considered for first line of therapy because they serve a dual purpose: prevention of both pregnancy and dysmenorrhea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link\">",
"     \"Overview of the use of estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;If treatment with one of these modalities (ie, NSAIDS or hormonal contraception) fails after two or three menstrual cycles, we suggest a course of treatment with the other modality. Treatment with both hormonal contraceptives and NSAIDs may be effective in women who remain symptomatic on either drug alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be followed closely for the first few months after treatment is initiated to evaluate the response and compliance to therapy. Adolescents who fail to respond to first or second line treatments, have recurrent pain, or have symptoms that worsen should be reevaluated for the causes of secondary dysmenorrhea (",
"    <a class=\"graphic graphic_table graphicRef78903 \" href=\"mobipreview.htm?18/0/18443\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31125/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/25/11666?source=see_link\">",
"       \"Patient information: Painful periods (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/47/755?source=see_link\">",
"       \"Patient information: Painful menstrual periods (dysmenorrhea) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary dysmenorrhea (PD) refers to recurrent, crampy lower abdominal pain that occurs during menstruation in the absence of pelvic pathology. Nausea, vomiting, diarrhea, headache, dizziness, or back pain may accompany the crampy abdominal pain. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation includes a directed medical history and complete menstrual history to exclude secondary causes of dysmenorrhea (",
"      <a class=\"graphic graphic_table graphicRef78903 \" href=\"mobipreview.htm?18/0/18443\">",
"       table 2",
"      </a>",
"      ). Features that suggest a cause other than PD include pelvic pain that began at menarche, pelvic pain unrelated to menses, progressively worsening pain, or a history of pelvic infection. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A pelvic examination should be performed to exclude the causes of secondary dysmenorrhea in all females with significant symptoms. An internal pelvic examination may be deferred in young, nonsexually active adolescents with only mild menstrual cramps. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The severity of menstrual symptoms and limitation of daily activities will help guide treatment decisions (",
"      <a class=\"graphic graphic_table graphicRef65347 \" href=\"mobipreview.htm?22/16/22795\">",
"       table 1",
"      </a>",
"      ). For adolescents with PD who require treatment, nonsteroidal anti-inflammatory drugs (NSAIDs) and combination estrogen-progestin contraceptives are the mainstays of treatment. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For those who choose not to or should not use hormonal contraception, we suggest a trial of treatment with a NSAID (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       Ibuprofen",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      are used commonly for the treatment of dysmenorrhea in clinical practice (",
"      <a class=\"graphic graphic_table graphicRef71912 \" href=\"mobipreview.htm?28/52/29516\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'First line treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those who desire contraception, or for those who do not respond to or do not tolerate NSAIDs, we suggest treatment with a combination estrogen-progestin contraceptive (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Second line treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If treatment with one of these modalities fails, we suggest a course of treatment with the other modality (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment with both hormonal contraceptives and NSAIDs may be effective in women who remain symptomatic on either drug alone.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/1\">",
"      Andersch B, Milsom I. An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol 1982; 144:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/2\">",
"      Hertweck SP. Dysfunctional uterine bleeding. Obstet Gynecol Clin North Am 1992; 19:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/3\">",
"      Campbell MA, McGrath PJ. Use of medication by adolescents for the management of menstrual discomfort. Arch Pediatr Adolesc Med 1997; 151:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/4\">",
"      Wilson CA, Keye WR Jr. A survey of adolescent dysmenorrhea and premenstrual symptom frequency. A model program for prevention, detection, and treatment. J Adolesc Health Care 1989; 10:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/5\">",
"      Klein JR, Litt IF. Epidemiology of adolescent dysmenorrhea. Pediatrics 1981; 68:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/6\">",
"      Johnson J. Level of knowledge among adolescent girls regarding effective treatment for dysmenorrhea. J Adolesc Health Care 1988; 9:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/7\">",
"      Hillen TI, Grbavac SL, Johnston PJ, et al. Primary dysmenorrhea in young Western Australian women: prevalence, impact, and knowledge of treatment. J Adolesc Health 1999; 25:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/8\">",
"      Willman EA, Collins WP, Clayton SG. Studies in the involvement of prostaglandins in uterine symptomatology and pathology. Br J Obstet Gynaecol 1976; 83:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/9\">",
"      Smith RP. Primary dysmenorrhea and the adolescent patient. Adolesc Pediatr Gynecol 1988; 1:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/10\">",
"      Alvin PE, Litt IF. Current status of the etiology and management of dysmenorrhea in adolescence. Pediatrics 1982; 70:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/11\">",
"      Chan WY, Dawood MY, Fuchs F. Prostaglandins in primary dysmenorrhea. Comparison of prophylactic and nonprophylactic treatment with ibuprofen and use of oral contraceptives. Am J Med 1981; 70:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/12\">",
"      Henzl MR, Buttram V, Segre EJ, Bessler S. The treatment of dysmenorrhea with naproxen sodium: a report on two independent double-blind trials. Am J Obstet Gynecol 1977; 127:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/13\">",
"      Larkin RM, Van Orden DE, Poulson AM, Scott JR. Dysmenorrhea: treatment with an antiprostaglandin. Obstet Gynecol 1979; 54:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/14\">",
"      Proctor M, Farquhar C. Dysmenorrhoea. Clin Evid 2003; :1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/15\">",
"      Zhang WY, Li Wan Po A. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Br J Obstet Gynaecol 1998; 105:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/16\">",
"      French L. Dysmenorrhea. Am Fam Physician 2005; 71:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/17\">",
"      Smith RP. Cyclic pelvic pain and dysmenorrhea. Obstet Gynecol Clin North Am 1993; 20:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/18\">",
"      Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010; :CD001751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/19\">",
"      Budoff PW. Use of mefenamic acid in the treatment of primary dysmenorrhea. JAMA 1979; 241:2713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/20\">",
"      Davis AR, Westhoff C, O'Connell K, Gallagher N. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Obstet Gynecol 2005; 106:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31125/abstract/21\">",
"      Wong, CL, Farquhar, C, Roberts, H, Proctor, M. Oral contraceptive pill for primary dysmenorrhoea. Cochrane Database Syst Rev 2009; :CD002120.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5847 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_25_31125=[""].join("\n");
var outline_f30_25_31125=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Typical symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      First line treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Second line treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5847\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5847|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/16/22795\" title=\"table 1\">",
"      Scoring system for dysmenorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/0/18443\" title=\"table 2\">",
"      Causes of secondary dysmenorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/52/29516\" title=\"table 3\">",
"      NSAID dose for medical therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11402?source=related_link\">",
"      Diagnosis and treatment of endometriosis in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/47/755?source=related_link\">",
"      Patient information: Painful menstrual periods (dysmenorrhea) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/25/11666?source=related_link\">",
"      Patient information: Painful periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27685?source=related_link\">",
"      Physiology of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28233?source=related_link\">",
"      Treatment of primary dysmenorrhea in adult women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_25_31126="Bullous pemphigoid direct immunofluorescence 200X";
var content_f30_25_31126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Direct immunofluorescence microscopy of bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Direct immunofluorescence microscopy reveals linear IgG and C3 basement membrane zone staining (IgG shown here). 200 X.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_25_31126=[""].join("\n");
var outline_f30_25_31126=null;
var title_f30_25_31127="Normal bowel gas pattern on plain abdominal radiograph";
var content_f30_25_31127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81896%7EOBGYN%2F56266%7EOBGYN%2F68029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81896%7EOBGYN%2F56266%7EOBGYN%2F68029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal bowel gas pattern on plain abdominal radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 482px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain abdominal radiograph&nbsp;shows a normal pattern with gas throughout nondilated loops of small and large bowel",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Deborah Levine, MD. Copyright &copy; Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postoperative ileus on plain abdominal radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 482px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain abdominal radiograph&nbsp;shows a pattern suggestive of ileus with dilated colon on the right in a patient with spinal fixation devices",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Deborah Levine, MD. Copyright &copy; Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small bowel obstruction on plain abdominal radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 482px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain upright abdominal&nbsp;film shows a distended stomach and slightly dilated loops of small bowel with air fluid levels and a paucity of colonic gas, consistent with small bowel obstruction",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Deborah Levine, MD. Copyright &copy; Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_25_31127=[""].join("\n");
var outline_f30_25_31127=null;
var title_f30_25_31128="Tinea corporis - multiple lesions";
var content_f30_25_31128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55949%7EDERM%2F75928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55949%7EDERM%2F75928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tinea corporis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5XooopgBpKWkoAUUlGaWgApKKKACijFBoAKKKKAFFFJRQAtJS0YFACUUYooAKKMUUAFFFFAAKWkFKc0ABpKXtSGgAooooAKKKKACgd6KB3oAcKU9KbTj0poBlFLSGkAUUUUAFA60UDrQAtFFFAAaSlFGBQAgpaMCigBKB0pSBSUALmjNJRQAuaSiigBR0opBS0AFFBooAKKKKACiiigAooooAKKKKACij8aKAEJzS470UUAIaWiigAooooAKKKKAEopaKAEopQPWigAFFJg0tABmikIpaAA0UUUAJiijmigABxQTQPeigBc0maWigBKKWkoAKKKWgBKB3oNA70ALS5oFFUgA0004001IBRRRQAUUUooAKKKKACiigUAFFFFABRRRQAhGBmil+tFACUUtFABSUtFACYpaKKACiiigAooooAKKKKACijFFABiiiigAooooAKKKKACgUUUAFFFFAB1pOlLRQAUUUUAANFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFBoooASlo7UUAIaXpRQKAAUtAp3amgGmmnrTj1pKQBikPWlooAQUtFFABRRRQAUUYpRQAlFLQaAEoopRQAlFOwaMc9qLgIKKcUPofwqRLaVuiMR9KAIcUVei0u7lbCxMB6kVfj8N3bJuYAClzIdmYWKK6GLwzcuQNrc9Kup4Muz1GB60uZFckuxyOKMGuzTwg6ElyT3NSweFUZiWH4GjmH7KRw+BRg49a9FXw1AoXMYP4U9vD0WeYh07ClzoPZSPONjelAQnsT+Fejx+HImP+rH5U5PDUKnJUDnsKPaIfspHnHluDja2fpRXpo0QFuIxx3xRS9oh+xZ5dRRRWhiFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUClxQAlFLRjjNACUUUUAFFFFACinUwU4c0AIaQ0+mnrQAlFLijFACUYpcUoFADcUvFLg9utKFJ4AyfQUNgNowT0rVstDvbsZjhYL78V0mneDAVDXTseOQBU3SLUJM4gK31/CpY7aaQ4jiYn6V6laeFrVU+S3/E1uWfh+2iXLRjHoBU+0RqsO3ueQW+i3suP3TDPtV+Dwpey/eG36ivXo7O3OVSILjgVbisIwgO35qn2rL+r2PKIPBTkgyMT7AVrW3g6EfeTI9TXpK2QzgJzUiWXooAqHNlRoxOHt/CtqAuYRx3xWjFodtCmPKVifQV1SWxHb5T6ClSyy+7oB60uZlezRza6ZGoyIlH4UxbFIxlk4PYiuq8gNn5VHvimyaek2R+FBpGC6nPR2mOW2kdRirPkblwAcfStFtK2FW3/KtV5RIFAjPvSuy+S+xRlsdyYA57CoF0uYqCcCt1I8L82AD3NSLESNwz3707iSMEaXJgsp496iFvMkhLITjjIFb5Ug+mPQ5qaOAsMkED+dK4ciW5gKhAw68mpo7QBeQCetX7q3jL/KwLY7VNaxEAjbz70luEqaSuZ6Wg7ADNFbQhB4bjFFMzsfLYo70UV1nnAaSnCloAZRTiDQM0ANpR70pznFGKAENJTsUDJFADaUUvNHPpQAlGKMH0pcUAJRS0YoAQ0AetLS4zQA3FGKdj1ptABikpaWgBKMUUUAFFLRQAAUEcUo4ooAb6UU6kxQAlJTsUuD2oAaKcKKUDNACUhp2KMZwO5ouA0delHXvV600u7umAigc++OK6jTfAt1MFeZtoPYUm0hqLexxaqScAZq/ZaPe3bDyoWwe5GK9V0jwVaW21nj3N/tV1lro8MKKEQZqHNI2jQb3PJ9M8CTyBTctjPYV2OkeC7O2VWeMMwPeu3W1VD8oHFRlQSQDWbm2dEKCM+PT7WFcbBkdAKmSyU4CRgKeOlasNsi7S3OfWrRCgYwAPakbpKOxkJpiAfMxHOcVeSFMAcDApHnBbCAsR2FIsU9ydrDYvqBU3KUW9ylcwpJKBGmGHcd6uW9qVQAjH1q/a2GwN3b1qyISmOSWHenYU5aWRnrBjkcjvTmhCsBg81f2DcCo5oRMk8Z96RmU9mHyMUMu5ecVb2ZPGKTyevTFA7FHywqZ3HJ7CoHVycAnntir1wNoH3RUduueWH/6qVzaMLK5SSyZ2yzEipVtERvlHI4rRZUHAznsKYiSAfvSMdeKBNvoUJYjGM4yfemDqRjA9TWg/llCpyQfXrTUtVC4Gee9G40lbUzgAsnVT9KSb5h8rEc9KvmyjXLJuDd81G0YzhsEjjNLYpJXK1rYcFnA9jVryCVG3IPtVmEZUDPzDipwp47U0ZSk2UvJbq3ynuKKvlSeCBmimZ6nyAUJ6ZP4U5IXb7qMfoK9ji8M2q8iFSo7Yqwvh+3X7kQA65xW/tEcSos8cg0+5mb5YXP1FWo9Av5P+WQH1avYjosLYIjAXHAFSJooMe54c4OMYxS9oh+xZ5APDOok/Kit7hhiibwxqUS7mjU+wbmvY4dDVsFFX3BNTf8I/u3bsKDwBnNHtB+xPCm0i+XhoGB+lOh0a7kBUwSI/YkcH2r22bQFiJYDA9QM1XOkeYo8o7geoJxij2hSwzfU8UbTLxc5t5M9MYobTrsKGMD4PtXuB8MsqKGbbn1GcU7/hHnVh+8Qr0G4daPaCeGfc8LFhdkn9xIPwpx0+7UcwSAfSvcZtJMbDdGrZOMgVZTRA8WWC49DQqgnQaPADazqPmjcfUUfZZepjl/Ba+gRoVizFZIz0yAFzVO60WCFw0LAAdnTrT511BYdy2Z4T9mlC58t8fSmeU/8Acb8q9wl0tJn/AHdtGwzxioZPDzSAf6Gqt06DFNTTH9WkeJ7e/NFe3jw3EUMc1jA3HOEwagfwhp8iKGtcYJ6UcyIdGSPGMGkK46169ceBtOlO9EdeOAOmf8KybrwDEWJinfPoafMiPZSR5txRj6V3zeAmHSU7u3HWmp4HVmCmZlx95u1HMhcjODxRj2r0keA7JUG+5kyeh7UwfD+KUM0V1lR69aOZD9nI85xRXpEfw8UoP3xY+3aoV+HjmUj7RhaXMgdOSPPQM9OaXBr0Vfh2dzA3B/KrMPw6hPDSuT60+ZC5JHmNGK9Zh+HlorAMXZfUmtCDwBYFD5cOfQtzS5kWqMmeLhCegJ+gp6QSMMhGI+le4/8ACNWdlHtezTJ7gVLHpFgo2m2QA9eKOdGn1WR4dHYXUjYSFifpWha+HNQnIxCQPevY20aHzA0EGPbbV2HSSqj5dtDmP6s1q2eY6f4CnmwZ5No9AK6XTfAUFuwY/P8AUV28NsYl+Zc81et9q9fwqHNspUEjE0/RYoMfKvXsMVsx2aoOACvpVhXUnhee+alUgHBI+tRdmijbYZFCpAHarUdsCcnt0pIQN3T8qm2sRncB9KB2GfZg+QuAB696qz6bKMmMAZrQjG3jPPepS3IAP5UFxlymULG6bbulxt9BT/sDOf3sxI7gVpgEgluQenNOWInGAPrSL5yta2UUI4UHB61IU6gDH0qwqbgSDjtTiq8Dbz3NBLbZXVWGNx7UsituAIx75q1tAIAHHoKWVV6tj6HtSArLHycGnbBg7cn2qQYJwCM4wOakVWUEcEnnPrQNjIYVOSVAzSNAMfKOM1bjQHnBP1pyqSflHGeh70yTNezEm3cvWqklo0cpKfTFdGYgF6EHtSLEDgFfmHek0mWqjSsc75cgK/JnP86YUmIG0EE+ozgV0eBypUdfSozGAXb+IdMUuUpTW9jnfKlRiWX6nFAlVCU2sPQmt11V+CCfXNVntF3E4HPU0WtsWpRe5kecP7jc1CtvJLJuH3c1smxKMSckfSlMOF4GAfalYOZLYrJbiFMseneozPGGOSfSprrcAFdfl7+9VGgL7Sp2j2NF7AoJ6sn+0RHHzDIPr0opjWyFFKjcS3PtRQT7OJkJYkIeNx9T2+tV5lWIAbPxPIrrhbKy8KrAHkdAc1n3dgd52xoTjp1FOWxFOEW9TFVeEJRRzwwNXreNHfDgL6E/yqXy3iQ58uJzyAB17VHZWpLkzswweoFJStoaugmr7E8dgpzlVIHQgdKmS0wB5jKQvC4Xqa04rbYmVck9CcU9UADKGOT69q0ujmaM5tP/AHUh4AyASKyLjSfJVpIEY9zjpXWjJYbcNgck8DFJgbiSoOTnH+NJ2ZUJOJzFmRcr5ZjVWUDC9enXNEclsj7PMicZywUY/AGt66tIJcDYc4OcHGM1SOlWxbAHJ6YrPXQ1Sg9TIv1V9pCLuOQpbqR7VNp8MmwDy/0zWyNPV1jDyl1iHyBj0+lWY02KcIOn41XmErKNkZ5tgyktGrAe2OaqXGlRzphmK+gxmtvBzlcqCOf8afHGHABILHnpnFO5jH3dTjv+Eflik3xHg9c1fj0+VUA2845ya6Ro8E/3j6Dj9aikjDKCFI/2zSWmxUpuW5gNYnccqVPQ1ELAgnaTtb9a6HyTtAcHOeoqB4CrEEdeh707kNXMJtOIJwMYPrmmNYq6nj2zXQNAGXqQe4pi22ByOvei5PKc22mqDkjIxzxTG0mE8bRg9wa6V4AFOSo9iKgmtgVyVAPtVXBRscvJpXlkp5WUznj0quljAqEujp6ZOK6k2xjYNycVHNDvU4UMPTHSjmK0ObFvGCwhnaPjoaW3+RiJGWTIxu6VvtaxsB5kS5HQ4pklqiuCY1I7n0p3QWiyokSsQFxj6VZ8gBcLgY7+lOZAVAQcdamBBQjGeO1FyWiKK2O3gBl75qxFEF4TI9qdEU4QHHvUkf3iCBu9aQEUkYdgsig+9JPaR7WCADv0qwSof51ye2KXBJyMgEd6ClJoqRxpsAAwRSSw7hnJx9MVdEe1sgDnpTRydr4NArtlIRo6kc5HakS1Zmyrg8Zwa0xaruBjxk9qZJaOjZXANFx6mf5Mysflzg08IP4uParLFlbnkj0p4ILdc57YpBcj8sY+XIFPjVj8p6e1WAocqRxj8hUoQYJ4zmjcCIJt+VetSKv8RA+lKqncOTge1WREcZxn+VMLEaR7hkjipnjChQASO9PVCcAnB9BUgRm4I/8A1UgIQDyBhV96ekfAI4P86lEfz/JjAFKVIGMjB7UWGiGbdGT0wO+OtZ885cHywWb0FT3Qlc4iyR0wTinWdqsanIGT71LOiEFFXe5SW3kOSARirCswQZY/U9K01wU5AHP6VDdIPLO0KyY544pDTUnZobayvvAZg3FaClwvygcVj2TATLypB5wvatmJfMc56GmmmjOrCzFUNjBB96CMnOcHpipiOOOp9TQeRx1HGaZkV2j4IwfemqBj5ev05qywKdGP0IpjIDzjGOhNAitKuVyMDtzUBjbdwRj0q468ZBDEdsUwgMQwxn8qB3KzR8HByRwO1NkQqxHSrMkZIAP1AphyMt9496YJmVequwnOWHHXtVS3UZO4cDpW41ukmc4Pes24sjn5CQo67alrqdEZxa5RhD5KgDHaiqzmWI/3s9B60UuZLcv2cnsdIYWC5TBHJwe9V3RJFKkZHcgVpFNsTLk5HQ57elZtxPHBG5LYbqFA61TOeCb2IVtIgclVLD8hT1g28g5Uc7TwKqi4kd22gcDo3anI0xY/N0OPUVFzodOTWpobSybUGAOppoUhAzgBc9feo0uWjOHCgjue5qVnNygHQE5JxVXRl7OSeoiqTuxz3IBqvdP5Kr1Pfg1oQ2UsYBQFh1JHNZ9wjNPslYLnlfQ0PYqEFzeRnO1xIxYbwrdF7mnKZd2xCwk7E8Ct+CAEJvXe23BOeD9ae9rEcjYSw6N6VCTL9pFO1jJhlcuu/GeuR6VoGJXCnOfYdM1RmgIm3qRszgj1FWLKREuAAEA7jOB19KqL7kzp3XNEkWEocOeSM89qlWNVIKce4/wq1K8ZYHcvynpUayKWdVcc9Djgiq0OfVkYic5ZSCem3+tRFGYbcAc5+tW8l225UH1FPGGYfL8oGD2pktFJo8jA2hgOg61EIdwweBxjmtPy1xyTwOMnpUJiDtjBA7UtAKZjjZeR82fTmmm2ydwGQenc1pNa45HXqeajjjJ7ZI7UrCMqS3GeSD6AUzysJyCeex6VryxnBYopx0OKjkhBzkkYHGKdhmWI1KkkBhULRJknjHoOcCrrhI+CCWzwKoXU+8sAu3HcdvrSbLjTlLZDJIMLwBntnioSmQEZAQRyfSnM84UcbsnII4pEmbcdyk5688U7jdKSKrw+TK3dT0yKXYMnhTzz61oKjFeMED19KbJHu5wPw7U7mfKUSgRhg8U9dwbA6dQPQ1OyZ+Xnp3pvlFeD09zxSDlK0zOGHBBPepo23qpIzzzj0pzp0GcgjvTQhUdecYJHSi4+UcGwQM8A9DT5Adw6FT3FRPjbzwRzTd+FGOR14oCxYbACkHaQOKfBPkkSHP1qr556MMioJAd5KggUDSNKZEzkEbT3qKROcq4PHIqqlwdwHap1kjlyDkN7dqB2JER0HqD6VPExBGVI+nNQxsy8hgR7VZXdJ98YHtQh2HeWWPfNWog2zrjikt12JgDP41aSPktjntinsSyOKEtg5IPf0/Op4oQWKnOBwD605H+bDDAParcQLL1A/rTJdyFIQCM4AomiR4zjI9MmptuVyeSDxThGWYYAAHOPWgE7anPSW2GO8Z9DnGKtWy5T76qwHrV28hL42Kv0FZiQvGX3xkY96zaaZ1r31cuqqZX592eOOaguJoCfKUtux1HpVfzGG4Y+70wKbb2krybzu3MOMUr32LVO2rHWUGZwIwcDnmtuCE85OM+tRW1oYlBzz1NXFZgckYx196pKxz1Z3egwxY6Aj60gDKMlRipCMgAj5qYykdckHp6CqRiM3BiBnHtSEfMSM0rbdxwB6dKFHqeDxQIiKksfmwaHAHJOSOgIqXqMA1ExA5HI9aAIWyeUBGPakj3H5Tgn2p8aOfTJpfLIKnjcOvNAyu27IxgGkdW24HLe38qtCLJPBz6ZpoADjPU9RTsFzLuYFC75Mfh60Vbv0bYVUceuelFRPc6qfvR1ZZvC6ABPmJA7cCsxofMAJZdx5yWyB9K1L9Qs5AOCxx8vSq8cUTZVSPvfM5/kBSluOn7quLb2amEZIMnPJPGP61LDYxoig9Sfm7VatoPk7r2AanfZ1QIRITzz81CIc3cqfZo3ym0c/wAQGMUyW2EBX5wVByeOnHetR1hDpjAzjAJ5pk8QbcrhVU9MnIoBSZQjlm80FGzEDhqjvbVi6n73dQOoqR4ApDk9MAY6Y96t2USMuyTI5OOf0pr3tGW2l7yMy2mdVPm8MnvxmrCbmQs5LNjqp4q7cacsqHb8vue9Untnijx5iBR3GefaizQe7LVFaeMyqRwFPAfPNQC35UKu5xwe+PerAtI7pNsMxfA3EEdD/wDWrTtLdY4Gkk/hxn8KixbkoqxkNaN8r446YxjPNH2Z1JCLuOSRg9B71uJCGYeWin6nJprBXZlxtYjHH8qdiPaMx1zDcAM5PQ4zWnBIsnYAdMZqGSybJeM4ZuDznNJA4RURRuXOSc8GqQSipK6LpiHBxkfdzQqneDg4PU1OvMfzfNjvT448KBIfmzn6U2jmIGDhgqqSD6etIiP5rfLjsRVuKNTtYEkA9DUrIC2V529vWkSyh5OWKt2PSo5Iz5TEKC3rWmYeDlevYdqYyBoyep55NUhXOWuY9xwW28n5iOlR2tmjrnhuPvYq9fW8nmKFyvPIApkZMRTBDA54rPZnb9nQhktI3IX+6c9e3pVaewQglcoOvStRTkAYwSckLQ6jOfmAA6mnuQm0c6yyW74wTz34zV2IRuu4MAT29Klv4sjIDMPXrzUVlEmTjCkdcihPWxU4px5kPaFVDA846CoWgwMg5+tajxFeQR0pn2YHJ5yT0qmc1jOkiGcfxGqxTyyMjI9+1a5tcj5fvdeaZLBu6rx0pWGZTQ5UFV3E+9NMBwvylce1acUZyQDsI4pzQiQYLcnnpTGY/K/eCkdM4qvNKqhsEbgO1al3DsVmVR17dqzfs7TsCgAx94Y5NI1jTT1ZTe4DL8mOeQcVEJnDjen07VrLp8edzphc9BS/Yt4+bG4jj1NDRqlDYjtGV2wuR2OetacZYOFbrntWHHHLBdkDJI647Vu2C+aPmQjjqxpxuyKlNQ1LsUeBgPg9+KnjBQnfjcO3qKdDCQ45AyOtTGFecncapo5Gwj+Z1wBjPX0NTquTtOB/tYqBiqJywGOoqJ9QRQVVS2Mc0tilCUtjQVNqsScj6dalhQMSBzWdFfRuoyv51oRTKVGxgA1CZLi1oxZkBV+ME9ariCNymQDgjGeasL+8JyAW57UYBVduOfb7tBSlykX2GIp0BP5UnkmMFQMe/WrALAgHJp4GQQV4pMHJlZVwNp49zTinzZB+v1qTZhsEjHXpSquORxQSQyqdwyfpTSFLAZOPTPSrMkYbBwdw7imeSqsShwcUXEV2iGwAZJqMKd3GeRz71d2Ek5Iz6imOBuweO3SncCrtbrtPHcd6h3EnA4NXH+TnpjsD1qtK6RKzOOcHgetBSRXeUxZ38Y/M1UnvGPEYwOm40X04blR8vQknrVWyTMhVmyD1XrUtnTGkrczJ4NRKkAgMfY81owSpcD5Bz6d6qpp3n3CxQbVeRtoJ9PemadHDHrfkrdMiZ2wzBeGbtkdue9NNomUINNouyqSpQ9emD2oq3IhE7rKP3gJDE9270VTMFNrQzNQBUsVbBYYBxyKm0lTGmJMDdxyBkmn3iZnbPyhT06bqbaHa+7aS+OPQVk9zr3hYuGR0RycADsBxUIMrYmklwHXOOmDU8JAQuSuCPumrTxrLGJCMKOPUt70NGN+UrKheWN1UGTHUDipBbq21mBBzgY5qRQkWXbIKgDjmnkbNzD1+76UyXLXQzb+IInKsxI4Uf560WzxyzgMo3E9jjBqe7RG8wTGVd42rtGSDTLO2SJ0VST/tMOaa3NU1y6mmATEwbselZuorsiLDaDxgZ6VthCABnnr9R71m3sAMjeZwp4IA/lWj2MqUtTM0/lpQSgOeMCtJwqxA9/5/hVS2dzIoyu3G1dq4OPc1pxw7I26knjntWS2NKr1uyhtDE5+8euOPwp2xI3Kn8PrVuaPaxKEkkcADmkSHdG+8cD1PU0tieZFaWMNETnIIwMDArLZ9gChThieTW44UR8KeeMY6Vmuq+Zu2jb90kdabNaTLtj+8iBdMBe2e9WTlMbRknFOsrfCfJjOfz+tWFhBII4zkVZzTkruxDCh6kYZuMDtUmMZ9PXPNPKc8g5zjinIoDnod3FCRm2REsGx0X1zTDGSxYkDv16mrJUEdsDpTGHy8DODkf/XoC5RuoAxbAG7HBPasG6ikidlVG4545rqvLVsAc+vNV5LdZJPu4x3qXFM3pVeXRnOCfyyQ2QSMVG17tY9OOORnNbdxZRtlcHHtUR0lf4Rhsc96VmbqdN6sw3mLA9QpyAB61b0+yyNzAru961INNihXLAluuTV1IFRQVX2+lNK2rJqVY2tEoNabMHG5ehx3pghHI6c1punBAGPX3qJ48Nx35ps573KcaDIBwOfSmiFQS3A9QaseVuBbcQ386ci5B4/D8KAaKD2yFs4Bqp9mZSCp3KTnHp9K2QmE/hIHaoZVwobnd0oHFszZ7VXRmbIJHWsp7UxkkbySRtx9a6TbuBGM8YAqG4si4bJBb+HAoaubU52VmYThlLogGVwSD1pg5+cKeCOa0JbZgmZcbwOAF/nVWK1uQNsZYAHg0rmqimZ1xsaZJLfqR82T3robOPeqs4yGHJFU7XSpC4eVRyenvWvBGyJsIBPTpTWhlWkrcqJUhUYx933pt1IETggZ4z6VYxuXBIGMEVQ1KJiASTt9/Wm2zGnFN2Zl7DdSnax3D0OamhtA0vXaV6n1pbeIRj5sKW/i75q9EjKVORjP8XcVKOqUuXRFWe02fPEd0bHgZ6e1JaTm2kCyDK+g7H0rSdGwW5APIArHuUKzGTc3ynPJ4pPQUffVmdDHJuVWOQDg4qdcKR1Yn8qo2Dl4wRkdiM1oRgBOSR6HNWcclyuwbMHKnr29KFVgcY4PWpOgy3XNJJztwSTnPHSgm4wcdqbhSScknGal+VgTnPsBTtgyCcClYLkIGUG3getAUry2AMdan2bQfl49M0wryMAgGiwXIwu7BH1+tNYEkqB9KlA2EDjpTTkk4HPUCiw7lW4CquWO3HYjmsW4uHaXJ444Ira1DAjBHXHT1rnpTtDNJhQWGMDtRLRHTRSerHmzWRFDEqcg9e9RrbCC4yMhjxnPetSPHlgj0yPSmr5bybQq5xjI4NKw/aPUpx3UtrdRPAu6QONmBnJ9K147J/ti3C6HKtwG3DdONit67ev4VSt9sOp20hZV2ODls4H41LBDbwTyZ1a2YMcgszZ/GmlZ6ik7rT9S3tky5m/1mTnPrnmimhhs4cMDxuHQ+9FWcqJNQtzKhI+Xbzx6/Wskk5HAWRj1HArpnjDJhiMflmsi/tdrmaPucVDj1OmjUWzFhZDGyk/KnXAzg1ZhYSK2VGAcAmsu2jdHkdV2vj5sjikbzo7ZWXl85JHIP+FTsaOCk7XNz9yYyN/XqAOlRB8IwUg9wB/WsyCdkCrMSgYHseO3NKisLYRsWBbo3qPShMn2VnZsdI32kOFlYOHBHPX/AArXslkMaB1AC+g6msqC0nlnV2+RPbit61RkKjlu2OufrVRT6k1mkrImLAHLAhsY461Tvo90RwNp5Oc1oMm0ENn1z6UyWIMOQCoGeD09vrVnJGVnc5hQUmy6qAxwG9PoK0VuQkgDkFscEc5NJdWfmtkRjyx19ajCNDINg3HBAGB0rNxaZ2tqa1LjMh2szDPXNSCQEk52jNZRnmJx5bYHHT+VJOj3EQRSVZWyPXGPXtSuT7LuyaedVkGwMQORnpgUtrCJLnhcLnJx0qqkUjgIAOvbr+NdBYwRwxBAvbk9aaV9wqSVOOm46NCQQQQOmBUgjHbIx71Jt+fgHjuO1KV+ckdMVZxtkQwBxzz370jBQSB1PFKcBivvRtKnBJBHU4oARlO3acDHpTXXaME8VISehPy4HT0prEsn3icDHJoBEHygnJ4HTFIpGcHPI5qJ5liJfI3Y9az5ruRpMRlScEjAPPtRc3jTctjTkXJzGR9fWmoWBO5TtP6VkpLOjr5vAX72OK2IJY5FKscN054NTe45wcEOMYZSAOD0zTwoC9Mn09KcqnOeoB5zxUgQEDHOf4qdjFyKzJtJwPmAqs4IIPHHNWZVycZOT7YOKqXkhi3IoOcd6C4K7sipcXSxAkjB6cHrWb/aEpJ2R7ge2cfrUsUSzXeyY5Xac44J9qtW1kgB3r8u4/KOPwqdzsShBaoqtcyEYAGOOant7kSt5R+9/OpHtjKWKjYMdM4qm9u8bEpkEfNSdwUYSVjTZQFBX6g06JcsGznnpTLSQNGC2cjr71dj27mPBIqkcsk1oRtGruGcDAFI6ImQqj/GrGQwPcdxQ4HGAaZHMzPkRj2IGcio1H7znJY9OK0ChfBGcduMVH5SI43ZDDvnrQ0O4yFQYyu3nvmqepR7oirZGOh/CtaMLkkcf4025VHRhyeMk0/IIycZXOWtN2WXad2eGPNaAiXglvmpk9jKp3xcY56cmqNw7jb5qenIPQ+9Z6rc7HHn1RpMwUFh8xArOmlMhwFHA3Z29RQ9xIEKKSMdz1Iz0qSK3aWUOj5HUk9D9KHrsOMeTVmhpcTC33HG4HOPWrke0hcEgdeafaxKkYGMDHbtTiVUlCoPPerOOT5pMfyeCBShTzgkY4NNVwD32n8qlIP/AAE96DPqR7AvJHepMgrjjP8AKmiMqvznJPTmhsAcelAtB0r7Ux/CTUYC7QU9cfWhWzgNnjpSqMcDgn0FAbARxz9KG6HAPSlRuozuNMYnPB6igZFMilDndgjBwM1zWowOAQqEg9zXVg/Mcjiqt7EJoCuB+NFr6GtGpyMwtOuD5flsCNo5+lSxzq0jc5Yc5qDZJGxCqPTuMj1qlNC5lZo8+vNT0Orki3c2YNSRB5ZtreXJJDSLk59KjuNQWOQN/Z9gT05jzmscB1CA8jsKfvDyxpJJ5a5GWxnA78UXdg9ilqXrGZjMylduTkY6DPpRTY4UaQmCUyp0DMmw/wD6qKuK0MJxTZ1zDI3DqRimfZ95y34ipFbIAUj3x2qVeFO7GaLnO3Yq+QpO1gPqRVWSzRiRghSe1aMw4POB1603dgEgE0mVGTKRsQ6r5hJA7Gp0tI42GRnHAzVleWPy9Rjkd6VlG8KR14qrIbqPuPRAEIA4/lSxIVXGckfz9aWOMlRjr70+FAqHoev/AOugybFB6jjPTKilwcnIGPp+tOUgAcE4xk4p/bJ4IHGKCbkEinC8gqfWoLmAMQO5PHPapwrv06ZyeaaF+TJyM8YFBcXYox2qsdmcgHIwelTR2ihgTjnqBVgYQ/KBtzk8VYjXCbmJ/wAaVhyqMp+UFbpyR371ZjQqM/Nz3NSEfOBj8h2pGLHjlW9cYyD2oJcrigDBD8DsKd5YUEtx2BFCxknjoPXoalcYxkkn09KDNld4wQD2I5xUTNsIzkYPQ1aZQFDdPoetU3LAsQOBgHPWguOpHcSbcucjt+FZz3MoBWNdy4znHSjUTIduxwRuwFFQW0LurOX+ZXwBjjP+FJvWx1wglG7GB5iPM2rxk/Mf881JDHskMgzuPOG7fSntH5JkMreZnkEcd6ljkEiIGIIXv3JNSVKWmgPGJUIPVvxqoo8uTd1J4Jz1qxcyKvAfB6ZA5oigAmROWJGMkYpPcUW0rs07UFkJYLzmptrE8rgZI4pkO7btGAeuPXipHysgVCSpHJPetDke5DLD5TZ4z61l3+Mk4zu4yK3SjeWPXHfmsjUIS0ZxyBycDFD2NaMtTPtvncMI9u7jkZ/KrjJgHYD0yQe1V4ZAHJwFXGM9auW75fao784PUVnHY2qN30GJG3lq2OQMcnFUrhTg+Zyc8H0rTeQIgz07g1mXczqwzF8p4De9N7BTu2PsoCJHJPB5GKtxRZJYDA6596lsYmNugcDdjPFI+I1b5sD0NVymc580mhZAF+ZWwBTfNKkZxg+/NY99qDklYiA4ByM9fpVKO5uJlyzNvBxih6Gqw7avc6fzF2DIOPSmzDeDkZrJivZVx5g2jO0g9q1bVWljYjGM4xnmhO5jOm4bjojkFCp44pyRnzARzyKbENu88nPvVoKcEg/N1FOyMmyF1DDG0jGRWdc2W4sEzgn5ufStoAZyOCcc1FJEMEgfMeenNBUKnK9DCXTQAxZmY98HNXLW3jSMKFOzt7VcAAOQOQeRSFB1HH0oLlUlLdkaAphQD9T3pGHXjBx1NTZAAyMjHFIFByxPPUelIm41QNu0jP8AjTwHAGMdfyoXaoJHJPAxQeOSRSsTfUVvQDjrUbHrgkD6UM4Y/Lz7Ujk4BIPPUYpisCZ69RnFRZKABjjnr60kp2DknHas6/uWXGOQOetBpGDkzTB3HdnoaAScgYGaxINVUKQ3OT2rXhnVlBC/KcdDQrMqdOUNyTBGQenvTSxAPcD1pFmVxhTkd+KjcknB6DtmnsR6g4RmOVHHOaYsUQUgKOR3HelaTcMKASOuKVvunAxQMjt7aGe7ijlRQrtgjoSPSrMWnxw+Xi0jM1zLho2XOyMcYGen1qCKFri5RA2Mnk+nrV6QQl7d1e4Cys0ZYtlvQfhTFKTvYyLlEtjLHCB5akhfce1FLqCGIygkHZlfaii5rTV1dm6gXaoXH+e9DBSCYzkdzUSt78Yp8f3Tk+9I57D2wBg801ePUE9zTVIyTnOKeSeNpzxSGPUNj7ucevapdo2kn8aiVyqDAH4U7zA3GRn61TJswVTnI+76YpyOFOMHk+vSk34LAn24qNpVBGMY64pBYu7lI5xnOM9abwHI3c1GrjK8Dbnt9KWR+CxC57CmTYeDjbn7wGOac5IX5RliKglk8zGG59cdKY0gTkPg9c5oHYljB3bWbk5x7VKDuUBc5X+VUEvEZgHODz9atRPHIFIOMdeeaQ3FotuxYHGM9P8A69IqnkFeB0NMRkZiRxz09KcASSRuC4ztpmY/cUbht47YFOlGDkDPt2qMDaW+bIH5ipcDb1IOOnagCEkkrtHBGar3ndCc55b/ABq0F5JOB6n0pk6qYSFXn1oKjuYN6rBgwyyAfd6VYt0jMeWUYbkAGo5N0kGGyGBOc9+aijlki4ZcBeDms+p17qyJZwGPII75HSoREPvAgoecnimyTeZKzH7uCMDnIq5p0YdVXkKvGD0JotcbvFXZRmhlmdRGikDgHP3hWpZwiLIzl/p0q6kWGUYwmOtTeUoIIGONuc1aVjCda6sRxoWxx0I+o9qDECM55U9qsBQin24o2hgdo/3aZjcidMhsMMDtVK9iLRFupJ69hV3a25iw6celMlBHA7jr24ouVF2ZzM9uyurAEDJzg5FOhuPLchcHoDntWqLYyI4U43DB96q3NgFwejZBz2NZ8r6HYqsZK0ipNd7QSQwAbPTORT1ieZY8gbS2W9vep/sTbhvXHfGM1NKVhh4HKnIC1SXcTnHRRIZrxIAoDdO39DWRe37yqPLyVPfuKdIks0zIqEA5JBxyKnitESLawJJ9elDbexrGMIavcyooxJOQ+1lwcEjGavRwqkC5UBj0/wDr0WcLRSsHQDsDV+ZVWNcsCcfwjvQOpPUzbuNlCl23DHOD0rT0OdXjK7veqc0OQoOCD61Np+IroKcbm6YpLSRFS0oWNKVlibJwc01buMHZuHJxiqOpykyEKPuj14NVgoaN2bAPDcf0NNy6GUaKcbs31dW6H5iB0HSng4xzye9ZGm3WGVXIKg8c+9a24kFqE7mE4ODsMcHflfYmk25HH44pwYbk65xzxTWyFHBwaZNxrj5c859RUOGYLz1qRc7iATuz0pFAL+hHaixS2EUnGDnPXNJtJAycd8YqXaDtJ4wKcVO3IIBpCTKpRlc4wakkIB684pY0fGG6+1JIgIw3UUFXVyOUB1y20iuf1XHC9OcntxW+g3HaTyPTpWXqlq0zgxY2g96GtDfDvlepiRIq7+CACOc1paRIP3gboOOe1ZlwssZIIDAN+Qra01FhtjkEsefrUQ3Oms/dLqBQTtXluTUq4KnIz1Aqs7jnC4xThKMYHX0961OFoVmAYKM56ZpGP+1kgfyphZTuHP4UhKn6DAxmkA6BpPOj8jJk3DaT61q4ugF22MQkUllPmA4J6nFZNtOkdxFKwJRWy2KtRRRR3Ina+jZVbdxnefbFNEyKd9DLFuEy4eTnOcg/Sipb+aN7KONGUu0jS7c/6sHtRSZpCTSJ1wpxn86nDblJXOcVWVgRjgMDnrVpAM8AZ+tMl6C5HynFLuJGccDinDA5AGB/Oo3+UjJx6UiU76jFYrkYz9aimukiQsx2+tV7q6EC5Y8djWUXkuZNuRhjkkngVLdjpp0nLVl1tSzKAHAXse/TrVsXn7wKpznocf54rNS0Qg8HI6Uk0bRKpAy+cfLzSu0auEJaI6KKUMgIYc9MGrAPGN3J/nXMWNzIpVXJZO9bsExZfnIOO/rVxdznq0XBi3M3kK7kjjnrjn1rKmu5XYBGGW7Z5FP1KQSR/MQQc8D0pLO18zDqCoxjGaTbvoaU4xjHmYkbyqhcAj2J70+0vJduxgN5yN2eSR3q3BBsUq4Geuf6VQvbST5fKUgk9T9aTTWqGpRnozZtrnCgMecc5/z3rQSXMYI9OcHNcqJZUfExKPj07VrWFwJAyhsLj16fjTUkY1aNldGurJnGGB4OacJNrnJOOoqskgEYOODnOB2qSIbss5IY9DVHM0Tff5BwfTHWhuMjkLnPqc0FDgEZx14pBwRtGD69qCSo9nmUg4IPcmoHtZPm6MvUA/4960t5QZxn68U9QTjJ2npwKTVzRTaMiKxXILDgduwrRtUSJVwORz6VIyBCVXjj8Kb5ZBXkc8jihaClNy3JGBVCQM5GenapI9p2ZBA96jGWzuznPWpcFVzhVApmYOoyfl5z0pvRMdBnGfSnkkgkg/401uSB0z1oAjO4r1x+FMRVJw3p0qwQCV7jtUW1RlQM89+pNIaIWQKcKcDHQUFCCA3IPHFP+bacAAZ5FODFQNoGevvTHcjMYC8jpzWVqLBAWbBHTArTlbliSQO5rF1AoXfcSCSMc0pbGtFXkNhUJI5UbgDgYPJ96uPGvQZCd81FZ+XgFCx4xkjnFWpFUp/EzYz7VMdi5y1KTNGu4GMsevHeq77Zo3U9uQB0q3cgBSw5P6fSstpF8/ghl2sp9Qf896ZpTXMRvMSNxGCBg5NXrKAu/nPjI6VnWtrJOio3AzgtjrXR2cIht1UEHAIA/CiKu7sqvNRVkZuqxh5Qw53DBHr71Hb7Vi6jI/h7Vavo9yZfO3+Hp+tZMZliDJnLYwRSlowh78bImlVEcOuDs5BHatCwcyox5KjvWJCJJbkIo5K4PcDNdHp9uLeAx5ycdu9OJOItFa7lgBQBgHGOaa6+mMgZFLIDk7Rn3pm7Oc88dhxTZx2GEckjrnqT1pVYH+HntSAqSeM+lMY8kZpF2Jn6kqfbp0qPPpxikBKrk5J61H5hx8p+Y9aBWHmTBPTA7571DKSQXz3pHYZ5HWo5NzdGGBzigtIajYb8KWRgVx+dIQQMg/UUny4IzzTKK81tG7cJz1OKaF8sEc8mpHdVBG7nvnjFQs28EKQWH5UirtkhdfQg5HFJHkE8detMjJQjPUfyqTeGY5OO+KCWNfkgEdaj35OH+ozTppAWAGB6VGWUtu7euOtMLk2mhJL6FWHyFsEE8GtWO5lKQt9mj3eeYpFEfK+h9qxLSP7Rdxwhtm58bvSrovbSKSR1uL0FuGYMMtTREtSjeri5mDPuIkIJHfmioS6FnK8rk7S3XHvRSKRZiuvMAIGc1pQTrsOCN3tXIfLburoGKjvn+lbmmSpMmc8e/GKmMr7nXWpWV0agc5IAODSNIcld3XqaReF+bqexNVrkhctnJ6VRzJamdq7AyIAeM9qLBELll4YkYHaql1IWmYMuMDj2q9bIPlcEBQoyM9PWs3qzutywsXyhB5ILL1OetNPluMM5zg8LTTIQrMEAUHj3FQxje6yAkqc4HSncxS7kUqfu22KF28cVcsZN4xIOg9c1RujJHLujA3DOPrViwilVQJTz3Gc0Lc0kvc1G3bMZTztUevcVfsW2qoLZJ6k1T1IDAO4ZU8Y5zUdnKftOB8ysCSWNNuzJceaBuuxB4bHSkKkk5YZPv61WjZnRBgjA5OOafLKQQI+MccjtRc51HUiFvuLDc2D8pB5ApkitbAlMqrdTn8sCtGJtyqExgjOc1FcKrBiW3NjOaVk9SlN3sxtncblCMQSpzluPwrRWTKk84HvWKWEVyBlSejbf4frWrA6kZ2nA61UWRVj1L8cgZFGMHtT2+bHIGOKrI+ANwyenHSpNy7fvEH+dUc7RJHxncOSfwpQyhu59s9aZx0yBSfKG6Egc5oET7hjAxg96UIAQB+dRbgANh5IpwJyPQcY9aQD164U9fX1p+/nk5qDkjtxwBn+dPcgR9cf1pkg7fMMdDx6YoAycMTntzSEhx13igkEADOR3oHYkjICkgAgdvWkXBzx1pqnlTj6gUN8oAK4+bOc0BYUAc549KaSocYOD1yOKG4OWwAKilPzA7QccZ9KBoR3XazEEE9K5rUJAZicp854z2/GtXUbgiIjcSx5weorA2NcXIWTB5x8vAx6mom9LHZh4W95mpaRsTGpACshOQepq+x2xhlzwDn6VHFCioAx57Y71LJu2EqCF7g96FoZSkmynPIVVivUDOMd6zLJkmv1RQzHk8jp61NdfI2xd53dMA/Wq9gVjukwTuJ5x6UXuzohG0GzoILdPKCpwM5xUmNqAr1zximx7VZgvQc59KeclxtABHFWcT31KUzqqBmTIOc5FYssitMWOQAOccn2rXvAWj2AA56DuKwbyMxyomDx973qJs7KCTRraXBHDllAI71pRkjJHPoPTJrE0x5NzJn5R6dDWrbSEoHHQj+tUnoY1otNlgMSDu4HrUcpAIxgcfSkD5+99KjkfI59T+VDMUhdw2jGM9qTADHIGc4znrUeMn0HX86dtyDuHNIYjEkYBxTeMDrmnMQQDwB0zSMFA+U4zxQNMQ5Iwe1RA5OABn86e/GeuT2qAgqcdz1J7UikSjOwn9Ko3tz5UWSQAKtNIypyc+4rmtXnLzhDnBOcU72RrShzS1I7m/kZiDxg/iajS9miPO7B5wfSiCJZ3CMwOMkE8U+SJUQ78kZ7mouzqbj8JqW9358YI4Pv2qRWJ5GCa5+wuBFLh2Kqc4ya21cAYQg+4qk7o5asOR6ExIIywxzzUbkAEnP07U3zQOePoaZJKSeccfrVGWpPp6o99biRcoXH3c59q0JpL8yOJNNhLZ7QZ/wD11m2i2rJ5k141vIrdAhP45FTbrcf8xqcDPXY3+NNCaM6V/wB6+5djbjuUDofSioJmAlkw24ZOGPU+9FIoqh38zoSG61taONuNwycYGajgtUDEnBHUE1ej2opO4j+tSo2Z11at1you5ySWOaqzKDkgmlDnBxkmkckEFTVHOtGYl+pil3YJyeRVnTZiV2yttQc5NTTweeuOx654NZxQwPwDxz1qJKzudkZqpHle5sCRSAVztJ71MSiFfvE4wMisiCcs3HJ6E9Mk96a9yFfJcgdAeuTU3QvZal+R1dmwh3AcH0q1ZL8hw4x1OOKp2eZ2AIDepznj0rSAVUKqOauK6mdR2XKinqOPkbGR+WaXT1DsXIHB6Y6VX1B1d4R1UHOOansCoQSbxk8YB6Ck/iK/5dmkwU8DOOepxVVm2x/MDhug61HdSucIqj3Y04BmQgM2B0z1/Kk2ZqNkSRSYUMSTt4z7VZLoVywJz6cVXjRkViCVx3NNuZhBGcqTjr7U1oDXM9Bs6mFgSvPf6VqwsERQzDHbjtWCkyz7S4JAO45z0rXtYwY8rnB9ecUQ11FVVo2Zo7lIwBge1PBOOMgH0qtGcLnBpUlwcEDb6CrOW3YtjG08AnFLndt56joDVUOQc4JB7ZqUEHJBwcdu1BNiYcn5GGKV2wBnoDzx0qujlCTyR6UTSA85OD1AoFbUnLKcg52k1H5gXJLYx71nXN8kQI5J9Capmd5SWBGCPxFLmNo0W1c6D7QoUkdzjmpoyG79sc1ziSyLwSSP7h65rUtLgMihuAf0NNSuKdKxpMxChQePSlHzA84z69agMg29gTxxQZGQ9PlHOeuKZg0TOeOePeoXYjgANn8qGl5BJ4z161UunOxwCfftigqKKN4CVcg5kXt61FaK08KOw2t0wOhqFZC0oBbJxx/9ar0EgRVDEZIzyen4Vne7OuScVZEryCNWOAD0wKerGRBgAn1H9aiJjbc5+8BkZ7n2FMG7B4IUn8/emZW0GXabACMjccA/4VFZ26ksQw3DqSOaZeTbTmLlgcruPep9NSVAnmdOSSeaUfiNdVA1LdAqjIxUoBwQRwetVUbaT6E9elSGTcuCxz/OtDjdyKVVdWB47A1nyaYrtuYk5HetFhuUEDJFRb2ByeOcY9aTNIylHYrxwJCAoT5OwqXciqMDjHamlvnDHJ4pkjgkHpSvYbvLcBJk8Z5HNInP3sen1qEuqggA5z1xQ0nBI7dKVyrEwO3J55HWk37c4HUVBuHlZbjvjvTnb5COnvTFYV3JUjtSJKBwOPrUO8bQDz64ph+fn+LtjjFILFl3YAnJznPPrUDPknLHOeBTN7H7/BFRTMq4BxQNIkY+YCevHSue1WNmuPmDYB+8B0HpW1LKIwDkLx3rHvrsyHCAEeoNDdkb0W07orWk2JhHGpZug9agvbvahU5Lk42mq0qsWYliozyQeas29moAAJYYxmpS7HRJxi7sr2cbTSiTy2CgdG5rdUhY8DrVeNgpwAAgGKduXvz6EGrSsctWfO7lhpOgHGOOBUUsiLgFsAdz1qIyKgLE9s4rKvbkuCTxzRexMI825u20FzdW5mtIRJGG253gfzNKNO1N2+e3C9v9av8AjXPaXCL/AFS3tJGZI5H+YjsO+PetZLXw9JFZymzulinuGthmc/KwxjPscihO5UrL+v8AgkE0xR2R8b1JBHuKKzLom3uJoWTy2SRlKg524PTPfFFDv0I0R02ns24hufTnNaRdQPmxms6yASLjABqG7u9uFUHf2xRsjZx5paGn5wVjg8+9TqwPLZxnoK5lbsCYrd+YFPTYRkH8asx3Ugy0ZJTPcjpUqZbom8uNuSMj0NRXEKTABs7R7Vmxag77s4wOcVOt/lP5fSqTTIVOUWKtmp3AHCngewqT+zY9waTt0p0cwbBGRjnipw+cnH69adkDnNPcIUSAfKAOagvL0Qodo3PnnnOKW/m8uFtvBOKyraM3Uu9+AvqOn1qZPoi6cVL35EssrylSQQQchhVq1uzEFRQrNn5uM4+tS28GBhR8o5p3lhEfySFz046mkk0VKcX7tiZ2L/MxAOeOP6UsMqkDLcryR3rOM8iLtJUEnBJ55/wpiyjyQ6vhydrJ3ovcXs77msbrGREQxUcAVXZvtMmGbBA6/wCNQQ27yuxcYB5B6H2z71agt0ikPzMxPUmkrsV4x23LdrbRxqN2HOOo6GrKSYJCnGOetVXYIpIIxioPtIj5ZsnsKvRGTTmaazbztOc08FQSD1rDl1BeSjHIHJPalivhIwIbORkZ70uZXsHsWb0RwAo6+9Sq/rwOnHasmC6V2ABx657VdL9oyCaoxnGzLDMMk5yMelR+Zxj5hxxUG/5jzk+lRPKMsTzjqM0BGJVvR++bkEY4J9aW3lCxjJIIHQ9qiuCJBkMBmqiRPIcFFKjqM4+lQ99Dsik42ZdmuD5mMAc5yK0LFhJ87HAHGT3qjFbZYFmYkjP0q9CqqhUdxxTSMqjjayL6uGXgE+p9KkzvXg++P/r1TiLBBknHSnlsHk5FVc5XEs+ZxjIqNmxkHHPbFMQgLj9ajlTzmT9420HOAeD9aVwSRl3qJHN83O7kLnGaI5kj5yDjqM81b1BCVU5wRwCOtY5ePz9zo24KcA96mSszsg1OOpqw3KSlzgB1IBXsKl8wEHLZfpjOeKwIbiG3OIomPqN3H506W8Ji3fMzknOOmKV7jdF3LFxLlx0YBsZWtK1nfZlRtUDpnrWDbLLcFY2RgoOQemK3YYdkaqG4HenHuKtZJIt+budRjIP6VLvXd83XtVIMd5UNkDvQGOcuc9+O1Vc5XG5aLNu44GKY2Txjv3quzk464NIJmwcHHrzSuLlJGycj3pgPUDOPeoS/v3pskmE4zmgomYjLAg+3HSmORt9+mars5CKc8554pGJ5IJ54JJ4oAe7HP096QOOhPB96heU5HGM0nm7wQPWgB+QScdKaZQo5HfGaiL4LE8Y71XklORgnBoAsGRS3zcZPBqHzBuBPQVFLIoH1PAqs78Yzii47DtZmyEAOR7VjGRUQgnt25q3fEyKDk9OKyUtm+bcSFz0z1pSV3c6KcoqOrFupGwOCSegzj8a07Rm8hd2Sx64qlHHHEuSdx7E0s99HAnBPSmtCJyc/diaEjhMdAPrVd5wo24/KsltSLnp+NI1wSCQQDTMmmtCxe3G1flrMafIHm/M3Yd6lkm3c4HFVnmjU/NjI6UNFxqO1rFvT2u31G1WwQrdeYBER2b/Ct/Trq4XW7u083S5neXzYg4Ii88Djy/Qn34zXN2N9PZ3tpewQPMVlAVQpIkPdQfXFaka6XBcpdRabr7ujiRLRrfC7s5AL+mapKxlObe5k3dxK13Objd529vM3dd2ef1orG1HVJZ7u5lm+WaSRmcYxhieR+FFBPMj0L7SyQhd3zA0inzBtyTnPzGopw2wMCM96ijuWG1UX5sHPas2egndaF0xA4U5B9zwajVNr7FbaM9PXNNt5tzfe6H9asllLhn5GOlTuHM0KYsqyqMk9Pp7UyTCptlZs/wALAcj8KljcCQbvu/3RTLpS4AVRnPSnYSm07D7adYWPO5R79fery3cZb5WAOOvpWIi5lKuuSD+XtTwQ8RBzET0xyDTTaLlGMty/e3KtHtyD/sk1DBJ8m5D06ZPWqxP8JjDhhjk859agR2jL7iflxkYzk+lJvW5SirWR0XnBVCg9eOe9E0yhSScY4xWKLoq2FPA7g9KiluGcqqFn5xz2o5iPZa6mjuLEZ44xWhBCg2tjJz1xzWXaRMRl+CTn61qIxAxkcVUURVn0RaVcbjkZ60OwVc4x+NQq4xhhj9c1XuJGj3BeQRxnvTZitWLe3ewYGCTyee1UTmfJLfRaqvI0kn3ueOD/ACq9EybVJIVu30rO93qdekFoRxRb0dW3OCMEZ4+tThUgA8osCq4J/p9KRZXWQYwRnjjFKsuGJY89B9KVkS5tj7diIJC7ncCCF+tWrS7ZTtJyTzk1miX5XVQd5PXPGKb53kxu2Dn2Oapbia5kaVze+WrsGOTwBnFZyXDzz4kcgDuD1qtE8byYyc4yM81fijEEe9CN1J3Y1y01bqBjuDuG8ZAx83SiO/MW1RnjqT0J+lSSy7wwH1/GqIC+cWIDv1GfpStbYqElLc349QjMAZyN/YetSW94jDG8A54rnXty6LJIw5PQHAxTjIsSEI7YJ47VfO7mbpQex1SzHBJIYVJ5gKYUdR27Vzdld4Ta/Y9v51qRzqBzwcetNO5zzp8rsaQkBB7+9RtLhcoDjvVNpSxwT1FKHJO08e2c0EWLTuXQjAzjHFMlhV1yygE8VEWATefXFDzFQvT0oBPsRLYwsSjqDg5wD2qxFbW8KgRIAD1Lc1E85yDj8O9L5++LcQcjrkUJWKlKT3Y9im9gAPQnFO8zbgLg1RMoJ4IBP60eaQvJz6igC+WBYAHGaCwxz0qj5/y5GckcVH9pYnqSR6UEWNEnK5YgVC8gXgDJPvVVrrgZJx+tQyXGSApGM9PWkBcDjJ3H5RzTHlBOAeRzzWfJOwDZOMDOc01ZQwBPpQVbqXnkbkg8dPpSiVNo3ODWLf6gIh8owSMAA1izalOVOzPPQCk5WNY0XJXbOsluFY4B6enrVc3HDEDjPOK5eG8ljQmU4Y88mrSXwdFw3PpTTuKVLlNprsFSGPPpVV7nseB71nS3IXNV3uMDDMD7UzLQ05LkZyDnHSoJLk4yTWZJcnOQcVC9wSTtJ+oosFy/Lckj72fpUfnFRknn2rJluhHklhmqU1+cH5sCnZgbU9+EX5cZ6/WsuW+MgO4AE9MmsO51EE4DEMe/pVaa5LoGml2ooxljVco/aJLQ2BeuZGHOPY8Ur6gFGC1cnNrllF8rXKgDjiue1bxbGkzRQZdR/EDVKBjKsup6Bd61sHyPk9KypNaU53EnI7npXmN54kvJ2IVtorOk1C5l+/K351SiQ8TpZHs3h/WZ7rW9M02LULqFZLkeV5JyYnYYLqM9cd/Sujt/EulXWtppdt8RdXa6eXyY28giN3zgANuxyeBXz/4e1a90nXrDUbD97e28yvEjLuDnptx3znGPevWU8PDS5/7asvh7dLq8B+0pZPqsckcLj5t3kD94QDztNPlMnUbM7xrff2baJqdhfSajaTXMtrK00XlTQ3Ccssi5PJzkEe9FcP4g8TLqfh600yO0aKT7TLfX1w77mubl+C2MfKoHGPrRTsR7SR9ShuMHH1qpfhUw4+b+lMS455+lFyfMU4I/wrA9WDtK7JLeWJkDbmJ/iXb0FWy6OnXLDJ69RWEkvkuA4BU8DjtVlbiLaygM2TkHoRWZs1fVGmr7QfmG0evanGcBuQCvTr1rOSTKZbdj1qRZ03jocdqZNu5fXOGxkEjnHA/GmFlABjbkjoO9VJC0kZCNx1IFMiLYOeCo6+lDBFwuSqnO3PSq+4l8AgeuetD7cD/Z6e9UvOxOAnOTyfQUmaU22a8MMTR+h9qngiRSucetUYJGGSehqwJPlz79K0VjKUnexpRycAZUj27U4yHs35VmLJhuB75IqXeTwxw3vQZMvNMdvynP86z72eQREdaa8hzgMaimO9OhxSZUWkyGGZyAuflJ7DrWjA+Ad3yuODuFYrRzI/yMdoO7g9KYk8sMju4Mu455Pf1NZJW3OmTU9mdC06InPJ9e9QzXEY3OoBYfw5rGjvW2vnlye3/16ZD5jzbt3l5z0p+hCSW7NBLvzW3KdvY80+cyLHuRvmHPTOPaq0f7nPKk05bnBCOD6VSXcl1Ve8RsF0Ync8GQ8cc4rSS5yitLJGnPAzknist1jLEjIz3FRNCD8xZifWlZrYt1Iytc1ZNQQKWQjjrVdLpmfcDhT0HSoliiXJJDU+TawBAAxRYXtYrQdLqB3YYkgdB/hTYppZmAxleuO9RgJj7oDZqyJEjACjFKw/bJLRF61XyWy3DHjk9Kti4OcHDVjNOMjc2Qen1p6zkDcMDPUUzCUubVmwLgEZJAI61Ol0i85xxkkc1gvcLxxzTWuwCCGzTItc6BruMn3781Xe7DELyeTg9KxDdYclupGMk0rXYXrkHpn0oBRsbhunx8zEcdT3qOS5IJc8Aen86yPtYKjJPJx1pwudx288980CNBrjJypAHXNOEpIJdsjGeKyjcrjGRx+dQveKP4jimO5tLdAr8zYxwKTzguRuz75rEkvO+4ADjPrVd78jkscehoJubzT4GAw+tQmdRyxJIPFYMmoDcS5xj0qvNqOB94knpRYRvy3O7ndhc96Y13tUndn0Arm2v1wdzfrSC+Vzw4AA70crDmLF/duspfJxnioFukYbnyMdBVOW+tw26WUYHbNUrjVrRQD5qgHj3NChc1dY1prx5FI42joT0psU6RLzKCxOTiuR1TxXYWoIFyrEdQOa5m68cw/N5YJ9B0rRQZhPELY9RfUEAOX+gqjNqqZ++OO5ryO58ZXUq4SMD3zmsi51++l6zFR6Cr5DB110Pajr1uhOZRx1yaydT8XwKu1LqONQfXk15BPqdxOm1n/KqbOW680+QSrtdD0a68aWy4wzyt09Kxb3xldSErApWMHAya5HPpxRmmkkRKrKW5vN4lviSd9Z9zqt5c5E07lc5wDVAmkJpmfMyRpGY5YkmmAn1pPxpKBD6M0yigDoPAmq2uieMtH1K/DG1trhXkKrkqP7wHcjr+FdhpfhcaX4rt/EFx4x0Y6dBdC6N9FebriVQ2cCL7+89MH1rgNP0TVtQgM2n6Xf3UOdvmQW7yKD6ZAxmt7wn4W1xfFeitcaDqYhF7CZDJZvt27xnORjGKAMHxBexajr2pXtrF5MFzcyTRx/3VZiQP1oqfxkFXxfrqxhVQX84AUYAHmN0op2A+i5rsrk5PXp3pVuZyu4DPGcVjG6YsCSCoOBn1q1FeAHLDIxzzzXLue45JLQ0TPIFyyZB7HtUP2jaQRwO4qBb5XAI2tg8BjUKuDkgcsOlDRUJ9zRjuk2gPJgN2/lVmO6jCheA/c+tYjNGpA3gY7U2S4XBwfkU9Rk0rMr3Xqb8N6FLYHynmkkvlYKVwSepHWsdbkAENkg84qylzGEHyqGAppXJdkWzcNI7FQQme55FSQ+UGBZzn61jfaDLIFDFSc/MR0qcFImAZ/nx2PFKxTmkrHQxzqoG1x14yaka4AbIK+ma5ie48sfe6e1JFqBYs5BVe9O9jLlTV0dUtwMHdt6dqa1yP4XrC+3qYz+75HTnGaYb5DzuH581RgbrXHHzYyPehrsheSM+lc6dRBJKndjsf8ajXUez9T361NhNnQtcDfwfrUZnw/J4rn5tRWHIZiG+nFVn1eP8Avj154osCl5nTSTxjPIIpRPxwVx2Nci+uRKCXkGQMAg9KpP4mhUld43Z/vCjlYudHbPer075pFv1wQHyO+eorgT4mhaTAmUH16iny63tTzQ6qgH3yRg/ShRYnUiup3X24A4HQUh1BSc7xXmkni+1j3Hzd/HGD0qBvGttghifb2p8kuwvax7nqR1Bd/LZHanNfAY+YY+teS/8ACbIwOI3fHQr2qKXxyy8+Q2O2CKfs5C9tHuewG9U/xDp09KT+0UXPzYH1rxseO5QcrASDngnoagbxxMMFoQfUbuKPZyJ9vHue1jUlIb5hj+dIurIvy9yPyrw6Xx1cH7kYXHY1Wl8cag2dqoB2NP2bE68e57u2pKeBJz+lRnVIlzz+VeBv4y1ZgR5yj1wKjk8T6jJgm6YewFCpi+sI9+Oqpj7yk9arNriqMb1Azzmvn99e1FiQbyX8DVZ9Qu5R81xKf+BU/Zi+s9j6EbX4wwJnQHqRuxxUTeKrVeDcRAnqNwr56N1KSTvYnpkmm+c55zz60/Zol4hn0BJ4usFDf6THhT/e6VVm8caco4uozn0rwcyMRtzkUb+2eKfIifbyPbpPHlgobFwPXA5qlL4+tHwFkdgO+OlePrNgEBRzR5zZJJ+mKaghOtI9Sn8bp5nBYqeBj/Cqdz40ePcTGy7uQXPNecxzurhwfmFJPO80heRssf0qrIl1JM7WTxjdmN5NygdFAPJrOm8XamVISfaPYVzBY4Ixmmk0rInmfc3W8SaiyMTLkHvisya+uJ2JknkbPXLGqmTjHajNMfM31JWfccn8KYSc038aM0EjixIwSaSkzQTinYBc0hNGaSiwCg0ZpKBRYAPWiikzQAuaM0lFAC5oNJRQBr6V4m1zSLU22l6vf2dvuL+XBOyLuPU4B61c/wCE58Vf9DHq3/gU/wDjV/wZ4S0vxFpd/dXHiD7Dc2SGaW1Fm0zGEdZFww3AdwBx1qQeHfBmRnx0wHr/AGRL/wDFUaDONnlknmkmndpJZGLu7HJYk5JJop14kUV1MlvL50Kuyxy7du9QeGx2yOcUUCPcLe5VkYs2T1xmpxdqcbD19a86h8VojEtGSDVqLxTBIjKjNERzyOtZ8h2vEJs7prhCvzEbuoNBvHEYG4cZ/EV58viiJch95bPr2pZPFkcbcKzcUvZgsR5noEFw4O87G7ipIHLuwA5XkjPArzmXxYrDMCEcdDxUI8VXBjYLhX+vWjkG8Qt7nqaTMY2kB+TuRjAqCWccOvIHORXmkHiqWNGjJ2g9eetOfxTIz7lTCY6A5Bo5NBfWEnoegi+Csdp3nqWpwvS/3XUN2BrzxPFhACuqr/tAZNRT+LJMEQhdx6grT9mN4s9FmvJ1UlnATGMnmqn9pRIigykkdcmvMZ9cuZQcysue2eKry6jdMvNwWHpRyGcsS2eqya0IQsgPy+oNVpfE8CyZ7+ma8sa7k4/eNj0zUfmzORySM9jT5EZe2bPQrrxgIyBHGz575qhP40uWkYiMICMcmuOLSdC351A5bPzDmnyIn2kjqJ/FWoOB8/yj+51qg+vXL8M7KfUViFiBweKN5xzTSJ5mzXbVJ9pbzVcdxkg1Vmv5ZiASAB6VR3GkBPrTEXVmlXkOBnuehpst5M5+Z29cZ4/KqoYjoePT1oYgqOMGgCRZDnrzUn2k/dZVIqtmg0gLbXK8YiUe4psbIxYk4bqOarCn9KYD3kO7Kk0wuTxmmt1ozQApbkZpM8UhOaSlYB+6kzntTaKAHcUoOBTKKAHZozTc0ZoAdmgnFNooAM0d80UZoAWgjikzRTAUd6DTaKAFopKKAFopKKAFoxSUUAKaSiigAozRRQAZoozRmgAoozRmgAoozRxQBv8AhzRvE04XUfDun6pIFLRi4s4nOCRhl3L7Hke9SjwJ4sJGPDWsEn/p0k/wqbwJr+q6ZNeWFhb3d/aX0LRzWcDMrE4+WRSoJVlODnHseDTb6Hxpp0Jnvl8Q20K8mSXzlUfUnpQBzdxDLbzyQzo0csbFHRhgqwOCCOxFFMkd5HZ5GZ3YksxOSSe5ooAdu9OKXzGFR0UASsQTmm7iKaDRntQAu4UoYimGigCyhWVSp4ftUW5lJGSD3pgJBBHFOZt3J4IoAlE+RiRA4HfoaazpnAHHvURpKAH7hnvTc0lFADw2B9aAxHQ4plFADs9z1p/mkrtOCKiooAdmjtTaKAFyaWm0UALk+tJk0UUAGTRk0UUAOXrSk80E4FNzQAvWkJ9KM0lABk0ZNFFABS5pKKAAUUZ5xRQAUUUUALmjNJRQAUUUUAFFFFABRSHrRQAtFJRQAtFJRQACjJoooAWkyaKKADJoNFFABRRRQAUUUUAFAooFAHp3gh7+78B3Om+ENQhstfa8Ml1H9oW3muINgCBHJGQDnKgjrmtLwtpXj/SNZt7vWdUk0/So3DXb6hqCvC0WfnUoWO/IyMAGuX8PWGg6Z4PXxB4h0+41V7m8azt7WO4MCxhVDM7MBnPzAAVoL4T0y91bw/q2iyTXvhm+v4bW5hmb99ZuzDMUhHYjO1x1+tIZw2vS2c2t6jLpcfl2D3EjW6EY2xljtGO3GKKk8T20Nl4l1a1tk2QQXk0Ua5zhVcgDP0FFMRm0UGm0AOoptKKAFooooAKUHikooAKKQ0CgBaKKByM0AFFFHagAoopO9AC0CijvQAGij2pDQAtIaSloAUU4CmqKVjzimAneiikPWkAppM0UUAKKKSigAzRmiigAozRRQAZozRRQAZpaSigBaKSkoAdSZpKWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDb0rxLe6doeoaQiW8+n3oy8VxEHEUmMCSM/wvjjIqTwf4r1TwlqJu9IkTDgCaCZQ8UwByAy+x5BHI7V0HgbQ4P7MTUriC0nurhpfI+25NvbQwqGlnkUffI3Kqr0yec8Vb0K6i8T6bdf2/HpcsEUqRSNb2iW1zapIwRZ0KAB0DkBkOePTrSGef6pePqOpXd7KqrJczPMwXoCzEnHtzRRqllJpupXdjOQZraZ4XK9CVJBx+VFMRVooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKBzRSr1FADwMCmnqaeaZTAbRSUtIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKB1oooA73wNr1sNOTTbue1t7m2eVrZrwE21xHKoWW3lI5UHCkN2I7cGtpH0nQ7eR7i30nTrJnSWa3tNQ+3XN7sYOkKkEiOMsAWJweB1ryjtR3oAs6neS6jqN1e3BHnXMrzPjpliScfnRVaigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple annular erythematous plaques with peripheral scale are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tinea corporis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An inflammatory, annular plaque with peripheral scale is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_25_31128=[""].join("\n");
var outline_f30_25_31128=null;
var title_f30_25_31129="Methylprednisolone: Drug information";
var content_f30_25_31129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methylprednisolone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/5/14422?source=see_link\">",
"    see \"Methylprednisolone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"    see \"Methylprednisolone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15254327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Fungal Meningitis Outbreak Associated with Contaminated Injectables",
"     </span>",
"     <span class=\"collapsible-date\">",
"      October 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For information regarding the recent meningitis outbreak from products compounded by the New England Compounding Center (NECC), including treatment recommendations, please refer to the following websites:",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"       <a href=\"file://www.cdc.gov/hai/outbreaks/meningitis.html\" target=\"_blank\">",
"        file://www.cdc.gov/hai/outbreaks/meningitis.html",
"       </a>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       <a href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm285497.htm\" target=\"_blank\">",
"        file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm285497.htm",
"       </a>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm323947.htm?source=govdelivery\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm323947.htm?source=govdelivery",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      A-Methapred&reg;;",
"     </li>",
"     <li>",
"      Depo-Medrol&reg;;",
"     </li>",
"     <li>",
"      Medrol&reg;;",
"     </li>",
"     <li>",
"      Medrol&reg; Dosepak&trade;;",
"     </li>",
"     <li>",
"      Solu-MEDROL&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Depo-Medrol&reg;;",
"     </li>",
"     <li>",
"      Medrol&reg;;",
"     </li>",
"     <li>",
"      Methylprednisolone Acetate;",
"     </li>",
"     <li>",
"      Solu-Medrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F195428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Systemic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F195386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Only sodium succinate may be given I.V.;",
"     </b>",
"     methylprednisolone sodium succinate is highly soluble and has a rapid effect by I.M. and I.V. routes. Methylprednisolone acetate has a low solubility and has a sustained I.M. effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Acute spinal cord injury (unlabeled use):",
"     </b>",
"     I.V. (sodium succinate): 30 mg/kg over 15 minutes, followed in 45 minutes by a continuous infusion of 5.4 mg/kg/hour for 23 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Due to insufficient evidence of clinical efficacy (ie, preserving or improving spinal cord function), the routine use of methylprednisolone in the treatment of acute spinal cord injury is no longer recommended. If used in this setting, methylprednisolone should not be initiated &gt;8 hours after the injury; not effective in penetrating trauma (eg, gunshot) (Consortium for Spinal Cord Medicine, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Allergic conditions:",
"     </b>",
"     Oral: Tapered-dosage schedule (eg, dose-pack containing 21 x 4 mg tablets):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Day 1: 24 mg on day 1 administered as 8 mg (2 tablets) before breakfast, 4 mg (1 tablet) after lunch, 4 mg (1 tablet) after supper, and 8 mg (2 tablets) at bedtime",
"     <b>",
"      OR",
"     </b>",
"     24 mg (6 tablets) as a single dose or divided into 2 or 3 doses upon initiation (regardless of time of day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Day 2: 20 mg on day 2 administered as 4 mg (1 tablet) before breakfast, 4 mg (1 tablet) after lunch, 4 mg (1 tablet) after supper, and 8 mg (2 tablets) at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Day 3: 16 mg on day 3 administered as 4 mg (1 tablet) before breakfast, 4 mg (1 tablet) after lunch, 4 mg (1 tablet) after supper, and 4 mg (1 tablet) at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Day 4: 12 mg on day 4 administered as 4 mg (1 tablet) before breakfast, 4 mg (1 tablet) after lunch, and 4 mg (1 tablet) at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Day 5: 8 mg on day 5 administered as 4 mg (1 tablet) before breakfast and 4 mg (1 tablet) at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Day 6: 4 mg on day 6 administered as 4 mg (1 tablet) before breakfast",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anti-inflammatory or immunosuppressive:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 2-60 mg/day in 1-4 divided doses to start, followed by gradual reduction in dosage to the lowest possible level consistent with maintaining an adequate clinical response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M. (sodium succinate): 10-80 mg/day once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M. (acetate): 10-80 mg every 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. (sodium succinate): 10-40 mg over a period of several minutes and repeated I.V. or I.M. at intervals depending on clinical response; when high dosages are needed, give 30 mg/kg over a period &ge;30 minutes and may be repeated every 4-6 hours for 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Arthritis:",
"     </b>",
"     Intra-articular (acetate): Administer every 1-5 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Large joints (eg, knee, ankle): 20-80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Medium joints (eg, elbow, wrist): 10-40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Small joints: 4-10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Asthma exacerbations, including status asthmaticus (emergency medical care or hospital doses):",
"     </b>",
"     Oral, I.V.: 40-80 mg/day in 1- 2 divided doses until peak expiratory flow is 70% of predicted or personal best (NIH Asthma Guidelines, NAEPP, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Asthma, severe persistent, long-term control:",
"     </b>",
"     Oral: 7.5-60 mg/day (or on alternate days) (NIH Asthma Guidelines, NAEPP, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dermatitis, acute severe:",
"     </b>",
"     I.M. (acetate): 80-120 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dermatitis, chronic:",
"     </b>",
"     I.M. (acetate): 40-120 mg every 5-10 days",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Dermatologic conditions (eg, keloids, lichen planus):",
"     </b>",
"     Intralesional (acetate): 20-60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dermatomyositis/polymyositis:",
"     </b>",
"     I.V. (sodium succinate): 1 g/day for 3-5 days for severe muscle weakness, followed by conversion to oral prednisone  (Drake, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lupus nephritis:",
"     </b>",
"     High-dose &ldquo;pulse&rdquo; therapy: I.V. (sodium succinate): 0.5-1 g/day for 3 days (Ponticelli, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Pneumocystis",
"      </i>",
"     </b>",
"     <b>",
"      pneumonia in AIDS patients:",
"     </b>",
"     I.V.: 30 mg twice daily for 5 days, then 30 mg once daily for 5 days, then 15 mg once daily for 11 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F195409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"      see \"Methylprednisolone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosing should be based on the lesser of ideal body weight or actual body weight.",
"     <b>",
"      Only sodium succinate may be given I.V.;",
"     </b>",
"     methylprednisolone sodium succinate is highly soluble and has a rapid effect by I.M. and I.V. routes. Methylprednisolone acetate has a low solubility and has a sustained I.M. effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Acute spinal cord injury (unlabeled use):",
"     </b>",
"     I.V. (sodium succinate): 30 mg/kg over 15 minutes, followed in 45 minutes by a continuous infusion of 5.4 mg/kg/hour for 23 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Due to insufficient evidence of clinical efficacy (ie, preserving or improving spinal cord function), the routine use of methylprednisolone in the treatment of acute spinal cord injury is no longer recommended. If used in this setting, methylprednisolone should not be initiated &gt;8 hours after the injury; not effective in penetrating trauma (eg, gunshot) (Consortium for Spinal Cord Medicine, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Anti-inflammatory or immunosuppressive:",
"     </b>",
"     Oral, I.M., I.V. (sodium succinate): 0.5-1.7 mg/kg/day",
"     <b>",
"      or",
"     </b>",
"     5-25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses every 6-12 hours; &ldquo;Pulse&rdquo; therapy: 15-30 mg/kg/dose over &ge;30 minutes given once daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Asthma exacerbations, including status asthmaticus (emergency medical care or hospital doses) (NIH Asthma Guidelines, NAEPP, 2007):",
"     </b>",
"     Children &lt;12 years: Oral, I.V.: 1-2 mg/kg/day in 2 divided doses (maximum: 60 mg/day) until peak expiratory flow is 70% of predicted or personal best",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lupus nephritis:",
"     </b>",
"     I.V. (sodium succinate): 30 mg/kg over &ge;30 minutes every other day for 6 doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F195387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F195388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis effects: Slightly dialyzable (5% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Administer dose posthemodialysis.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium succinate [strength expressed as base]: 40 mg, 125 mg, 500 mg, 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-Methapred&reg;: 40 mg [contains benzyl alcohol (in diluent), lactose 25 mg/vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-Methapred&reg;: 40 mg [contains lactose 25 mg/vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-Methapred&reg;: 125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-Methapred&reg;: 125 mg [contains benzyl alcohol (in diluent)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solu-MEDROL&reg;: 500 mg, 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solu-MEDROL&reg;: 2 g [contains benzyl alcohol (in diluent)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium succinate [strength expressed as base, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solu-MEDROL&reg;: 40 mg [contains lactose 25 mg/vial; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solu-MEDROL&reg;: 125 mg, 500 mg, 1 g [supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension, as acetate: 40 mg/mL (1 mL, 5 mL, 10 mL); 80 mg/mL (1 mL, 5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depo-Medrol&reg;: 20 mg/mL (5 mL) [contains benzyl alcohol, polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depo-Medrol&reg;: 40 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depo-Medrol&reg;: 40 mg/mL (5 mL, 10 mL); 80 mg/mL (5 mL) [contains benzyl alcohol, polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension, as acetate [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depo-Medrol&reg;: 80 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 4 mg, 8 mg, 16 mg, 32 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Medrol&reg;: 2 mg, 4 mg, 8 mg, 16 mg, 32 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [dose-pack]: 4 mg [21s]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Medrol&reg; Dosepak&trade;: 4 mg [scored; 21s]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F195342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes preservative free injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F195362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Administer with meals to decrease GI upset.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Parenteral: Methylprednisolone sodium succinate may be administered I.M. or I.V.; I.V. administration may be IVP over one to several minutes or IVPB or continuous I.V. infusion.",
"     <b>",
"      Acetate salt should not be given I.V.",
"     </b>",
"     Avoid injection into the deltoid muscle due to a high incidence of subcutaneous atrophy. Avoid injection or leakage into the dermis; dermal and/or subdermal skin depression may occur at the site of injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      I.V.: Succinate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Low dose: &le;1.8 mg/kg or &le;125 mg/dose: I.V. push over 3-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderate dose: &ge;2 mg/kg or 250 mg/dose: I.V. over 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     High dose: 15 mg/kg or &ge;500 mg/dose: I.V. over &ge;30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Doses &gt;15 mg/kg or &ge;1 g: Administer over 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Do",
"     <b>",
"      not",
"     </b>",
"     administer high-dose I.V. push; hypotension, cardiac arrhythmia, and sudden death have been reported in patients given high-dose methylprednisolone I.V. push (&gt;0.5 g over &lt;10 minutes); intermittent infusion over 15-60 minutes; maximum concentration: I.V. push 125 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      I.M.:",
"     </b>",
"     Avoid injection into the deltoid muscle due to a high incidence of subcutaneous atrophy. Avoid injection or leakage into the dermis; dermal and/or subdermal skin depression may occur at the site of injection. Do not inject into areas that have evidence of acute local infection.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F195435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Stable",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, LR, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, alprostadil, amifostine, amiodarone, amphotericin B cholesteryl sulfate complex, anidulafungin, aztreonam, bivalirudin, cefepime, ceftazidime, cisplatin, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, dopamine, doripenem, doxorubicin, doxorubicin liposome, enalaprilat, famotidine, fludarabine, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), inamrinone, linezolid, melphalan, meperidine, methotrexate, metronidazole, milrinone, morphine, nicardipine, oxaliplatin, pemetrexed, piperacillin/tazobactam, prochlorperazine, remifentanil, sodium bicarbonate, tacrolimus, teniposide, theophylline, thiotepa, topotecan.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amsacrine, caspofungin, ciprofloxacin, docetaxel, etoposide phosphate, fenoldopam, filgrastim, gemcitabine, ondansetron, paclitaxel, palonosetron, propofol, sargramostim, tigecycline, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Aminophylline, cisatracurium, diltiazem, fosaprepitant, heparin with hydrocortisone sodium succinate, midazolam, pantoprazole, potassium chloride, telavancin, vitamin B complex with C.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Granisetron, iohexol, iopamidol, iothalamate meglumine 60%, ioxaglate meglumine 39.3% and ioxaglate sodium 19.6%, metoclopramide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Doxapram, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Midazolam.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F195361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Primarily as an anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases including those of hematologic, allergic, inflammatory, neoplastic, and autoimmune origin. Prevention and treatment of graft-versus-host disease following allogeneic bone marrow transplantation.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F10411137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute spinal cord injury",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F195438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       MethylPREDNISolone may be confused with medroxyPROGESTERone, methotrexate, methylTESTOSTERone, predniSONE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Depo-Medrol&reg; may be confused with Solu-Medrol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Medrol&reg; may be confused with Mebaral&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Solu-MEDROL&reg; may be confused with salmeterol, Solu-CORTEF&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Medrol [U.S., Canada, and multiple international markets] may be confused with Medral brand name for omeprazole [Mexico]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F195426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, bradycardia, cardiac arrest, cardiomegaly, circulatory collapse, congestive heart failure, edema, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture (post MI), syncope, tachycardia, thromboembolism, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Delirium, depression, emotional instability, euphoria, hallucinations, headache, intracranial pressure increased,  insomnia, malaise, mood swings, nervousness, neuritis, personality changes, psychic disorders, pseudotumor cerebri (usually following discontinuation), seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, allergic dermatitis, alopecia, dry scaly skin, ecchymoses, edema, erythema, hirsutism, hyper-/hypopigmentation, hypertrichosis, impaired wound healing, petechiae, rash, skin atrophy, sterile abscess, skin test reaction impaired, striae, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Adrenal suppression, amenorrhea, carbohydrate intolerance increased, Cushing's syndrome, diabetes mellitus, fluid retention, glucose intolerance, growth suppression (children),  hyperglycemia, hyperlipidemia, hypokalemia, hypokalemic alkalosis, menstrual irregularities, negative nitrogen balance, pituitary-adrenal axis suppression, protein catabolism, sodium and water retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, appetite increased, bowel/bladder dysfunction (after intrathecal administration), gastrointestinal hemorrhage, gastrointestinal perforation, nausea, pancreatitis, peptic ulcer, perforation of the small and large intestine, ulcerative esophagitis, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukocytosis (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatomegaly, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Postinjection flare (intra-articular use), thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthropathy, aseptic necrosis (femoral and humoral heads), fractures, muscle mass loss, muscle weakness, myopathy (particularly in conjunction with neuromuscular disease or neuromuscular-blocking agents), neuropathy, osteoporosis, parasthesia, tendon rupture, vertebral compression fractures, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts, exophthalmoses, glaucoma, intraocular pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glycosuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Abnormal fat disposition, anaphylactoid reaction, anaphylaxis, angioedema, avascular necrosis, diaphoresis, hiccups, hypersensitivity reactions, infections, secondary malignancy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F195365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methylprednisolone or any component of the formulation; systemic fungal infection (except intra-articular injection in localized joint conditions); administration of live virus vaccines. methylprednisolone formulations containing benzyl alcohol preservative are contraindicated in premature infants; I.M. administration in idiopathic thrombocytopenia purpura; intrathecal administration",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F195346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do",
"     <b>",
"      not",
"     </b>",
"     provide the systemic steroid needed to treat patients having trauma, surgery, or infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Rare cases of anaphylactoid reactions have been observed in patients receiving corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermal changes: Avoid injection or leakage into the dermis; dermal and/or subdermal skin depression may occur at the site of injection. Avoid deltoid muscle injection; subcutaneous atrophy may occur",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, cause activation of latent infections, mask acute infection (including fungal infections), prolong or exacerbate viral or parasitic infections, or limit response to vaccines. Exposure to chickenpox or measles should be avoided; corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for cerebral malaria or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment). Amebiasis should be ruled out in any patient with recent travel to tropic climates or unexplained diarrhea prior to initiation of corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy: Acute myopathy has been reported with high dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); discontinuation may result in clinical improvement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with HF; long-term use has been associated with fluid retention, hypokalemia and hypertension. Cardiomegaly and congestive heart failure have been reported following concurrent use of amphotericin B and hydrocortisone for the management of fungal infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head injury: Increased mortality was observed in patients receiving high-dose I.V. methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarction (MI): Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Not recommended for the treatment of optic neuritis; may increase frequency of new episodes. Consider routine eye exams in chronic users.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some dosage forms contain benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Because of the risk of adverse effects, systemic corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: May affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F195422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F195351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of MethylPREDNISolone. Management: Consider an alternative corticosteroid. If this combination cannot be avoided, monitor for diminished methylprednisolone effects during carbamazepine treatment, and increased methylprednisolone effects following carbamazepine discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of MethylPREDNISolone. MethylPREDNISolone may increase the serum concentration of CycloSPORINE (Systemic). MethylPREDNISolone may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of MethylPREDNISolone. Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of MethylPREDNISolone. Management: Consider an alternative corticosteroid. If this combination cannot be avoided, monitor for diminished methylprednisolone effects during phenytoin treatment, and increased methylprednisolone effects following phenytoin discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of MethylPREDNISolone. Management: Consider an alternative corticosteroid. If this combination cannot be avoided, monitor for diminished methylprednisolone effects during phenytoin treatment, and increased methylprednisolone effects following phenytoin discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F195378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase gastric mucosal irritation. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Methylprednisolone interferes with calcium absorption. May cause GI upset. Management: Administer with food. Limit caffeine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease methylprednisolone levels. Cat's claw and echinacea have immunostimulant properties. Management: Avoid St John's wort, cat&rsquo;s claw, and echinacea.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6472614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Methylprednisolone crosses the placenta. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy. Pregnant women exposed to methylprednisolone for antirejection therapy following a transplant may contact the National Transplantation Pregnancy Registry (NTPR) at 215-955-4820. Women exposed to methylprednisolone during pregnancy for the treatment of an autoimmune disease may contact the OTIS Autoimmune Diseases Study at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F195395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6472616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low levels of methylprednisolone are excreted in breast milk",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F195369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with meals to decrease GI upset.; need diet rich in pyridoxine, vitamin C, vitamin D, folate, calcium, phosphorus, and protein.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F195368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (A-Methapred Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (1): $2.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (1): $3.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (MethylPREDNISolone Sodium Succ Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (1): $5.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (1): $10.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $15.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (1): $31.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Solu-MEDROL Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $56.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (1): $3.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (1): $5.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $13.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (1): $25.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Depo-Medrol Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (5 mL): $18.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/mL (1 mL): $9.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/mL (1 mL): $15.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (MethylPREDNISolone Acetate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/mL (1 mL): $7.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/mL (1 mL): $11.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Medrol (Pak) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (21): $35.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Medrol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $88.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $166.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (25): $58.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     16 mg (50): $180.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     32 mg (25): $134.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (MethylPREDNISolone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $142.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (25): $50.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     16 mg (50): $155.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     32 mg (25): $115.62",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F195356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, blood glucose, electrolytes, growth in children",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F195370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Advantan (MX);",
"     </li>",
"     <li>",
"      Alergolon (BR);",
"     </li>",
"     <li>",
"      Cipridanol (PY);",
"     </li>",
"     <li>",
"      Cryosolona (MX);",
"     </li>",
"     <li>",
"      Depo-Medrol (LU, MX);",
"     </li>",
"     <li>",
"      Flason (ID);",
"     </li>",
"     <li>",
"      Lexcomet (ID);",
"     </li>",
"     <li>",
"      M-Prednihexal (DE);",
"     </li>",
"     <li>",
"      Madomed (TH);",
"     </li>",
"     <li>",
"      Meapron (KP);",
"     </li>",
"     <li>",
"      Medixon (ID, PH);",
"     </li>",
"     <li>",
"      Mednin (TW);",
"     </li>",
"     <li>",
"      Medrate (DE);",
"     </li>",
"     <li>",
"      Medrol (AE, BB, BE, BH, BM, BS, BZ, CH, CL, CN, CO, CR, CY, CZ, DE, DK, EC, EE, EG, ES, FI, FR, GB, GR, GT, GY, HN, HR, ID, IE, IL, IN, IQ, IR, IT, JM, JO, KP, KW, LB, LU, LY, MT, NI, NL, NO, NZ, OM, PA, PE, PH, PL, PT, QA, RU, SA, SE, SK, SR, SV, SY, TR, TT, VE, YE, ZA);",
"     </li>",
"     <li>",
"      Medrone (GB);",
"     </li>",
"     <li>",
"      Melone 16 (TW);",
"     </li>",
"     <li>",
"      Melsone (IN);",
"     </li>",
"     <li>",
"      Menisone (TW);",
"     </li>",
"     <li>",
"      Meprednisona All Pro (AR);",
"     </li>",
"     <li>",
"      Mepresone (PH);",
"     </li>",
"     <li>",
"      Mesolone (KP);",
"     </li>",
"     <li>",
"      Metcor (ID);",
"     </li>",
"     <li>",
"      Methylon (KP);",
"     </li>",
"     <li>",
"      Methylpred (AU);",
"     </li>",
"     <li>",
"      Methylprednisolone David Bull (LU);",
"     </li>",
"     <li>",
"      Methysol (KP);",
"     </li>",
"     <li>",
"      Predlitem (MX);",
"     </li>",
"     <li>",
"      Prednol (TR);",
"     </li>",
"     <li>",
"      Prednox (PH);",
"     </li>",
"     <li>",
"      Prena (KP);",
"     </li>",
"     <li>",
"      Pretilon (ID);",
"     </li>",
"     <li>",
"      Prolon (ID);",
"     </li>",
"     <li>",
"      Sanexon (ID);",
"     </li>",
"     <li>",
"      Sologen (KP);",
"     </li>",
"     <li>",
"      Solomet (FI);",
"     </li>",
"     <li>",
"      Solu Medrol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Solu-Medrol (AU, BG, HK, MX, MY, PK, TH, UY);",
"     </li>",
"     <li>",
"      Solu-Pred (MY);",
"     </li>",
"     <li>",
"      Thimelon (ID);",
"     </li>",
"     <li>",
"      Tropidrol (ID);",
"     </li>",
"     <li>",
"      Urbason (AT, CZ, DE, ES, HR, NL);",
"     </li>",
"     <li>",
"      Urbason Retard (BE, IT);",
"     </li>",
"     <li>",
"      Yalone (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F195345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In a tissue-specific manner, corticosteroids regulate gene expression subsequent to binding specific intracellular receptors and translocation into the nucleus. Corticosteroids exert a wide array of physiologic effects including modulation of carbohydrate, protein, and lipid metabolism and maintenance of fluid and electrolyte homeostasis. Moreover cardiovascular, immunologic, musculoskeletal, endocrine, and neurologic physiology are influenced by corticosteroids. Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F195364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect (route dependent): Oral: 1-2 hours; I.M.: 4-8 days; Intra-articular: 1 week; methylprednisolone sodium succinate is highly soluble and has a rapid effect by I.M. and I.V. routes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration (route dependent): Oral: 30-36 hours; I.M.: 1-4 weeks; Intra-articular: 1-5 weeks; methylprednisolone acetate has a low solubility and has a sustained I.M. effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.7-1.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3-3.5 hours; reduced in obese",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Clearance: Reduced in obese",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abraham E and Evans T, &ldquo;Corticosteroids and Septic Shock [editorial],&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(7):886-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/12186608/pubmed\" id=\"12186608\" target=\"_blank\">",
"        12186608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Annane D, Sebille V, Charpentier C, et al, &ldquo;Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(7):862-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/12186604/pubmed\" id=\"12186604\" target=\"_blank\">",
"        12186604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benson CA, Kaplan JE, Masur H, et al, &ldquo;Treating Opportunistic Infections Among HIV-Exposed and Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health and the HIV Medicine Association/IDSA,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2004, 53(RR-15):1-112",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/15841069/pubmed\" id=\"15841069\" target=\"_blank\">",
"        15841069",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bracken MB, Shepard MJ, Collins WF, et al, &ldquo;A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord Injury. Results of the Second National Acute Spinal Cord Injury Study,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1990, 322(20):1405-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/2278545/pubmed\" id=\"2278545\" target=\"_blank\">",
"        2278545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratton SL, Chestnut RM, Ghajar J, et al, &ldquo;Guidelines for the Management of Severe Traumatic Brain Injury. XV. Steroids,&rdquo;",
"      <i>",
"       J Neurotrauma",
"      </i>",
"      , 2007, 24(Suppl 1):91-5",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/17511554/pubmed\" id=\"17511554\" target=\"_blank\">",
"        17511554",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Consortium for Spinal Cord Medicine, &ldquo;Early Acute Management in Adults With Spinal Cord Injury: A Clinical Practice Guideline for Health-Care Professionals,&rdquo;",
"      <i>",
"       J Spinal Cord Med",
"      </i>",
"      , 2008, 31(4):403-79.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper MS and Stewart PM, &ldquo;Corticosteroid Insufficiency in Acutely Ill Patients,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(8):727-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/12594318/pubmed\" id=\"12594318\" target=\"_blank\">",
"        12594318",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coursin DB and Wood KE, &ldquo;Corticosteroid Supplementation for Adrenal Insufficiency,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 287(2):236-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/11779267/pubmed\" id=\"11779267\" target=\"_blank\">",
"        11779267",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Jonghe B, Sharshar T, Lefaucheur JP, et al, &ldquo;Paresis Acquired in the Intensive Care Unit. A Prospective Multicenter Study,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(22):2859-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/12472328/pubmed\" id=\"12472328\" target=\"_blank\">",
"        12472328",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2008, 34(1):17-60. Available at",
"      <a href=\"file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf\" target=\"_blank\">",
"       file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/18058085/pubmed\" id=\"18058085\" target=\"_blank\">",
"        18058085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Drake LA, Dinehart SM, Farmer ER, et al, &ldquo;Guidelines of Care for Dermatomyositis. American Academy of Dermatology,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1996, 34(5 Pt 1):824-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/8632081/pubmed\" id=\"8632081\" target=\"_blank\">",
"        8632081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edwards P, Arango M, Balica L, et al, &ldquo;Final Results of MRC Crash, A Randomized Placebo-Controlled Trial of Intravenous Corticosteroid in Adults With Head Injury - Outcomes at 6 Months,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2005, 365(9475):1957-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/15936423/pubmed\" id=\"15936423\" target=\"_blank\">",
"        15936423",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gamsu HR, Mullinger BM, Donnai P, et al, &ldquo;Antenatal Administration of Betamethasone to Prevent Respiratory Distress Syndrome in Preterm Infants: Report of a UK Multicentre Trial,&rdquo;",
"      <i>",
"       Br J Obstet Gynaecol",
"      </i>",
"      , 1989, 96(4):401-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/2665800/pubmed\" id=\"2665800\" target=\"_blank\">",
"        2665800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hotchkiss RS and Karl IE, &ldquo;The Pathophysiology and Treatment of Sepsis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(2):138-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/12519925/pubmed\" id=\"12519925\" target=\"_blank\">",
"        12519925",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liggins GC and Howie RN, &ldquo;A Controlled Trial of Antepartum Glucocorticoid Treatment of Respiratory Distress Syndrome in Premature Infants,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1972, 50:515-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/4561295/pubmed\" id=\"4561295\" target=\"_blank\">",
"        4561295",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marik PE, Pastores SM, Annane D, et al, &ldquo;Recommendations for the Diagnosis and Management of Corticosteroid Insufficiency in Critically Ill Adult Patients: Consensus Statements From an International Task Force by the American College of Critical Care Medicine,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(6):1937-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/18496365/pubmed\" id=\"18496365\" target=\"_blank\">",
"        18496365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGee S and Hirschmann J, &ldquo;Use of Corticosteroids in Treating Infectious Diseases,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2008, 168(10):1034-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/18504331/pubmed\" id=\"18504331\" target=\"_blank\">",
"        18504331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo; Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ostensen M, &ldquo;Optimisation of Antirheumatic Drug Treatment in Pregnancy,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1994, 27(6):486-503.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/7882637/pubmed\" id=\"7882637\" target=\"_blank\">",
"        7882637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ponticelli C, Glassock RJ, and Moroni G, &ldquo;Induction and Maintenance Therapy in Proliferative Lupus Nephritis,&rdquo;",
"      <i>",
"       J Nephrol",
"      </i>",
"      , 2010, 23(1):9-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/20091481/pubmed\" id=\"20091481\" target=\"_blank\">",
"        20091481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo;",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(12):968-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/14745915/pubmed\" id=\"14745915\" target=\"_blank\">",
"        14745915",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberts I, Yates D, Sandercock P, et al, &ldquo;Effect of Intravenous Corticosteroids on Death Within 14 days in 10,008 Adults With Clinically Significant Head Injury (MRC CRASH trial): Randomised Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2004, 364(9442):1321-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/15474134/pubmed\" id=\"15474134\" target=\"_blank\">",
"        15474134",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salem M, Tainsh RE Jr, Bromberg J, et al, &ldquo;Perioperative Glucocorticoid Coverage. A Reassessment 42 Years After Emergence of a Problem,&rdquo;",
"      <i>",
"       Ann Surg",
"      </i>",
"      , 1994, 219(4):416-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/8161268/pubmed\" id=\"8161268\" target=\"_blank\">",
"        8161268",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sprung CL, Annane D, Keh D, et al, &ldquo;Hydrocortisone Therapy for Patients With Septic Shock,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(2):111-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/18184957/pubmed\" id=\"18184957\" target=\"_blank\">",
"        18184957",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steinberg KP, Hudson LD, Goodman RB, et al, &ldquo;Efficacy and Safety of Corticosteroids for Persistent Acute Respiratory Distress Syndrome. National Heart, Lung and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(16):1671-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/16625008/pubmed\" id=\"16625008\" target=\"_blank\">",
"        16625008",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tornatore KM, Logue G, Venuto RC, et al, &ldquo;Pharmacokinetics of Methylprednisolone in Elderly and Young Healthy Males,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1994, 42(10):1118-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/25/31129/abstract-text/7930339/pubmed\" id=\"7930339\" target=\"_blank\">",
"        7930339",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9639 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-D9A34E86B4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_25_31129=[""].join("\n");
var outline_f30_25_31129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15254327\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195382\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195383\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195428\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195386\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195409\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195387\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195388\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195358\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195342\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195362\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195435\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195361\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10411137\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195438\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195426\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195365\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195346\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195422\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195351\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195378\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6472614\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195395\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6472616\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195369\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195368\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195356\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195370\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195345\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195364\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9639\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9639|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/5/14422?source=related_link\">",
"      Methylprednisolone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=related_link\">",
"      Methylprednisolone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_25_31130="Gamma hydroxybutyrate (GHB) intoxication";
var content_f30_25_31130=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gamma hydroxybutyrate (GHB) intoxication",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/25/31130/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/25/31130/contributors\">",
"     Deborah L Zvosec, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/25/31130/contributors\">",
"     Stephen W Smith, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/25/31130/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/25/31130/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/25/31130/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/25/31130/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/25/31130/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/25/31130/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H32702817\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamma hydroxybutyrate (GHB) is a central nervous system (CNS) depressant first synthesized in France as an analog of gamma aminobutyric acid (GABA) and capable of crossing the blood brain barrier. Initially used as an anesthetic in Europe, GHB's inadequate analgesic effects and side effects, including myoclonus and emergence delirium, prevented approval in the United States (US) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 1980s GHB was marketed as a bodybuilding and weight loss drug and sold in health food stores. Subsequently, use became more widespread as GHB was abused for euphoric, sexual, stimulant, and relaxant effects. Following reports of adverse effects and the enactment of government restrictions on GHB, the marketing of gamma butyrolactone (GBL) and 1,4 butanediol (BD), two common industrial solvents, as &ldquo;dietary supplements&rdquo; began. Both of these compounds are analogs or congeners of GHB, which when ingested are rapidly metabolized to GHB, with the same clinical effects. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pharmacology and cellular toxicology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    GBL and BD have been sold spuriously as &ldquo;non-toxic&rdquo; and &ldquo;organic&rdquo; solvents, &ldquo;cleaning products,&rdquo; and &ldquo;chemical samples&rdquo; to avoid detection and prosecution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/2\">",
"     2",
"    </a>",
"    ]. Available formulations include industrial GBL and BD, street supplies, home-synthesized GHB (made from recipes available on the Internet), and pharmaceutical formulations. Internet websites, chat rooms, and forums have figured prominently in the dissemination of information and misinformation regarding GHB sources and supplies, use and effects, and legal status around the world [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Formulations and dosing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The toxicology and management of acute GHB intoxication are reviewed here. GHB withdrawal, the toxicology of other specific agents that may be coingested, and general management of the poisoned patient are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/27/3514?source=see_link\">",
"     \"Gamma hydroxybutyrate (GHB) dependence and withdrawal\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/3/21560?source=see_link\">",
"     \"MDMA (ecstasy) intoxication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Throughout this review we use the term \"GHB\" to refer to GHB and its analogs, unless specifically noted. The pharmacology of GHB and its analogs are discussed in the text. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pharmacology and cellular toxicology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of gamma hydroxybutyrate (GHB) use among adults in the United States (US) is unknown. GHB is not included in the National Household Survey on Drug Use and Health, which provides data on drug and alcohol use for a large nationwide sample of adults. Data is limited to the Monitoring the Future survey, sponsored by the National Institute of Drug Abuse (NIDA) which is collected from a limited sample of high school and college students. Findings from the 2010 survey indicate an annual prevalence of GHB use of 0.6 percent, 0.6 percent, and 1.4 percent in 8",
"    <sup>",
"     th",
"    </sup>",
"    , 10",
"    <sup>",
"     th",
"    </sup>",
"    , and 12",
"    <sup>",
"     th",
"    </sup>",
"    grades, respectively, as compared to peak levels of use in 2000, of 1.2 percent (8",
"    <sup>",
"     th",
"    </sup>",
"    grade), 1.1 percent (10",
"    <sup>",
"     th",
"    </sup>",
"    grade), and 1.9 percent (12",
"    <sup>",
"     th",
"    </sup>",
"    grade) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    US surveillance data on adverse events related to GHB is limited to a national probability sample of hospital emergency departments (ED) participating in the Drug Abuse Warning Network (DAWN) of the NIDA. The results of this surveillance likely underestimate the incidence of adverse events, as GHB is not detectable on routine toxicology screens and may be easily missed or confused with other drugs. According to DAWN, ED visits related to GHB abuse increased from 56 in 1994, peaked at 4969 in 2000, and declined to 3330 in 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/7\">",
"     7",
"    </a>",
"    ]. New methods for data collection were initiated for DAWN in 2003. Subsequent reports, while not directly comparable to earlier data, document that GHB-related ED visits (not merely those related to abuse), declined to 1036 in 2005, but more than doubled to 2207 in 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/8\">",
"     8",
"    </a>",
"    ]. Approximately 90 percent of those abusing GHB were male. The American Association of Poison Control Centers reported a peak of 1916 GHB exposures in 2001, a low of 448 in 2008, and a subsequent increase to 541 in 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidemiologic data available on GHB use in Europe is also limited. Targeted surveys indicate low use among the general population, but higher use among subgroups, such as young club-goers. Norway and Sweden are the only European Union (EU) countries that report yearly figures for the detection of GHB in biological samples; both report low levels overall, but document 10 to 20-fold increases from the late 1990s to 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Patterns of GHB overdose in Europe and Australia roughly parallel those in the US, with the earliest reports in the early 1990s followed by increases in the late 1990s and early 2000s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/14-20\">",
"     14-20",
"    </a>",
"    ]. Reports through the mid-2000&rsquo;s show continued use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/21-25\">",
"     21-25",
"    </a>",
"    ], with increases in reports of GBL-related adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Those who use GHB and its analogues gamma butyrolactone (GBL) and 1,4 butanediol (BD) illicitly generally fall into two categories: (1) individuals using the drugs for purported health benefits, such as bodybuilders and people attempting self-treatment of insomnia, depression, anxiety, and alcohol and drug dependence; and (2) recreational users, who take these compounds at social gatherings, clubs, and bars. Among recreational users, GHB, GBL, and BD are often used concurrently with other drugs, such as MDMA (ecstasy), cocaine, and methamphetamine, as well as alcohol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/1,2,5,27,28\">",
"     1,2,5,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GHB-intoxicated driving has been widely documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/2,29-35\">",
"     2,29-35",
"    </a>",
"    ]. Detection is impeded by the absence of a routine toxicological screen and the potential for confusing the effects of GHB with those of other intoxicants. Norway and Sweden collect systematic data on GHB-intoxicated drivers and both report significant increases during the 2000s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Accidental ingestion has been reported among children ingesting GBL solvents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/17,40,41\">",
"     17,40,41",
"    </a>",
"    ] and among adults mistaking GHB or GBL for water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/42\">",
"     42",
"    </a>",
"    ], sometimes resulting in death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Acute toxicity in children who ingested BD-coated toy beads has been reported in the UK [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/45\">",
"     45",
"    </a>",
"    ], Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/46\">",
"     46",
"    </a>",
"    ], and the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surreptitious drugging with GHB to facilitate sexual assault has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/29,48-51\">",
"     29,48-51",
"    </a>",
"    ]. Detection of GHB in cases of alleged assault is impeded by the lack of a readily available screen, the short half-life of GHB, amnestic effects, and delays in presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/52\">",
"     52",
"    </a>",
"    ]. Voluntary intoxication with GHB puts individuals at risk for sexual assault [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/28\">",
"     28",
"    </a>",
"    ] and risky sexual behaviors. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'GHB-facilitated sexual assault'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Data on GHB-associated fatalities is limited to case reports and case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/44,53,54\">",
"     44,53,54",
"    </a>",
"    ]. To date, approximately 400 deaths associated with ingestion of GHB, GBL,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    BD have been documented in the US, Europe, Australia, and New Zealand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/55\">",
"     55",
"    </a>",
"    ]. Of 226 deaths reported in one series, 35 percent did not appear to involve cointoxicants. Many cases involve decedents who were left by witnesses to &ldquo;sleep it off&rdquo; and later found dead, despite a known ingestion and observed adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/44\">",
"     44",
"    </a>",
"    ]. Interview data indicates that GHB overdose (defined as losing consciousness) is often viewed by users as neither dangerous nor harmful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Lethality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    GHB-associated deaths are likely under-detected and under-reported due to the lack of routine testing by hospitals and medical examiners, variable familiarity of medical examiners and coroners with GHB and its analogs, limited resources for testing, absence of billing codes for GHB as a cause of death, and lack of death registries. The detection of Xyrem&reg;-related fatalities is equally difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamma hydroxybutyrate (GHB) is a short-chain fatty acid that exists endogenously in mammalian tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. It is a metabolite and precursor of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. GHB interacts with GHB-specific receptors and also acts as a direct agonist of GABA-B receptors. In high doses it may exert additional GABA-like effects through conversion to GABA. GHB affects multiple neurotransmitter systems, including those of opioids, dopamine, serotonin, glutamate, and acetylcholine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gamma butyrolactone (GBL) and 1,4 butanediol (BD) are GHB analogs that are rapidly metabolized to GHB after ingestion, with the same toxic and recreational effects. GBL is an endogenous lactone that is converted to GHB via a peripheral lactonase. Animal studies demonstrate GBL to have more rapid absorption, greater lipid solubility, higher serum concentrations, and more prolonged hypnotic effects than GHB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/63-65\">",
"     63-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BD is an endogenous aliphatic alcohol that is converted to gamma hydroxybutyraldehyde and subsequently to GHB by alcohol dehydrogenase and aldehyde dehydrogenase respectively. As with GBL, effects are mediated through GABA-B and GHB receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/66\">",
"     66",
"    </a>",
"    ]. In contrast to GBL, which appears to exert effects solely through conversion to GHB, animal studies suggest there may be additional toxic effects from unmetabolized BD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/67\">",
"     67",
"    </a>",
"    ]. Animal research also suggests potential interactions between BD and ethanol due to competition for alcohol dehydrogenase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FORMULATIONS AND DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Illicit GHB, GBL, and BD are most commonly ingested in liquid form, although GHB is also sold in powder form, and GBL and BD have been sold in capsule form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Liquid GHB is odorless and clear, with a salty or soapy taste. GBL and BD supplements and solvents reportedly have a chemical taste and may also have colorants, scents, and flavorings added. Lists of GHB, GBL, and BD-containing products and slang terms are available (",
"    <a class=\"graphic graphic_table graphicRef52665 \" href=\"mobipreview.htm?29/54/30572\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/2,69\">",
"     2,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Product concentrations vary widely, from undiluted GHB and industrial grade GBL and BD, to dilute GBL and BD supplement and solvent products; street doses are reported to vary from 500 mg to 5 grams per teaspoon or capful dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/70\">",
"     70",
"    </a>",
"    ]. Recreational doses of GHB (ie, for euphoric effects) are approximately 2.5 grams [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/71\">",
"     71",
"    </a>",
"    ], but vary widely. Dependent users report the development of tolerance and may use up to 7 grams per dose several times per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GHB toxicity may be compounded by toxic contaminants or additives in GBL or BD-containing solvents, paint removers, and cleaners, as well as undissolved sodium hydroxide and other contaminants used in home-synthesized GHB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GHB is used as a therapeutic agent in the United States (US) and in Europe. In the US, GHB is available as Xyrem&reg; (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15990?source=see_link\">",
"     sodium oxybate",
"    </a>",
"    ), which has been approved by the US Food and Drug Administration for treatment of narcolepsy with cataplexy or excessive daytime sleepiness. In the US, GHB has a bifurcated Drug Enforcement Administration scheduling status: GHB used for illicit purposes is a Schedule I Controlled Substance, while pharmaceutical GHB (Xyrem&reg;, sodium oxybate) used for therapeutic purposes is a Schedule III drug. In Europe, GHB is available as Xyrem&reg;, Alcover, which has been studied for treatment of alcohol and drug dependence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/75\">",
"     75",
"    </a>",
"    ], and Somsanit, an anesthetic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/76\">",
"     76",
"    </a>",
"    ]. Xyrem&reg; is distributed in the US through a single central pharmacy and a risk management program is maintained. While post-marketing safety surveillance reports a low incidence of abuse or misuse of Xyrem&reg; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/29\">",
"     29",
"    </a>",
"    ], cases of",
"    <span class=\"nowrap\">",
"     Xyrem&reg;/sodium",
"    </span>",
"    oxybate diversion, toxicity, dependence, and withdrawal have been documented, as well as Xyrem&reg;-associated sexual assault, impaired driving, and fatalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/29,30,77-79\">",
"     29,30,77-79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommended adult doses of Xyrem&reg; for treatment of narcolepsy are approximately 2.25 to 4.5 grams per dose, administered twice nightly; efficacy and safety have not been investigated for doses higher than 9 grams per night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     KINETICS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absorption and elimination &ndash; GHB is rapidly absorbed and eliminated following oral ingestion. Absorption and elimination are capacity limited [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/81-83\">",
"       81-83",
"      </a>",
"      ]. Elimination is biphasic: the first phase occurs at plasma levels above 25 to 50",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      (doses higher than 30",
"      <span class=\"nowrap\">",
"       mg/kg),",
"      </span>",
"      and is capacity-limited (ie, zero order kinetics), with a rapid and linear decrease of levels; this is followed by a slower, first order, rate of elimination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/83-86\">",
"       83-86",
"      </a>",
"      ]. Following single oral doses of 25 to 72",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      GHB mean peak serum levels range from 40 to 130",
"      <span class=\"nowrap\">",
"       mg/L.",
"      </span>",
"      The mean time to peak blood levels ranges from 36 to 57 minutes, and the mean elimination half-life is between 30 to 52 minutes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/84-87\">",
"       84-87",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      BD is rapidly and extensively metabolized to GHB, with measurable plasma GHB detectable in a majority of subjects within five minutes of ingestion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/88\">",
"       88",
"      </a>",
"      ]. Pharmacokinetic studies of GBL in humans have not been reported, but animal studies demonstrate more rapid absorption, higher serum concentrations, and more prolonged hypnotic effects of GBL compared with GHB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/63-65\">",
"       63-65",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      GHB levels in oral fluid show no correlation with blood GHB levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/84-89\">",
"       84-89",
"      </a>",
"      ]. GHB levels in sweat appear to be minimal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Variability of pharmacokinetic parameters &ndash; Significant intersubject variability exists in the pharmacokinetic parameters of GHB and BD, as determined by measurements in blood, saliva, sweat, and urine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/84,85,90,91\">",
"       84,85,90,91",
"      </a>",
"      ]. Variability may result from differences in bioavailability, absorption rate, drug metabolizing enzyme activities, or tolerance resulting from chronic use.",
"     </li>",
"     <li>",
"      Metabolism &ndash; GHB is metabolized via several intracellular pathways, the most important of which produces succinic acid, which then enters the tricarboxylic acid (ie, Krebs) cycle. GHB recovery in urine ranges from 1.2 to 5 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/85,86,89\">",
"       85,86,89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Factors affecting pharmacokinetics &ndash; Food has been shown to reduce peak plasma concentrations and systemic absorption of GHB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/92\">",
"       92",
"      </a>",
"      ]. Coadministration of ethanol with GHB resulted in statistically insignificant elevations in maximum plasma concentrations and the elimination half-life of GHB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/86\">",
"       86",
"      </a>",
"      ]. At higher recreational doses, however, such elevations could result in greater clinical toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/86\">",
"       86",
"      </a>",
"      ]. Gender does not affect kinetics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Onset, peak, and dose response &ndash; The clinical and EEG effects of GHB begin rapidly, typically within 15 to 20 minutes of an oral dose, with peak clinical effects reached between 30 to 60 minutes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/93\">",
"       93",
"      </a>",
"      ]. IV doses produce effects within five minutes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/94\">",
"       94",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      GHB manifests a steep dose-effect curve [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/95\">",
"       95",
"      </a>",
"      ]. Abrupt onset of sedation and loss of consciousness are reported, as well as abrupt clearing of effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/89,96-98\">",
"       89,96-98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Duration of effects &ndash; The duration of GHB's clinical effects depends upon the dose, and ranges from 2.5 to 4 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/87,95,97,99\">",
"       87,95,97,99",
"      </a>",
"      ]. Case series of patients with acute toxicity report symptom durations of between 2 to 4 hours in nonintubated patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/14,15,100\">",
"       14,15,100",
"      </a>",
"      ]. Symptom duration may be longer, particularly in the presence of cointoxicants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/101,102\">",
"       101,102",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Variability of effects &ndash; Low oral doses of GHB result in variable effects in the same user at different times and among users generally [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/1\">",
"       1",
"      </a>",
"      ]. Among drivers intoxicated with GHB, significant variability in effect has been reported for those who received clinical impairment tests concurrent with blood draws [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/37\">",
"       37",
"      </a>",
"      ]. Significant variability in sedative effects can occur following IV doses administered for anesthesia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EFFECTS NOTED DURING CLINICAL STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic and observational trials of GHB describe clinical effects found with low doses and no coingestants. Below we summarize the effects noted during clinical studies.",
"   </p>",
"   <p>",
"    GHB primarily affects the central nervous system (CNS) and dose-related central nervous system (CNS) depression is most commonly described. However, clinical studies document a mixed sedative-stimulant pattern among patients treated with GHB. Psychostimulant effects predominate during the first hour and sedative effects may predominate in the second hour after administration of oral doses (40 to 72",
"    <span class=\"nowrap\">",
"     mg/kg).",
"    </span>",
"    Effects are dose-dependent and correlate with plasma concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/87,104\">",
"     87,104",
"    </a>",
"    ]. The stimulant effects described are consistent with popular reports of GHB use for energy. The effect is similar to ethanol toxicity, in that agitation or CNS activation can develop early after intoxication.",
"   </p>",
"   <p>",
"    Confusion, dizziness, and drowsiness occur following low oral doses of GHB (12.5 to 25",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    and BD (25",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/83,88,105\">",
"     83,88,105",
"    </a>",
"    ]. Higher doses (40 to 64",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    result in psychomotor impairment, dizziness, impaired memory, and variable levels of sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/83,86,91,106,107\">",
"     83,86,91,106,107",
"    </a>",
"    ]. Studies of simulated driving following a 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose report a significant increase in collisions and decrease in performance (eg, slower reaction time, greater deviations in speed and lane position, and lower self-rating of driving ability) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/108\">",
"     108",
"    </a>",
"    ]. Loss of consciousness and profound coma have been reported with oral doses above 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/96\">",
"     96",
"    </a>",
"    ]. Memory impairment is reported in GHB administration and anesthesia studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/94,95,106,107,109\">",
"     94,95,106,107,109",
"    </a>",
"    ]. Coadministration of ethanol exacerbates these cognitive effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depression has been reported in clinical trials of Xyrem&reg; for patients with narcolepsy, during pre-approval (3.2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/80\">",
"     80",
"    </a>",
"    ] and post-approval studies (10.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/110\">",
"     110",
"    </a>",
"    ], as well as in case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. Suicidal ideation, suicide attempts, and completed suicides among patients treated with Xyrem&reg; have also been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/29,80,111\">",
"     29,80,111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiorespiratory symptoms include minor increases in blood pressure and, at higher doses, a significant decrease in heart rate. Decreased respiratory rates and lower oxygen saturation levels may occur with low oral doses of GHB and BD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/86,88\">",
"     86,88",
"    </a>",
"    ]. Coadministration of ethanol can potentiate these effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/86\">",
"     86",
"    </a>",
"    ]. Cheyne-Stokes breathing has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/109\">",
"     109",
"    </a>",
"    ]. Profound respiratory depression has been documented during clinical trials of Xyrem&reg; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/80,113,114\">",
"     80,113,114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myoclonus was reported during surgical induction with GHB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/42,115\">",
"     42,115",
"    </a>",
"    ] and during clinical trials of Xyrem&reg; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/80\">",
"     80",
"    </a>",
"    ]. Disconjugate gaze (exophoria) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/84\">",
"     84",
"    </a>",
"    ], nausea, vomiting, and urinary and fecal incontinence have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/80,86,95,104\">",
"     80,86,95,104",
"    </a>",
"    ]. Vomiting is more common with coadministration of ethanol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/86\">",
"     86",
"    </a>",
"    ]. Confusion and \"sleepwalking\" (4 percent) were documented in clinical trials of Xyrem&reg;. Sleepwalking was associated with injury in several cases, including a fall and one patient who set their clothes on fire while attempting to smoke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF ACUTE TOXICITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Risk factors for acute toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk of acute gamma hydroxybutyrate (GHB) toxicity is heightened by the drug's steep dose-response curve (ie, narrow safety margin), abrupt onset of effects, variability and unpredictability of effects, and the availability of a wide variety of forms with highly variable concentrations, often unknown to the user [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/1,44,95\">",
"     1,44,95",
"    </a>",
"    ]. GHB users report difficulties titrating doses and overdose is common, often despite a limited history of abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/56,70\">",
"     56,70",
"    </a>",
"    ]. The risk of acute toxicity is greater among GHB dependent users who dose frequently throughout the day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/2,116\">",
"     2,116",
"    </a>",
"    ]. Use of cointoxicants, including other illicit drugs and ethanol, is common among GHB users and presents additional risk from additive effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/14,15,21,24,70,100\">",
"     14,15,21,24,70,100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/27/3514?source=see_link\">",
"     \"Gamma hydroxybutyrate (GHB) dependence and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     General presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute GHB toxicity manifests primarily as dose-related central nervous system (CNS) depression, although stimulant effects such as agitation are reported. Sudden onset of effects, as well as abrupt awakening and resolution of effects, frequently occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/42,98\">",
"     42,98",
"    </a>",
"    ]. The signs and symptoms of acute GHB toxicity are described below.",
"   </p>",
"   <p>",
"    Ingested doses for patients presenting with acute GHB toxicity are most often unknown, but likely exceed significantly those described in GHB and BD administration studies.",
"   </p>",
"   <p>",
"    Use of cointoxicants such as ethanol, MDMA (ecstasy), and methamphetamine is common. Large case series of GHB toxicity often fail to differentiate clinical effects between patients presenting with and without cointoxicants. In order to elucidate acute toxic effects solely attributable to GHB, in the following sections we specify effects found in patients without cointoxicants and indicate when coingestants are specified or unspecified whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Vital signs",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood pressure &ndash; Hypotension (systolic blood pressure &le;90 mmHg) is described in case reports of GHB toxicity without cointoxicants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/41\">",
"       41",
"      </a>",
"      ] and in cases of GHB coingested with ethanol or other drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/14-16,100\">",
"       14-16,100",
"      </a>",
"      ]; two case series note hypotension to be coincident with low Glasgow Coma Scores (GCS 3 to 6) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Heart rate &ndash; Bradycardia is described in GHB toxicity cases without depressant cointoxicants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/17,45,117\">",
"       17,45,117",
"      </a>",
"      ] and with stimulant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/118\">",
"       118",
"      </a>",
"      ] and depressant cointoxicants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/119\">",
"       119",
"      </a>",
"      ]. Several large case series of GHB describe bradycardia (pulse &lt;55 bpm) in up to 38 percent of patients, but the presence of cointoxicants is unspecified. As for hypotension, some series note that bradycardia correlated with low GCS scores [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/14-16,100\">",
"       14-16,100",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Respiratory rate &ndash; Acute GHB toxicity, with or without cointoxicants, may result in significantly depressed respiratory rates, [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/117,119-121\">",
"       117,119-121",
"      </a>",
"      ]. Respiratory arrest is described in cases with [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/120\">",
"       120",
"      </a>",
"      ] and without cointoxicants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/40,45,122,123\">",
"       40,45,122,123",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Temperature &ndash; Hypothermia is described in acute GHB intoxication without cointoxicants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/117\">",
"       117",
"      </a>",
"      ]. Temperatures ranging from 32&ordm;C (90&ordm;F) to 39&ordm;C (102&ordm;F) have been reported in series with cointoxicants unspecified [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/14,15,100\">",
"       14,15,100",
"      </a>",
"      ]. In another series, up to 31 percent of patients whose temperatures were recorded had readings below 35&ordm;C (95&ordm;F) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Central nervous system effects",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coma &ndash; Coma is common with GHB intoxication. Loss of consciousness may occur quickly (within 15 minutes) and abruptly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/69\">",
"       69",
"      </a>",
"      ]. Glasgow Coma Scale (GCS) scores of 3 have been recorded in cases without cointoxicants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/17,25,31,117,124,125\">",
"       17,25,31,117,124,125",
"      </a>",
"      ] and are frequently reported in large case series in which cointoxicants are unspecified [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/15,16,100\">",
"       15,16,100",
"      </a>",
"      ]. One series documented significantly deeper and more prolonged coma among patients with stimulant cointoxicants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Agitation &ndash; Agitation is well documented in cases of GHB toxicity with [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/120\">",
"       120",
"      </a>",
"      ] and without cointoxicants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/2,15,17,32,117,124,126,127\">",
"       2,15,17,32,117,124,126,127",
"      </a>",
"      ]. Agitation manifests in various forms, including emergence delirium, agitation in response to interventions such as intubation, and spontaneous agitation, occurring before, after, or in abrupt alternation with somnolence, obtundation, or coma. Self-injurious behavior, such as striking the head on the floor or with fists, as well as bizarre behaviors, facial tics, and grimacing have all been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/2,116,124,128\">",
"       2,116,124,128",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Amnesia &ndash; Amnesia is reported by GHB users [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/70\">",
"       70",
"      </a>",
"      ] and by patients presenting with acute GHB intoxication, with and without cointoxicants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/17,32,121,129\">",
"       17,32,121,129",
"      </a>",
"      ]. Amnestic effects play an important role in cases of GHB-facilitated sexual assault. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'GHB-facilitated sexual assault'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Seizures and seizure-like effects &ndash; Myoclonus and seizure-like effects have been reported in cases of acute GHB intoxication without cointoxicants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/102,130\">",
"       102,130",
"      </a>",
"      ]. These effects are also documented in numerous case series in which cointoxicants were not specified, with the incidence reported to be up to 13 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/1,14-16,24,100,131\">",
"       1,14-16,24,100,131",
"      </a>",
"      ]. These effects may, in some instances, be confused with seizures. Far less commonly, seizure is reported in patients without cointoxicants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/132,133\">",
"       132,133",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other CNS effects &ndash; Ataxia and sudden loss of muscle control have been reported, sometimes associated with falls and related trauma, in the absence of cointoxicants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/2,32,134\">",
"       2,32,134",
"      </a>",
"      ]. Disconjugate gaze [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/32,120\">",
"       32,120",
"      </a>",
"      ] and nystagmus (horizontal and vertical) have been documented [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/32,117,124,134\">",
"       32,117,124,134",
"      </a>",
"      ] with and without cointoxicants, as well as visual effects including blurred vision and loss of peripheral vision [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/32,48,121\">",
"       32,48,121",
"      </a>",
"      ]. Although pupils may be miotic during deep coma, pupillary reactions are variable and may be affected by coingestants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Respiratory effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apnea and respiratory depression from GHB overdose is well documented in the absence of cointoxicants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/17,31,45,117,121,122\">",
"     17,31,45,117,121,122",
"    </a>",
"    ], as well as in case series with cointoxicants unspecified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/15,16,135\">",
"     15,16,135",
"    </a>",
"    ]. Respiratory arrest has been reported in patients without cointoxicants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/18,40,102,117\">",
"     18,40,102,117",
"    </a>",
"    ], with cointoxicants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/18,123,136\">",
"     18,123,136",
"    </a>",
"    ], and in case series where cointoxicants were not specified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/31,101,131\">",
"     31,101,131",
"    </a>",
"    ]. Oxygen saturation levels below 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/16,135,137\">",
"     16,135,137",
"    </a>",
"    ] and PaCO2 levels above 45 mmHg (indicative of hypoventilation and respiratory depression) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/100\">",
"     100",
"    </a>",
"    ] have been reported. Pulmonary edema (likely of neurogenic origin) occurred following accidental ingestion of a paint remover containing GBL (with no cointoxicants) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/40\">",
"     40",
"    </a>",
"    ]. Toxic effects of additional chemicals, additives, or contaminants in commercial GBL and BD products may compound the effects of GBL and BD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cardiovascular effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;GHB can cause bradycardia and hypotension. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Vital signs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other documented cardiovascular effects associated with GHB toxicity are limited to isolated reports of the following: atrial fibrillation (without cointoxicants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/138\">",
"     138",
"    </a>",
"    ] and with barbiturates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/100\">",
"     100",
"    </a>",
"    ]); paroxysmal sympathetic surge with one to two minute cyclical increases in pulse and blood pressure (no cointoxicants) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/139\">",
"     139",
"    </a>",
"    ]; and three reports of cardiac arrhythmias, all transient but one for which temporary pacing was used (cointoxicants unspecified) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/140\">",
"     140",
"    </a>",
"    ]. There is one reported case of cardiac arrest, from which the patient recovered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/141\">",
"     141",
"    </a>",
"    ]. There are no reports of consistent or significant electrocardiographic changes associated with GHB toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis is reported in a case of GHB toxicity in which the patient developed withdrawal that involved seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/132\">",
"     132",
"    </a>",
"    ]. Rhabdomyolysis is reported in a case of GBL ingestion followed by prolonged unconsciousness and immobility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/142\">",
"     142",
"    </a>",
"    ]. Elevated creatine kinase (CK) levels are noted in 12 to 58 percent of patients in three case series of GHB toxicity, but cointoxicants in these cases were unspecified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Gastrointestinal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vomiting is commonly reported in acute GHB toxicity without cointoxicants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/31,102,117,125\">",
"     31,102,117,125",
"    </a>",
"    ], but it appears to occur much more frequently in cases with ethanol coingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Aspiration may result. Urinary and fecal incontinence have been reported, with and without cointoxicants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/2,16,117,129\">",
"     2,16,117,129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9403071\">",
"    <span class=\"h2\">",
"     GHB-associated trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;GHB toxicity may result in falls and associated trauma such as extremity sprains, fractures, and head injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/2,5,143-146\">",
"     2,5,143-146",
"    </a>",
"    ]. Trauma may also result from motor vehicle collisions (MVC) caused by GHB-intoxicated drivers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/5,29,35,124\">",
"     5,29,35,124",
"    </a>",
"    ]. Clinical effects of GHB that may impair driving include cognitive effects such as confusion, inattention, and loss of critical thinking, psychomotor effects such as loss of coordination, and visual effects such as loss of peripheral vision and visual distortion. In addition, the abrupt onset of vomiting and sudden loss of consciousness that can occur with GHB intoxication may lead to MVCs. The risk for trauma is higher in GHB-dependent users who dose frequently throughout the day to control or prevent withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/124,144-146\">",
"     124,144-146",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/27/3514?source=see_link\">",
"     \"Gamma hydroxybutyrate (GHB) dependence and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Lethality",
"    </span>",
"    &nbsp;&mdash;&nbsp;GHB toxicity may be lethal with or without cointoxicants. Respiratory arrest is the primary mechanism of death. Death may also occur from aspiration pneumonia, positional asphyxiation, or trauma sustained while intoxicated. Trauma-related fatalities have occurred from motor vehicle collisions (involving both GHB-intoxicated pedestrians and GHB-impaired drivers), fires, falls, and drowning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/44,53,54\">",
"     44,53,54",
"    </a>",
"    ]. Due to the presence of endogenous GHB, which may increase following death, care must be taken to distinguish exogenous and endogenous GHB when performing postmortem analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Xyrem&reg;-associated deaths have been reported. In addition to cases of suicide and acute overdose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/29,77\">",
"     29,77",
"    </a>",
"    ], three case reports document deaths with postmortem GHB levels consistent with therapeutic dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/30,77\">",
"     30,77",
"    </a>",
"    ]. Sedative cointoxicants were found in all three deaths, as well as conditions of potential respiratory compromise, such as sleep apnea, obesity, and sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/30,77\">",
"     30,77",
"    </a>",
"    ]. A protocol has been developed for monitoring Xyrem&reg;-treated narcolepsy patients for the development of sleep-disordered breathing (ie, sleep apnea) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/147\">",
"     147",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of GHB toxicity as a cause of altered mental status is made clinically, based on history and exclusion of other potentially serious etiologies. Abrupt onset of coma (particularly in the absence of other intoxicants) that resolves spontaneously or abruptly within several hours raises suspicion for GHB toxicity.",
"   </p>",
"   <p>",
"    Characteristic patterns of agitation prior to, following, or in abrupt alternation with coma are also suggestive. Such patterns include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Agitation in alternation with somnolence",
"     </li>",
"     <li>",
"      Agitation followed by somnolence",
"     </li>",
"     <li>",
"      Self-injurious or bizarre behaviors, particularly in the absence of stimulant cointoxicants",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bottles found on site, particularly water bottles or containers for supplements or cleaning products, as well as eyedroppers or small containers of fluids or cleaners, may aid in diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Obtundation, stupor, and coma",
"    </span>",
"    &nbsp;&mdash;&nbsp;GHB intoxication is difficult to distinguish from other causes of obtundation without a clear history of ingestion. Other etiologies of obtundation, stupor, and coma to consider include medications, opioids, ethanol, and sedative-hypnotic agents (",
"    <a class=\"graphic graphic_table graphicRef65571 \" href=\"mobipreview.htm?39/19/40254\">",
"     table 2",
"    </a>",
"    ). Head injury, intracranial hemorrhage, increased intracranial pressure from stroke or other causes, hypo or hyperglycemia, shock, hypoxia, acidosis, postictal state, electrolyte disorders, CNS infection, and renal or liver failure all may result in altered mental status (",
"    <a class=\"graphic graphic_table graphicRef59893 \" href=\"mobipreview.htm?3/43/3773\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70449 \" href=\"mobipreview.htm?1/11/1214\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28825?source=see_link\">",
"     \"Stupor and coma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians should suspect GHB intoxication based upon a suggestive history (eg, witnessed ingestion, history of GHB abuse, presentation after a party), characteristic examination findings (eg, agitation followed by obtundation, bradycardia, hypothermia), and the absence of signs suggesting alternative diagnoses (eg, no evidence of trauma, no response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    or dextrose). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical features of acute toxicity'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Psychomotor agitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychomotor agitation may result from intoxication with ethanol or sympathomimetic drugs of abuse (eg, cocaine, phencyclidine, amphetamines, methamphetamine). Psychiatric disorders and withdrawal from sedative-hypnotic drugs or ethanol must be considered, as well as the causes of altered mental status listed immediately above. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6425?source=see_link\">",
"     \"Phencyclidine (PCP) intoxication in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/29/474?source=see_link\">",
"     \"Methamphetamine intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Specific tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;GHB is not detected on a routine hospital toxicology screen. Definitive confirmation requires analysis using gas",
"    <span class=\"nowrap\">",
"     chromatography/mass",
"    </span>",
"    spectrometry",
"    <span class=\"nowrap\">",
"     (GC/MS),",
"    </span>",
"    which may require 7 to 14 days and therefore does not contribute to the diagnosis or management of acute toxicity. Specimen collection (especially first-catch urine, if possible) is recommended if there is suspicion of drug-facilitated sexual assault. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'GHB-facilitated sexual assault'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In preparation for",
"    <span class=\"nowrap\">",
"     GC/MS",
"    </span>",
"    testing, collect 100 mL of urine into a standard urine collection cup and refrigerate the specimen. Also collect 10 to 30 mL of blood into a gray-top tube (containing sodium fluoride and potassium oxalate) and refrigerate the specimen.",
"   </p>",
"   <p>",
"    GHB occurs naturally in the body in low levels. Recommended cutoffs to differentiate endogenous and exogenous levels of GHB are 4",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    in blood and 10",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    in urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/148\">",
"     148",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although several rapid assays for GHB detection in urine and serum have been developed, targeted analysis using",
"    <span class=\"nowrap\">",
"     GC/MS",
"    </span>",
"    remains the mainstay for detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/149-152\">",
"     149-152",
"    </a>",
"    ]. Rapid screens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/76\">",
"     76",
"    </a>",
"    ] and tests for the detection of GHB in hair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/153\">",
"     153",
"    </a>",
"    ], saliva [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/154\">",
"     154",
"    </a>",
"    ], and alcoholic beverages are in development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/155\">",
"     155",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     General testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory evaluation of the poisoned patient should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestions",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG), to rule out conduction system poisoning by drugs that effect the QRS or QTc intervals",
"     </li>",
"     <li>",
"      Pregnancy test in women of childbearing age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A negative toxicology screen, either comprehensive or specifically for drugs of abuse, supports the diagnosis of GHB intoxication. Because GHB toxicity is clinically similar to ethanol intoxication, a serum ethanol level may be of use in differentiating the two. However, ethanol is a common coingestant. Further testing varies according to clinical presentation. As an example, creatine kinase and urine myoglobin should be obtained in patients at risk for rhabdomyolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of acute GHB toxicity consists of supportive care, including airway protection (which may involve tracheal intubation and mechanical ventilation), monitoring, sedation for agitation, and treatment of complications. Throughout this review, we use the term \"GHB\" to refer to GHB and its analogs, unless specifically noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Airway and breathing support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians must ensure airway patency with basic maneuvers (head-tilt, chin-lift, jaw thrust) and assist ventilation with bag-valve mask, supplemental oxygen, or tracheal intubation and mechanical ventilation, as necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Intubation and mechanical ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agitation may occur in response to intubation attempts. We recommend rapid sequence intubation (RSI) using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    , unless contraindications exist. Induction agents for RSI may not be necessary in patients already heavily sedated from GHB. Although the potential for hypotension from GHB toxicity theoretically makes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    a better induction agent than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    , such hypotension is likely to be transient and clinically insignificant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the frequency of cases with rapid, spontaneous recovery, some clinicians suggest a conservative approach to intubation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/16,100\">",
"     16,100",
"    </a>",
"    ]. Close monitoring of vital signs and respiratory status is critical in all cases; the infrequency of intubation-related complications and the potentially life-threatening risk of respiratory depression and arrest must guide treatment decisions. We believe end-tidal CO2 monitoring can play an important and useful role in monitoring the ventilatory status of these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/18/44328?source=see_link\">",
"     \"Carbon dioxide monitoring (capnography)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac and pulse oximetry monitoring should be performed in all patients. Capnography can be invaluable for monitoring the respiratory status of stuporous or sedated patients. Monitoring is no longer necessary once the patient is fully awake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Agitation and seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of physical and chemical restraints may be necessary for the control of agitation. Chemical restraint is much preferred, and physical restraints should be removed as soon as sedation is achieved. Appropriate monitoring is crucial, particularly while physical restraints are in place. Benzodiazepines (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ) and antipsychotics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ) may be used for sedation.",
"   </p>",
"   <p>",
"    Note that antipsychotics are not recommended in the treatment of patients with GHB withdrawal. Benzodiazepines should be used for sedation if the history of GHB abuse is unclear and clinical findings suggest the possibility of withdrawal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/27/3514?source=see_link\">",
"     \"Gamma hydroxybutyrate (GHB) dependence and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although seizures have been reported in rare instances, causality is by no means established. Benzodiazepines should be effective for controlling seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should examine the patient carefully for injuries resulting from falls, motor vehicle collisions, or other accidents sustained while the patient was intoxicated. Aspiration has been noted in rare instances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the risk of abrupt loss of consciousness and a loss of airway-protective reflexes, the induction of vomiting has no role in management.",
"   </p>",
"   <p>",
"    Gastric lavage and decontamination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    are typically not performed because GHB is rapidly absorbed and the time of ingestion frequently unknown. We suggest administering activated charcoal in cases when a potentially harmful coingestion is suspected. Charcoal should be withheld in patients who are sedated and may not be able to protect their airway, unless tracheal intubation is performed first. However, tracheal intubation should not be performed solely for the purpose of giving charcoal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Antidotes and reversal agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;No clinically proven reversal agents or antidotes for GHB toxicity exist.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/6/41062?source=see_link\">",
"     Flumazenil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    are not clinically effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/14,127\">",
"     14,127",
"    </a>",
"    ]. Some clinicians report using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     physostigmine",
"    </a>",
"    , but we do not recommend doing so because of the lack of proven efficacy and potential adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/156,157\">",
"     156,157",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of GHB toxicity cases resolve spontaneously without complications. In some cases, severe coma necessitating intubation and mechanical intubation may require admission to the ICU.",
"   </p>",
"   <p>",
"    Most patients may be discharged from the emergency department (ED) following observation, when clinically stable and mental status changes have fully resolved. Monitoring is no longer necessary once the patient is fully awake. Recovery may be rapid and abrupt. Discharge is appropriate when the patient is clinically stable, shows no signs of withdrawal, is able to ambulate, and demonstrates a clear understanding of discharge instructions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/27/3514?source=see_link\">",
"     \"Gamma hydroxybutyrate (GHB) dependence and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians should educate the patient about the potentially lethal risks of GHB abuse and dependence, and, if possible, arrange substance abuse counseling. Consultation with social services may be helpful.",
"   </p>",
"   <p>",
"    GHB withdrawal typically begins within one to six hours of the last dose, and may occur in dependent patients presenting with acute toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/2,132,158\">",
"     2,132,158",
"    </a>",
"    ], trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/159\">",
"     159",
"    </a>",
"    ], or other conditions resulting in the abrupt cessation of dosing.",
"   </p>",
"   <p>",
"    The following may be helpful in preventing acute withdrawal or determining which patients are at risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Question the patient and family members about past GHB (or supplement) use to identify chronic and dependent users.",
"     </li>",
"     <li>",
"      Review records for prior presentations with toxicity, withdrawal, or injuries of unexplained mechanism, which may be related to GHB intoxication.",
"     </li>",
"     <li>",
"      Monitor the patient for the onset of withdrawal symptoms, including anxiety, tremor, diaphoresis, and agitation. Patients that manifest signs of withdrawal require immediate admission for treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Pitfalls in diagnosis and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;GHB toxicity may be confused with or masked by the effects of cointoxicants. Presentations suggestive of GHB intoxication may be misinterpreted. They include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Coma with rapid and abrupt onset",
"     </li>",
"     <li>",
"      Coma or altered mental status that clears suddenly",
"     </li>",
"     <li>",
"      Coma in the absence of depressant intoxicants",
"     </li>",
"     <li>",
"      Agitation in alternation with somnolence",
"     </li>",
"     <li>",
"      Agitation followed by somnolence",
"     </li>",
"     <li>",
"      Self-injurious or bizarre behaviors, particularly in the absence of stimulant cointoxicants",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     GHB-FACILITATED SEXUAL ASSAULT",
"    </span>",
"    &nbsp;&mdash;&nbsp;GHB is used to facilitate sexual assault [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/48,51,160\">",
"     48,51,160",
"    </a>",
"    ]. Perpetrators of such assaults are attracted by GHB's rapid onset, disinhibitory and amnestic effects, and rapid clearance from blood and urine, which makes the drug difficult to detect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/52\">",
"     52",
"    </a>",
"    ]. Findings suggestive of sexual assault include complaints of unexplained lapses in memory, sudden onset of intoxication out of proportion to reported ethanol consumption or blood ethanol level, and missing or disheveled clothing. Symptoms consistent with GHB intoxication (eg, agitation, sedation, coma) may be present. The general management of sexual assault victims is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20601?source=see_link\">",
"     \"Evaluation and management of adult sexual assault victims\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Targeted analysis with gas",
"    <span class=\"nowrap\">",
"     chromatography/mass",
"    </span>",
"    spectrometry",
"    <span class=\"nowrap\">",
"     (GC/MS)",
"    </span>",
"    is necessary for detection of GHB and must be specifically requested. GHB is detectable in blood for 4 to 6 hours and in urine for 6 to 12 hours. Urine is the specimen of choice for toxicological testing in potential assault cases; a first-catch urine specimen is optimal. Collect 100 mL of urine in a standard urine collection cup and refrigerate. Collect 10 to 30 mL of blood in a gray-top tube (containing sodium fluoride and potassium oxalate) and refrigerate. Maintain specimens in compliance with chain of custody rules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/25/31130/abstract/161\">",
"     161",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105598620\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/4/28738?source=see_link\">",
"       \"Patient information: Care after rape or sexual assault (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/30/1509?source=see_link\">",
"       \"Patient information: Care after sexual assault (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gamma hydroxybutyrate (GHB) and its analogs (GBL and BD) have been used recreationally for intoxicant effects, surreptitiously to facilitate sexual assault, and as \"dietary supplements\" for purported health benefits. GHB may be lethal in overdose, with or without cointoxicants. The pharmacology, formulations, and kinetics of GHB are discussed in detail above. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pharmacology and cellular toxicology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Formulations and dosing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Kinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute GHB toxicity manifests primarily as dose-related central nervous system (CNS) depression. Coma is common. Stimulant effects such as psychomotor agitation may occur. Abrupt onset of effects and sudden awakening and resolution of effects frequently occur. Cointoxicants are common. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features of acute toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of GHB toxicity as a cause of altered mental status is made clinically, based upon history, clinical findings, and exclusion of other potentially serious etiologies. GHB intoxication is difficult to distinguish from other causes of obtundation without a clear history. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GHB is not detectable on routine hospital toxicology screens. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of acute GHB intoxication is supportive. The primary goals are airway protection, control of any agitation with sedative medications, and treatment of any complications. Intubation and mechanical ventilation may be necessary. Close monitoring of vital signs and respiratory status (including end-tidal CO2 if available) is critical in all cases. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GHB-dependent patients may present with acute toxicity and progress directly into GHB withdrawal. Symptoms of withdrawal generally appear within one to six hours of cessation. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Disposition'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/27/3514?source=see_link\">",
"       \"Gamma hydroxybutyrate (GHB) dependence and withdrawal\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/1\">",
"      Dyer JE. gamma-Hydroxybutyrate: a health-food product producing coma and seizurelike activity. Am J Emerg Med 1991; 9:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/2\">",
"      Zvosec DL, Smith SW, McCutcheon JR, et al. Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 2001; 344:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/3\">",
"      Boyer EW, Shannon M, Hibberd PL. Web sites with misinformation about illicit drugs. N Engl J Med 2001; 345:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/4\">",
"      Wax PM. Just a click away: recreational drug Web sites on the Internet. Pediatrics 2002; 109:e96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/5\">",
"      Barker JC, Harris SL, Dyer JE. Experiences of gamma hydroxybutyrate (GHB) ingestion: a focus group study. J Psychoactive Drugs 2007; 39:115.",
"     </a>",
"    </li>",
"    <li>",
"     Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings 2010. Ann Arbor, MI: National Institute on Drug Abuse, National Institutes of Health, 2011:58.",
"    </li>",
"    <li>",
"     Drug Abuse Warning Network (DAWN). The DAWN Report: Trends in drug-related Emergency Department visits, 1994-2002 At a Glance. Rockville, MD: U.S. Department of Health and Human Services SAMHSA, Office of Applied Studies, 2003.",
"    </li>",
"    <li>",
"     Drug Abuse Warning Network (DAWN). Drug Abuse Warning Network, 2007: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/9\">",
"      Litovitz TL, Klein-Schwartz W, Rodgers GC Jr, et al. 2001 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2002; 20:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/10\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009; 47:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/11\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clin Toxicol (Phila) 2010; 48:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/12\">",
"      Editorial team. The EMCDDA annual report 2010: the state of the drugs problem in Europe. Euro Surveill 2010; 15.",
"     </a>",
"    </li>",
"    <li>",
"     Hillebrand J, Olszewski D, Roumen S. GHB and its precursor GBL: an emerging trend case study. EMCDDA. Lisbon, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/14\">",
"      Mir&oacute; O, Nogu&eacute; S, Espinosa G, et al. Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate. J Toxicol Clin Toxicol 2002; 40:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/15\">",
"      Liechti ME, Kupferschmidt H. Gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL): analysis of overdose cases reported to the Swiss Toxicological Information Centre. Swiss Med Wkly 2004; 134:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/16\">",
"      Liechti ME, Kunz I, Greminger P, et al. Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug Alcohol Depend 2006; 81:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/17\">",
"      Rambourg-Schepens MO, Buffet M, Durak C, Mathieu-Nolf M. Gamma butyrolactone poisoning and its similarities to gamma hydroxybutyric acid: two case reports. Vet Hum Toxicol 1997; 39:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/18\">",
"      Elliott SP. Nonfatal instances of intoxication with gamma-hydroxybutyrate in the United Kingdom. Ther Drug Monit 2004; 26:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/19\">",
"      Williams H, Taylor R, Roberts M. Gamma-hydroxybutyrate (GHB): a new drug of misuse. Ir Med J 1998; 91:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/20\">",
"      Dillon, P, Degenhardt, L. Ketamine and GHB: New trends in club drug use? J Subst Use 2001; 6:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/21\">",
"      Galicia M, Nogu&eacute; S, To-Figueras J, et al. [Poisoning by liquid ecstasy (GHB) in hospital emergency departments of Barcelona: a 2-years study]. Med Clin (Barc) 2008; 130:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/22\">",
"      Hovda KE, Bjornaas MA, Skog K, et al. Acute poisonings treated in hospitals in Oslo: a one-year prospective study (I): pattern of poisoning. Clin Toxicol (Phila) 2008; 46:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/23\">",
"      Degenhardt L, Dunn M. The epidemiology of GHB and ketamine use in an Australian household survey. Int J Drug Policy 2008; 19:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/24\">",
"      Munir VL, Hutton JE, Harney JP, et al. Gamma-hydroxybutyrate: a 30 month emergency department review. Emerg Med Australas 2008; 20:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/25\">",
"      Dietze PM, Cvetkovski S, Barratt MJ, Clemens S. Patterns and incidence of gamma-hydroxybutyrate (GHB)-related ambulance attendances in Melbourne, Victoria. Med J Aust 2008; 188:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/26\">",
"      Wood DM, Warren-Gash C, Ashraf T, et al. Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD). QJM 2008; 101:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/27\">",
"      Sumnall HR, Woolfall K, Edwards S, et al. Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB). Drug Alcohol Depend 2008; 92:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/28\">",
"      Stein LA, Lebeau R, Clair M, et al. A web-based study of gamma hydroxybutyrate (GHB): patterns, experiences, and functions of use. Am J Addict 2011; 20:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/29\">",
"      Wang YG, Swick TJ, Carter LP, et al. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med 2009; 5:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/30\">",
"      Akins BE, Miranda E, Lacy JM, Logan BK. A multi-drug intoxication fatality involving Xyrem (GHB). J Forensic Sci 2009; 54:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/31\">",
"      Couper FJ, Thatcher JE, Logan BK. Suspected GHB overdoses in the emergency department. J Anal Toxicol 2004; 28:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/32\">",
"      Couper FJ, Logan BK. GHB and driving impairment. J Forensic Sci 2001; 46:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/33\">",
"      Dresen S, Kempf J, Weinmann W. Prevalence of gamma-hydroxybutyrate (GHB) in serum samples of amphetamine, metamphetamine and ecstasy impaired drivers. Forensic Sci Int 2007; 173:112.",
"     </a>",
"    </li>",
"    <li>",
"     Oestreich A, Iten PX. First cases of driving under the influence of Gamma hydroxybutyric acid (GHB) in Switzerland. 39th Annual Meeting of the International Association of Forensic Toxicologists (TIAFT). Prague, August 30th, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/35\">",
"      Caldicott DG, Edwards N. Traumatic brain injury after a motor vehicle accident: fact or \"fantasy\"? Emerg Med J 2001; 18:458.",
"     </a>",
"    </li>",
"    <li>",
"     Vevelstad M. Gamma-hydroxybutyrate (GHB), pregabalin and driving impairment. ICADTS 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/37\">",
"      Al-Samarraie MS, Karinen R, M&oslash;rland J, Stokke Opdal M. Blood GHB concentrations and results of medical examinations in 25 car drivers in Norway. Eur J Clin Pharmacol 2010; 66:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/38\">",
"      Jones AW, Holmgren A, Kugelberg FC. Gamma-hydroxybutyrate concentrations in the blood of impaired drivers, users of illicit drugs, and medical examiner cases. J Anal Toxicol 2007; 31:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/39\">",
"      Jones AW, Holmgren A, Kugelberg FC. Driving under the influence of gamma-hydroxybutyrate (GHB). Forensic Sci Med Pathol 2008; 4:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/40\">",
"      Piastra M, Barbaro R, Chiaretti A, et al. Pulmonary oedema caused by \"liquid ecstasy\" ingestion. Arch Dis Child 2002; 86:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/41\">",
"      Savage T, Khan A, Loftus BG. Acetone-free nail polish remover pads: toxicity in a 9-month old. Arch Dis Child 2007; 92:371.",
"     </a>",
"    </li>",
"    <li>",
"     Dyer, JE, Haller, CA. Gamma hydroxybutyrate and the comatose patient. Pulmonary and Critical Care Update, Chest Online 2001, Lesson 22. Available online at: www.chestnet.org/education/online/pccu/vol14/index.php (Accessed on August 22, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/43\">",
"      Fieguth A, Albrecht K, Weller JP, et al. [First report of lethal gamma-hydroxybutyrate (GHB) intoxication after consumption of gamma-butyrolactone (GBL) in Lower Saxony]. Arch Kriminol 2009; 223:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/44\">",
"      Zvosec DL, Smith SW, Porrata T, et al. Case series of 226 &gamma;-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am J Emerg Med 2011; 29:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/45\">",
"      Runnacles JL, Stroobant J. [gamma ]-Hydroxybutyrate poisoning: Poisoning from toy beads. BMJ 2008; 336:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/46\">",
"      Gunja N, Doyle E, Carpenter K, et al. Gamma-hydroxybutyrate poisoning from toy beads. Med J Aust 2008; 188:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/47\">",
"      Suchard J, Nizkorodov S, Wilkinson S. 1,4-Butanediol content of aqua dots children's craft toy beads. J Med Toxicol 2009; 5:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/48\">",
"      Stillwell ME. Drug-facilitated sexual assault involving gamma-hydroxybutyric acid. J Forensic Sci 2002; 47:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/49\">",
"      Scott-Ham M, Burton FC. Toxicological findings in cases of alleged drug-facilitated sexual assault in the United Kingdom over a 3-year period. J Clin Forensic Med 2005; 12:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/50\">",
"      N&eacute;meth Z, Kun B, Demetrovics Z. The involvement of gamma-hydroxybutyrate in reported sexual assaults: a systematic review. J Psychopharmacol 2010; 24:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/51\">",
"      Marinetti L, LeBeau M. The use of GHB and analogs to facilitate sexual assault. For Sci Rev 2010; 22:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/52\">",
"      Carter LP. Potential impact of drug effects, availability, pharmacokinetics, and screening on estimates of drugs implicated in cases of assault. Drug Test Anal 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/53\">",
"      Kugelberg FC, Holmgren A, Eklund A, Jones AW. Forensic toxicology findings in deaths involving gamma-hydroxybutyrate. Int J Legal Med 2010; 124:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/54\">",
"      Caldicott DG, Chow FY, Burns BJ, et al. Fatalities associated with the use of gamma-hydroxybutyrate and its analogues in Australasia. Med J Aust 2004; 181:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/55\">",
"      Zvosec DL, Smith SW. Commenting on\"a review of tolerability and abuse liability of gamma-hydroxybutyric acid for insomnia in patients with schizophrenia,\" by Kantrowitzet al. Clin Ther 2010; 32:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/56\">",
"      Degenhardt L, Darke S, Dillon P. GHB use among Australians: characteristics, use patterns and associated harm. Drug Alcohol Depend 2002; 67:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/57\">",
"      Wang YG. Xyrem (sodium oxybate) postmarketing adverse event reporting system. Sleep Med 2010; 11:595; author reply 595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/58\">",
"      Doherty JD, Hattox SE, Snead OC, Roth RH. Identification of endogenous gamma-hydroxybutyrate in human and bovine brain and its regional distribution in human, guinea pig and rhesus monkey brain. J Pharmacol Exp Ther 1978; 207:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/59\">",
"      BESSMAN SP, FISHBEIN WN. GAMMA-HYDROXYBUTYRATE, A NORMAL BRAIN METABOLITE. Nature 1963; 200:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/60\">",
"      Crunelli V, Emri Z, Leresche N. Unravelling the brain targets of gamma-hydroxybutyric acid. Curr Opin Pharmacol 2006; 6:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/61\">",
"      Cash CD. Gamma-hydroxybutyrate: an overview of the pros and cons for it being a neurotransmitter and/or a useful therapeutic agent. Neurosci Biobehav Rev 1994; 18:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/62\">",
"      Snead OC 3rd, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med 2005; 352:2721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/63\">",
"      Kohrs FP, Porter WH. gamma-Hydroxybutyrate intoxication and overdose. Ann Emerg Med 1999; 33:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/64\">",
"      Lettieri J, Fung HL. Improved pharmacological activity via pro-drug modification: comparative pharmacokinetics of sodium gamma-hydroxybutyrate and gamma-butyrolactone. Res Commun Chem Pathol Pharmacol 1978; 22:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/65\">",
"      Roth RH, Delgado JM, Giarman NJ. Gamma-butyrolactone and gamma-hydroxybutyric acid. II. The pharmacologically active form. Int J Neuropharmacol 1966; 5:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/66\">",
"      Carai MA, Colombo G, Reali R, et al. Central effects of 1,4-butanediol are mediated by GABA(B) receptors via its conversion into gamma-hydroxybutyric acid. Eur J Pharmacol 2002; 441:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/67\">",
"      Poldrugo F, Snead OC 3rd. 1,4 Butanediol, gamma-hydroxybutyric acid and ethanol: relationships and interactions. Neuropharmacology 1984; 23:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/68\">",
"      Poldrugo F, Snead OC 3rd. 1,4-Butanediol and ethanol compete for degradation in rat brain and liver in vitro. Alcohol 1986; 3:367.",
"     </a>",
"    </li>",
"    <li>",
"     Dyer JE, Haller CA. Gamma hydroxybutrate, gamma butyrolactone, and 1,4 butanediol. In: Medical Toxicology, Dart RC.  (Ed), Lippincott, Williams, &amp; Wilkins, New York 2004. p.1096.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/70\">",
"      Miotto K, Darakjian J, Basch J, et al. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 2001; 10:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/71\">",
"      Couper, FJ, Marinetti, LJ. Gamma hydroxybutyrate: effects on human performance and behavior. Forensic Sci Rev 2002; 14:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/72\">",
"      Zvosec, DL, Smith, SW. Gamma hydroxybutyrate (GHB) addiction and withdrawal. From the GHB Addiction Study (Abstract). Ann Emerg Med 2004; 44:S91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/73\">",
"      Dyer JE, Reed JH. Alkali burns from illicit manufacture of GHB (Abstract). J Tox Clin Toxicol 1997; 35:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/74\">",
"      Wiley, J, Dick, R, Arnold, T. Hematuria from home-manufactured GHB (Abstract). J Tox Clin Toxicol 1998; 36:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/75\">",
"      Addolorato G, Leggio L, Ferrulli A, et al. The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opin Investig Drugs 2009; 18:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/76\">",
"      Andresen H, Aydin BE, Mueller A, Iwersen-Bergmann S. An overview of gamma-hydroxybutyric acid: pharmacodynamics, pharmacokinetics, toxic effects, addiction, analytical methods, and interpretation of results. Drug Test Anal 2011; 3:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/77\">",
"      Zvosec DL, Smith SW, Hall BJ. Three deaths associated with use of Xyrem. Sleep Med 2009; 10:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/78\">",
"      Dargan PI, Jayachandran A, Button J, et al. A significant Xyrem&reg; overdose managed conservatively despite high GHB concentrations [Abstract 251]. Clin Toxicol 2008; 46:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/79\">",
"      LeTourneau JL, Hagg DS, Smith SM. Baclofen and gamma-hydroxybutyrate withdrawal. Neurocrit Care 2008; 8:430.",
"     </a>",
"    </li>",
"    <li>",
"     Xyrem&reg; (sodium oxybate) oral solution.  Available online at: jazzph.isat-tech.com/media/PI.pdf (Accessed on March 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/81\">",
"      Scharf MB, Lai AA, Branigan B, et al. Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep 1998; 21:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/82\">",
"      Ferrara SD, Zotti S, Tedeschi L, et al. Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol 1992; 34:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/83\">",
"      Palatini P, Tedeschi L, Frison G, et al. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 1993; 45:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/84\">",
"      Abanades S, Farr&eacute; M, Segura M, et al. Disposition of gamma-hydroxybutyric acid in conventional and nonconventional biologic fluids after single drug administration: issues in methodology and drug monitoring. Ther Drug Monit 2007; 29:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/85\">",
"      Brenneisen R, Elsohly MA, Murphy TP, et al. Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J Anal Toxicol 2004; 28:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/86\">",
"      Thai D, Dyer JE, Benowitz NL, Haller CA. Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J Clin Psychopharmacol 2006; 26:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/87\">",
"      Abanades S, Farr&eacute; M, Segura M, et al. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann N Y Acad Sci 2006; 1074:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/88\">",
"      Thai D, Dyer JE, Jacob P, Haller CA. Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers. Clin Pharmacol Ther 2007; 81:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/89\">",
"      Hoes MJ, Vree TB, Guelen PJ. Gamma-hydroxybutyric acid as hypnotic. Clinical and pharmacokinetic evaluation of gamma-hydroxybutyric acid as hypnotic in man. Encephale 1980; 6:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/90\">",
"      Haller C, Thai D, Jacob P 3rd, Dyer JE. GHB urine concentrations after single-dose administration in humans. J Anal Toxicol 2006; 30:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/91\">",
"      Abanades S, Farr&eacute; M, Barral D, et al. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users. J Clin Psychopharmacol 2007; 27:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/92\">",
"      Borgen LA, Okerholm R, Morrison D, Lai A. The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects. J Clin Pharmacol 2003; 43:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/93\">",
"      Mason PE, Kerns WP 2nd. Gamma hydroxybutyric acid (GHB) intoxication. Acad Emerg Med 2002; 9:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/94\">",
"      Grove-White IG, Kelman GR. Effect of methohexitone, diazepam and sodium 4-hydroxybutyrate on short-term memory. Br J Anaesth 1971; 43:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/95\">",
"      Carter LP, Richards BD, Mintzer MZ, Griffiths RR. Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology 2006; 31:2537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/96\">",
"      Metcalf DR, Emde RN, Stripe JT. An EEG-behavioral study of sodium hydroxybutyrate in humans. Electroencephalogr Clin Neurophysiol 1966; 20:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/97\">",
"      Virtue RW, Lund LO, Beckwitt HJ, Vogel JH. Cardiovascular reactions to gamma hydroxybutyrate in man. Can Anaesth Soc J 1966; 13:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/98\">",
"      Van Sassenbroeck DK, De Neve N, De Paepe P, et al. Abrupt awakening phenomenon associated with gamma-hydroxybutyrate use: a case series. Clin Toxicol (Phila) 2007; 45:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/99\">",
"      Jenney, EH, Murphree, HB, Goldstein, L, Pfeiffer, CC. Behavioral and EEG effects of gamma-butyrolactone and gamma-hydroxybutyric acid in man. Cardiovasc Pharmacol 1962; 4:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/100\">",
"      Chin RL, Sporer KA, Cullison B, et al. Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med 1998; 31:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/101\">",
"      Harraway, T, Stephenson, L. Gamma hydroxybutyrate: The Gold Coast Experience. Emerg Med (Australia) 1999; 11:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/102\">",
"      Strickland RM, Felgate P, Caldicott DG. Survival of massive gamma-hydroxybutyrate/1,4-butanediol overdose. Emerg Med Australas 2005; 17:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/103\">",
"      HELRICH M, MCASLAN TC, SKOLNIK S, BESSMAN SP. CORRELATION OF BLOOD LEVELS OF 4-HYDROXYBUTYRATE WITH STATE OF CONSCIOUSNESS. Anesthesiology 1964; 25:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/104\">",
"      Oliveto A, Gentry WB, Pruzinsky R, et al. Behavioral effects of gamma-hydroxybutyrate in humans. Behav Pharmacol 2010; 21:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/105\">",
"      Ferrara SD, Giorgetti R, Zancaner S, et al. Effects of single dose of gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers. Eur J Clin Pharmacol 1999; 54:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/106\">",
"      Haller, C, Thai, D, Manktelow, TC, et al. Cognitive and mood effects of GHB and ethanol in humans (Abstract). J Tox Clin Tox 2004; 42:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/107\">",
"      Carter LP, Griffiths RR, Mintzer MZ. Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. Psychopharmacology (Berl) 2009; 206:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/108\">",
"      Dempsey DA, Meyers M, Fiorentino D, et al. Gamma-hydroxybutyrate (GHB) effects upon driving a car (abstract). Clin Pharmacol Ther 2008; 83:S75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/109\">",
"      Steel GC. Clinical application of gamma hydroxybutyric acid as a sleep cover in lumbar epidural block. Proc R Soc Med 1968; 61:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/110\">",
"      A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003; 26:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/111\">",
"      Ortega-Alb&aacute;s JJ, L&oacute;pez-Bernab&eacute; R, Garc&iacute;a AL, G&oacute;mez JR. Suicidal ideation secondary to sodium oxybate. J Neuropsychiatry Clin Neurosci 2010; 22:352r.e26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/112\">",
"      Rossetti AO, Heinzer RC, Tafti M, Buclin T. Rapid occurrence of depression following addition of sodium oxybate to modafinil. Sleep Med 2010; 11:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/113\">",
"      George CF, Feldman N, Inhaber N, et al. A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing. Sleep Med 2010; 11:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/114\">",
"      Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004; 27:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/115\">",
"      Vickers MD. Gamma hydroxybutyric acid. Clinical pharmacology and current status. Proc R Soc Med 1968; 61:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/116\">",
"      Zvosec DL, Smith SW. Agitation is common in gamma-hydroxybutyrate toxicity. Am J Emerg Med 2005; 23:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/117\">",
"      Couper FJ, Logan BK. Determination of gamma-hydroxybutyrate (GHB) in biological specimens by gas chromatography--mass spectrometry. J Anal Toxicol 2000; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/118\">",
"      Lora-Tamayo C, Tena T, Rodr&iacute;guez A, et al. Intoxication due to 1,4-butanediol. Forensic Sci Int 2003; 133:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/119\">",
"      Louagie HK, Verstraete AG, De Soete CJ, et al. A sudden awakening from a near coma after combined intake of gamma-hydroxybutyric acid (GHB) and ethanol. J Toxicol Clin Toxicol 1997; 35:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/120\">",
"      Li J, Stokes SA, Woeckener A. A tale of novel intoxication: seven cases of gamma-hydroxybutyric acid overdose. Ann Emerg Med 1998; 31:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/121\">",
"      Ingels M, Rangan C, Bellezzo J, Clark RF. Coma and respiratory depression following the ingestion of GHB and its precursors: three cases. J Emerg Med 2000; 19:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/122\">",
"      Higgins TF Jr, Borron SW. Coma and respiratory arrest after exposure to butyrolactone. J Emerg Med 1996; 14:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/123\">",
"      Winickoff JP, Houck CS, Rothman EL, Bauchner H. Verve and Jolt: deadly new Internet drugs. Pediatrics 2000; 106:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/124\">",
"      Couper FJ, Logan BK. Addicted to driving under the influence--a GHB/GBL case report. J Anal Toxicol 2004; 28:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/125\">",
"      MacKenzie G, Draper H, Barnett G, Wakeel BA. An unconscious man with transient exposure of an accessory pathway. Eur J Emerg Med 2000; 7:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/126\">",
"      Centers for Disease Control and Prevention (CDC). Gamma hydroxy butyrate use--New York and Texas, 1995-1996. MMWR Morb Mortal Wkly Rep 1997; 46:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/127\">",
"      Ross TM. Gamma hydroxybutyrate overdose: two cases illustrate the unique aspects of this dangerous recreational drug. J Emerg Nurs 1995; 21:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/128\">",
"      Chin MY, Kreutzer RA, Dyer JE. Acute poisoning from gamma-hydroxybutyrate in California. West J Med 1992; 156:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/129\">",
"      Centers for Disease Control and Prevention (CDC). Adverse events associated with ingestion of gamma-butyrolactone--Minnesota, New Mexico, and Texas, 1998-1999. MMWR Morb Mortal Wkly Rep 1999; 48:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/130\">",
"      Lenz D, Rothschild MA, Kr&ouml;ner L. Intoxications due to ingestion of gamma-butyrolactone: organ distribution of gamma-hydroxybutyric acid and gamma-butyrolactone. Ther Drug Monit 2008; 30:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/131\">",
"      Centers for Disease Control (CDC). Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate. MMWR Morb Mortal Wkly Rep 1990; 39:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/132\">",
"      Hodges B, Everett J. Acute toxicity from home-brewed gamma hydroxybutyrate. J Am Board Fam Pract 1998; 11:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/133\">",
"      Adornato BT, Tse V. Another health food hazard--gamma-hydroxybutyrate-induced seizures. West J Med 1992; 157:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/134\">",
"      Stephens BG, Baselt RC. Driving under the influence of GHB? J Anal Toxicol 1994; 18:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/135\">",
"      Sporer KA, Chin RL, Dyer JE, Lamb R. Gamma-hydroxybutyrate serum levels and clinical syndrome after severe overdose. Ann Emerg Med 2003; 42:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/136\">",
"      Einspruch BC, Clark SM. Near fatality results from health food store sleeping potion. Tex Med 1992; 88:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/137\">",
"      Arneson AH, Goetze J. Dietary supplement or dangerous drug? Two case reports of gamma-butyrolactone toxicity. J Emerg Nurs 2000; 26:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/138\">",
"      Dribben, WH, Kirk, MA. A case of atrial fibrillation associated with GHB ingestion (Abstract). J Tox Clin Tox 2001; 39:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/139\">",
"      Reed MJ, Clegg GR. Paroxysmal sympathetic surge associated with gamma hydroxybutyrate. Eur J Emerg Med 2006; 13:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/140\">",
"      Knudsen, K. Intoxication with gamma-hydroxybutyric acid (GHB) is an increasing social and medical emergency in Sweden (Abstract). J Tox Clin Toxicol 2000; 38:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/141\">",
"      Roberts DM, Smith MW, Gopalakrishnan M, et al. Extreme &gamma;-butyrolactone overdose with severe metabolic acidosis requiring hemodialysis. Ann Emerg Med 2011; 58:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/142\">",
"      Ulrich S, M&uuml;ller V, Keel M, Seebach JD. Sudden leg paralysis in a 26-year-old nurse. Swiss Med Wkly 2005; 135:206; author reply 206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/143\">",
"      Personne, M, Landgren, A. GHB intoxications in Sweden (Abstract). J Tox Clin Toxicol 2000; 38:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/144\">",
"      Bell J, Collins R. Gamma-butyrolactone (GBL) dependence and withdrawal. Addiction 2011; 106:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/145\">",
"      O'Toole JG, Kristian MR, Devereux L, Kurien R. Gamma-hydroxybutyrate dependence in a rural setting in Wales. J Subst Abuse 2009; 14:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/146\">",
"      Zvosec DL, Smith SW. \"Acute complications of Gamma hydroxybutyrate addiction (abstract). Acad Emerg Med 2005; 12:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/147\">",
"      Feldman NT. Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing. Sleep Breath 2010; 14:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/148\">",
"      Elliott SP. Gamma hydroxybutyric acid (GHB) concentrations in humans and factors affecting endogenous production. Forensic Sci Int 2003; 133:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/149\">",
"      Mercer J, Shakleya D, Bell S. Applications of ion mobility spectrometry (IMS) to the analysis of gamma-hydroxybutyrate and gamma-hydroxyvalerate in toxicological matrices. J Anal Toxicol 2006; 30:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/150\">",
"      Gottardo R, Bortolotti F, Trettene M, et al. Rapid and direct analysis of gamma-hydroxybutyric acid in urine by capillary electrophoresis-electrospray ionization ion-trap mass spectrometry. J Chromatogr A 2004; 1051:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/151\">",
"      Bortolotti F, De Paoli G, Gottardo R, et al. Determination of gamma-hydroxybutyric acid in biological fluids by using capillary electrophoresis with indirect detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 800:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/152\">",
"      Villain M, Cirimele V, Ludes B, Kintz P. Ultra-rapid procedure to test for gamma-hydroxybutyric acid in blood and urine by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 792:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/153\">",
"      Kintz P, Villain M, Ludes B. Testing for the undetectable in drug-facilitated sexual assault using hair analyzed by tandem mass spectrometry as evidence. Ther Drug Monit 2004; 26:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/154\">",
"      De Paoli G, Walker KM, Pounder DJ. Endogenous &gamma;-hydroxybutyric acid concentrations in saliva determined by gas chromatography-mass spectrometry. J Anal Toxicol 2011; 35:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/155\">",
"      Bravo DT, Harris DO, Parsons SM. Reliable, sensitive, rapid and quantitative enzyme-based assay for gamma-hydroxybutyric acid (GHB). J Forensic Sci 2004; 49:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/156\">",
"      Traub SJ, Nelson LS, Hoffman RS. Physostigmine as a treatment for gamma-hydroxybutyrate toxicity: a review. J Toxicol Clin Toxicol 2002; 40:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/157\">",
"      Zvosec DL, Smith SW, Litonjua R, Westfal RE. Physostigmine for gamma-hydroxybutyrate coma: inefficacy, adverse events, and review. Clin Toxicol (Phila) 2007; 45:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/158\">",
"      Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001; 37:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/159\">",
"      Slagel B, Kingstone E, Bhalerao S. Gamma hydroxybutyrate withdrawal in an orthopedic trauma patient. Can J Psychiatry 2003; 48:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/160\">",
"      Varela M, Nogu&eacute; S, Or&oacute;s M, Mir&oacute; O. Gamma hydroxybutirate use for sexual assault. Emerg Med J 2004; 21:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/25/31130/abstract/161\">",
"      LeBeau, M. Toxicological investigations of drug-facilitated sexual assaults. Forensic Science Communications 1999; 1:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 307 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-190.102.30.19-CBD0E914AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_25_31130=[""].join("\n");
var outline_f30_25_31130=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32702817\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FORMULATIONS AND DOSING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      KINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EFFECTS NOTED DURING CLINICAL STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES OF ACUTE TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Risk factors for acute toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      General presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Vital signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Central nervous system effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Respiratory effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Gastrointestinal effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9403071\">",
"      GHB-associated trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Lethality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Obtundation, stupor, and coma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Psychomotor agitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Specific tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      General testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Airway and breathing support",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Intubation and mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Agitation and seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Antidotes and reversal agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Pitfalls in diagnosis and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      GHB-FACILITATED SEXUAL ASSAULT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105598620\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/307\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/307|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/54/30572\" title=\"table 1\">",
"      GHB product names",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/19/40254\" title=\"table 2\">",
"      Causes of coma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/43/3773\" title=\"table 3\">",
"      Causes of delirium and confusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/11/1214\" title=\"table 4\">",
"      Drugs that cause or prolong delirium",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=related_link\">",
"      Cocaine: Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20601?source=related_link\">",
"      Evaluation and management of adult sexual assault victims",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/27/3514?source=related_link\">",
"      Gamma hydroxybutyrate (GHB) dependence and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/3/21560?source=related_link\">",
"      MDMA (ecstasy) intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/29/474?source=related_link\">",
"      Methamphetamine intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/4/28738?source=related_link\">",
"      Patient information: Care after rape or sexual assault (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/30/1509?source=related_link\">",
"      Patient information: Care after sexual assault (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6425?source=related_link\">",
"      Phencyclidine (PCP) intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_25_31131="Clinician tasks";
var content_f30_25_31131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The clinician's tasks during a patient visit",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Get the visit off to a good start",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Learn what the patient hopes to accomplish in the visit (the patient's agenda)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elicit the patient's complaints (symptoms), concerns, and requests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perform an appropriately focused physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mentally test diagnostic hypotheses throughout the collection of historical and examination data",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Develop a differential diagnosis of the problem(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plan a cost-effective work-up if needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Choose a therapeutic intervention if needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss all of this with the patient in terms that are easily understood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Check the patient's understanding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Negotiate differences of opinion the patient and doctor may have about the nature of the problem, its evaluation, and its treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assure that attention is given to disease prevention strategies appropriate to the patient's age, gender, habits, genetic and socioeconomic risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Make plans for follow-up of the problem and its treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conclude the visit",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_25_31131=[""].join("\n");
var outline_f30_25_31131=null;
var title_f30_25_31132="HAV post exp treatment PI";
var content_f30_25_31132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F66335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F66335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for preventive treatment after exposure to hepatitis A",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Group or person",
"       </td>",
"       <td class=\"subtitle1\">",
"        Needs preventive treatment?",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Anyone who lives with an infected person",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        People who have occasional contact with an infected person",
"       </td>",
"       <td>",
"        <p>",
"         Depends on likelihood of exposure",
"        </p>",
"        Consult with a healthcare provider to determine if treatment recommended",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Staff and children at a daycare",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          If there are ANY children in diapers",
"         </strong>",
"         at the day care center: Yes, all children/staff should be treated if one child/staff member or two or more households* are infected",
"        </p>",
"        <strong>",
"         If there are NO children in diapers",
"        </strong>",
"        at the day care center: Yes, but only children/staff in the class with the infected person(s) should be treated",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Families of children who attend a daycare where there is an infected person",
"       </td>",
"       <td>",
"        <strong>",
"         If the child who attends day care wears diapers:",
"        </strong>",
"        Yes, the family members should be treated if",
"        <strong>",
"         three or more",
"        </strong>",
"        households* are infected",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Sexual partners of an infected person",
"       </td>",
"       <td>",
"        Yes, if the person had sex within one month of the infection",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        People who have shared IV drugs with an infected person",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        All food handlers who work with an infected person",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        People who ate at restaurant once when an infected person was working",
"       </td>",
"       <td>",
"        <p>",
"         Yes,",
"         <strong>",
"          if:",
"         </strong>",
"        </p>",
"        <p>",
"         1) The infected person had diarrhea and handled food",
"         <strong>",
"          and",
"         </strong>",
"        </p>",
"        2) Patrons can be identified and treated &le;2 weeks after exposure",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        People who",
"        <strong>",
"         regularly",
"        </strong>",
"        dined at a restaurant when an infected person was working",
"       </td>",
"       <td>",
"        <p>",
"         Depends on likelihood of exposure",
"        </p>",
"        Consult a healthcare provider to determine if treatment recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Co-workers or classmates of an infected person",
"       </td>",
"       <td>",
"        No, if a",
"        <strong>",
"         single",
"        </strong>",
"        person is infected (suggesting that the source of the infection is likely to be outside of school or work)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Household is defined as anyone who lives in the house.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_25_31132=[""].join("\n");
var outline_f30_25_31132=null;
var title_f30_25_31133="Occupational agents causing adverse pregnancy outcomes";
var content_f30_25_31133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Occupational agents causing adverse pregnancy outcomes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Agent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Outcome seen in human studies",
"      </td>",
"      <td class=\"subtitle1\">",
"       Outcome seen in animal studies",
"      </td>",
"      <td class=\"subtitle1\">",
"       Data*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anesthetic gases",
"      </td>",
"      <td>",
"       Spontaneous abortion",
"      </td>",
"      <td>",
"       Birth defects",
"      </td>",
"      <td>",
"       1,3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Antineoplastic drugs",
"      </td>",
"      <td>",
"       Spontaneous abortion",
"      </td>",
"      <td>",
"       Birth defects, fetal loss",
"      </td>",
"      <td>",
"       1,3,5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Arsenic",
"      </td>",
"      <td>",
"       Spontaneous abortion, low birth weight",
"      </td>",
"      <td>",
"       Birth defects, fetal loss",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Benzo(a)pyrene",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Birth defects",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cadmium",
"      </td>",
"      <td>",
"       Low birth weight, skeletal disease",
"      </td>",
"      <td>",
"       Fetal loss, birth defects",
"      </td>",
"      <td>",
"       2, 3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Carbon disulfide",
"      </td>",
"      <td>",
"       Menstrual disorders, spontaneous abortion",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Carbon monoxide (CO)",
"      </td>",
"      <td>",
"       None specific to CO",
"      </td>",
"      <td>",
"       Birth defects, low birth weight",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chlordecone",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Fetal loss",
"      </td>",
"      <td>",
"       2, 5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chloroform",
"      </td>",
"      <td>",
"       Eclampsia",
"      </td>",
"      <td>",
"       Fetal loss",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chloroprene",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Birth defects",
"      </td>",
"      <td>",
"       2, 3, 5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ethylene glycol ethers",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Fetal loss",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ethylene oxide",
"      </td>",
"      <td>",
"       Spontaneous abortion",
"      </td>",
"      <td>",
"       Fetal loss",
"      </td>",
"      <td>",
"       1,3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Formamides",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Fetal loss, birth defects",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inorganic mercury",
"      </td>",
"      <td>",
"       Spontaneous abortion",
"      </td>",
"      <td>",
"       Fetal loss",
"      </td>",
"      <td>",
"       1, 3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lead",
"      </td>",
"      <td>",
"       Spontaneous abortion, prematurity, neurological dysfunction in child",
"      </td>",
"      <td>",
"       Birth defects, fetal loss",
"      </td>",
"      <td>",
"       2, 4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Organic mercury",
"      </td>",
"      <td>",
"       Cerebral palsy, CNS malformation",
"      </td>",
"      <td>",
"       Birth defects, fetal loss",
"      </td>",
"      <td>",
"       2, 4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ozone",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Fetal loss",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Physical stress",
"      </td>",
"      <td>",
"       Prematurity",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Polybrominated biphenyis (PBBs)",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Fetal loss",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mixed solvents",
"      </td>",
"      <td>",
"       Spontaneous abortion, CNS defects",
"      </td>",
"      <td>",
"       Spontaneous abortion, CNS defects",
"      </td>",
"      <td>",
"       2, 3, 7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Radiation",
"      </td>",
"      <td>",
"       CNS defects, skeletal abnormalities",
"      </td>",
"      <td>",
"       Fetal loss, birth defects",
"      </td>",
"      <td>",
"       2, 4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Selenium",
"      </td>",
"      <td>",
"       Spontaneous abortion",
"      </td>",
"      <td>",
"       Low birth weight",
"      </td>",
"      <td>",
"       2,7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tellerium",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Birth defects",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2, 4-D",
"      </td>",
"      <td>",
"       Skeletal defects",
"      </td>",
"      <td>",
"       Birth defects",
"      </td>",
"      <td>",
"       1, 3, 8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Video display terminals",
"      </td>",
"      <td>",
"       Spontaneous abortion",
"      </td>",
"      <td>",
"       Birth defects",
"      </td>",
"      <td>",
"       1, 8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vinyl chloride",
"      </td>",
"      <td>",
"       CNS defects",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       3, 6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Xylene",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Fetal loss",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * 1: limited positive animal data; 2: strong positive animal data; 3: limited positive human data; 4: strong positive human data; 5: limited negative animal data; 6: strong negative animal data; 7: limited negative human data; 8: strong negative human data.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Welch, L. In: Preventing Occupational Disease and Injury, 2nd Edition, Levy, BS, Wagner, GR, Rest, KM, Weeks, JL (Eds). American Public Health Association, Washington, DC 2005. Copyright &copy; 2005 American Public Health Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_25_31133=[""].join("\n");
var outline_f30_25_31133=null;
var title_f30_25_31134="Estrogen treshold hypothesis";
var content_f30_25_31134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Estrogen threshold hypothesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 237px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Barbieri, RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992; 166:740. Copyright &copy; 1992 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_25_31134=[""].join("\n");
var outline_f30_25_31134=null;
var title_f30_25_31135="Indications for lung transplant";
var content_f30_25_31135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 615px\">",
"   <div class=\"ttl\">",
"    Indications for adult lung transplants by year",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 595px; height: 331px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IPAH: idiopathic pulmonary arterial hypertension; AT Def: alpha-1 antitrypsin deficiency emphysema; COPD: chronic obstructive pulmonary disease; IPF: idiopathic pulmonary fibrosis; CF: cystic fibrosis.",
"    </div>",
"    <div class=\"reference\">",
"     1. Reproduced with permission from: Christie JD, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fifth Official Adult Lung and Heart/Lung Transplantation Report-2008. J Heart Lung Transplant 2008; 27:957. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy; 2008 Elsevier Inc.",
"     <br>",
"      2. For additional and updated information, please see the International Society for Heart and Lung Transplantation slide set \"Overall Lung and Adult Lung Transplantation Statistics,\" slide titled \"Adult lung transplantation: Major indications by year (Number)\" at:",
"      <a href=\"file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\">",
"       file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry",
"      </a>",
"      .",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_25_31135=[""].join("\n");
var outline_f30_25_31135=null;
